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ABSTRACT 
 
Alpha-synuclein (aSyn) plays a crucial role in Parkinson’s disease (PD) and other 
synucleinopathies, since it misfolds and accumulates in typical proteinaceous 
inclusions known as Lewy bodies. The physiological function of aSyn is thought to be 
related to vesicle binding and trafficking, but the precise molecular mechanisms 
leading to aSyn pathogenicity are still obscure.  
Based on studies using patient-derived brain tissue, animal models, and in vitro 
experiments, it has been hypothesized that aSyn pathology can spread in a prion-like 
manner and be transferred between interconnected neurons, contributing to the 
propagation of the disease. This hypothesis assumes that pathogenic aSyn may act as 
template to seed the aggregation of non-pathogenic protein. 
In the present study we investigated the molecular mechanisms involved in the 
interaction of aSyn with membranes and the trafficking machinery in cellular models 
of PD. First, we demonstrated that different species of aSyn can enter cells and form 
high molecular weight species. By screening a pool of small GTPases family proteins, 
the RABs, we found that aSyn partially colocalizes with Rab 5A and Rab 7, suggesting 
the involvement of the endocytic pathway and of the autophagy-lysosomal pathway in 
the internalization and processing of aSyn monomers. Additionally, Rab 4A seems to 
play an important and active role in the internalization of aSyn, although further data 
are needed in order to clarify the molecular mechanism and the effectors involved.  
We also demonstrated that membrane binding is essential for the internalization of 
aSyn and the consequent interaction with the selected pathways. Taken together, our 
results suggest that the uptake of aSyn monomers might be sufficient to initiate the 
spreading of aSyn pathology. 
We also investigated the structural features of a variant of aSyn, known as SynT, which 
renders aSyn more prone to aggregation in cell models. Using Nuclear Magnetic 
Resonance (NMR) we performed a detailed structural characterization of SynT 
through a systematic comparison with the unmodified aSyn. We found that the 
conformations adopted by SynT resemble those described for the unmodified protein. 
However, subtle differences were observed at the N-terminal region involving transient 
intra and/or intermolecular interactions. Our results indicate that disturbances in the 
N-terminal region of SynT, and the consequent decrease in membrane binding of the 
modified protein, might contribute to the pathobiology of aSyn. 
XII 
This work emphasizes the importance of membrane binding properties in the 
physiological and pathological function of aSyn, and the fundamental role of RAB 
proteins in the modulation of aSyn processing, clearance and spreading.  
Taken together, our results suggest that targeting the activity of RAB proteins may hold 
important therapeutic value in PD. 
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1.1 ALPHA-SYNUCLEIN AND SYNUCLEINOPATHIES 
 
 
1.1.1 LIFE EXPECTANCY, AGING AND NEURODEGENERATIVE 
DISORDERS  
 
In the 20th century, the tremendous increase of life expectancy has been one of the biggest 
accomplishments and definitely, a major goal of human race since its existence.  
In high-income and in developing countries, national life expectancy has increased  
steadily  for  decades and projection studies suggest we will break the 90-year barrier by 
20301–3. This development has been achieved due to medical progresses, advances in public 
health, growing life standards and a consequential drop in child mortality1–3. 
Despite increasing of life expectancy do reflect a positive development, new challenges 
arises: the aging process is still intrinsically correlated with a biological and cognitive 
decline.  
Age is a major, and perhaps most important, risk factor for cardiovascular diseases and 
several types of cancer. The risk to develop neurodegenerative disorders also increases 
significantly in the elderly population, representing the largest cause of disability in the 
world4. 
Because of these serious, negative effects, aging is considered one of the greatest social and 
economic challenges that the world will face in the upcoming years5. Chronic 
neurodegenerative disorders and the related mental health deterioration (dementia) are 
often mentioned as especially problematic, imposing a significant burden on working 
relatives and requiring substantial expenses for professional care5. 
 
 
1.1.2 PARKINSON´S DISEASE 
 
Among the neurodegenerative disorders, Parkinson’s disease (PD) is recognized as the 
second most common after Alzheimer’s Disease (AD), and as the most diffuse movement 
disorder, affecting 1% of the population above 65 years old6.  
PD was first described as the “shaking palsy” in 1817 by James Parkinson and the classical 
clinical manifestations of the disease include motor symptoms as bradykinesia, rigidity, 
resting tremor and postural instability. Non-motor symptoms include depression, anxiety 
Introduction 
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and irritability, cognitive and personality changes, hallucinations, sleep disorders and 
hyposmia7–10.  
Pathologically, the primary brain region affected in PD is the substantia nigra pars compacta 
(SNpc) that consists of pigmented, dopaminergic neurons that project into the putamen. 
The peculiar degeneration of this specific neurons and the consequent development of 
dystrophic striatal projections are hallmarks of PD7,11 (Figure 1A).  
Another pathological hallmark of PD is the presence in the neuronal body of intracellular 
proteinaceous inclusions commonly known as Lewy bodies (LB) and Lewy neurites (LN). 
These inclusions are characterized by the presence of the protein alpha-synuclein 
(aSyn)7,12,13 (Figure 1B).  
SNCA, the gene that encodes for aSyn, was the first gene associated with autosomal-
dominant forms of PD14. Although mutations in SNCA are overall rare, several point 
mutations, together with duplications and triplications of the SNCA gene have been 
reported. Misfolded or excess aSyn proteins may cluster together to form LB and impair 
the function of these neurons in specific regions of the brain.  
Thus, over the last two decades, the study of aSyn has been a major, fundamental goal for 
the scientific community, as it was hoped it could shed light into the molecular 
mechanisms associated with PD, thereby leading to novel, effective therapeutic strategies 
against PD and other neurodegenerative disorders. 
 
  
Figure 1. Pathological hallmark of Parkinson´s Disease                  
(A) Representation of the differences between the SNpc region of a healthy brain and a brain with Parkinson´s 
Disease. It is possible to see the lack of pigmented, dopaminergic neurons in the region of interest (Image credit: 
Blausen Gallery 2014 / Wikiversity Journal of Medicine, doi: 10.15347/wjm/2014.010). (B) ICC of a neuronal 
population from PD brain. The presence of Lewy body and its characteristic halo-like morphology is highlighted. 
(From National Library of Medicine, NIH)  
A B 
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1.1.3 PROTEINOPATHIES AND SYNUCLEINOPATHIES 
 
The aggregation and accumulation of proteins inside or outside cells in the brain is a 
common feature among many neurodegenerative disorders such as AD, PD, Huntington’s 
disease, or spongiform encephalopathies15. Consequently, these diseases are also referred 
to as proteinopathies. 
The general principle of proteinopathies is that the proteins involved change their 
conformation, either gaining toxic activity or losing their normal functions.  
In the healthy brain, these proteins are found in a monomeric, physiological form.  
In disease, proteins experience conformational changes leading to the formation of 
abnormal inclusions that accumulate in aggregates or in higher order structures16.  
Different diseases are primarily associated with the accumulation of particular types of 
protein aggregates. However, in many instances there is also overlap in pathology among 
different proteinopathies, complicating the diagnosis upon autopsy (Figure 2). 
Although the clinical and pathological phenotypes that trigger neurodegenerative diseases 
are distinct, they share numerous similarities in terms of the molecular mechanisms 
involved, suggesting that the pathological cascades are likely to be more conserved that 
one might have anticipated. 
 
Figure 2.  Overlap of neurodegenerative proteinopathies.  
The different neurodegenerative disorders represented are arranged in colour blocks that indicate their primary 
proteinaceous aggregate. AD is characterized by proteinaceous inclusions of both Aβ (yellow) and tau (red) 
and is displayed in orange. Diseases are connected to the protein responsible of the formation of aggregates 
throughout the use of lines. (Abbreviation used: Argyrophilic grain disease(AGD); Corticobasal degeneration 
(CBD); Dementia with Lewy bodies (DLB); Frontotemporal dementia (FTD); Huntington’s disease (HD); 
Multiple system atrophy (MSA); Perry syndrome (Perry synd); Pick’s disease (PiD); Progressive supranuclear 
palsy (PSP). From Reference 15. 
Introduction 
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The word “synucleinopathies” was adopted in order to characterize a subgroup of 
neurodegenerative disorders that share the accumulation of inclusions rich in the protein 
aSyn in certain populations of neurons or glial cells13,17–19.  Synucleinopathies include PD, 
Dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), as also other 
more maladies such as progressive supranuclear palsy, corticobasal degeneration, 
neurodegeneration with brain iron accumulation, type 1, etc20–24 .  
 
 
1.1.4 ASYN STRUCTURE  
 
aSyn is an abundant, 140 amino acid (aa) protein mainly localized in presynaptic 
terminals. The first sequence of aSyn was published in 1988 and it was obtained from 
the electric organ of the Torpedo californica25. The protein was called synuclein due to 
its localization in presynaptic nerve terminals (syn-) and in some part of the nuclear 
envelope (-nuclein). Following studies failed to confirm the nuclear localization of the 
protein, but the original name survived and, more recently, this topic has attracted 
renewed interest.  
Although the precise function of aSyn remains elusive, extensive information have 
been accumulated about its structural properties and conformations. 
Based on the amino acid composition, aSyn can be divided into three distinct regions:  
- The N-terminal region (residues 1-60), contains four imperfect 11 aa repeats that 
bear the consensus hexameric sequence KTKEGV, where the individual repeats 
are separated by region of 5-8 aa. The N-terminal region is predicted to form 
amphipathic α-helical structures when associated with membranes26,27 due to its 
strong homology to the lipid-binding domains of class A2 apolipoproteins28. 
- The central region (residues 61-95), also known as Non-Amyloid Component 
(NAC) domain, is highly hydrophobic and essential for aggregation29,30, and  
contains three additional KTKEGV repeats. The name of this domain is associated 
to the finding of a protein, named “non-amyloid beta (Aβ) component precursor”,  
in some amyloid plaques from brains of patients with AD31. Even in this case, 
subsequent work failed to confirm the presence of NAC fragment in the 
amyloidogenic deposits of AD brains32, but the name persisted for historical 
reasons.   
- The C-terminal region (residues 96–140) is enriched in acidic residues and prolines 
(Pro), which confers to this domain a strongly negative charge. Three highly 
conserved tyrosine (Tyr) residues, which are considered a signature of the α- and 
  Introduction 
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β-synuclein family, are located on it. Increasing evidences suggest that this domain 
is essential for the chaperone function of aSyn33–35 and that may modulate the 
protein-protein and protein-small molecule interactions of aSyn36. 
From a biophysical point of view, aSyn is a typical, intrinsically disordered protein 
(IDP). It is characterized by the lack of a well-defined secondary structure and exhibit 
significant conformational plasticity. 
aSyn has not been crystallized, and the study of its structure has required the 
employment of sophisticated assays. 
In Nuclear Magnetic Resonance (NMR) studies, the Cα secondary chemical shifts 
analysis of aSyn confirmed that the protein is largely unfolded and that lack a defined 
structure37,38. Nevertheless, NMR39–41, Electron Paramagnetic Resonance (EPR)42, 
molecular dynamics40 and electron transfer studies43 shown that aSyn possess a 
relatively higher compact ensemble - mainly due to clustering of hydrophobic residues 
- compared to a fully unfolded peptide chain. Those studies highlighted as well the 
presence of transient long-range contacts between the C-terminal tail and the central 
region of the protein38,44, which were suggested to play a role in the inhibition of 
spontaneous aSyn oligomerization and aggregation38,45.  
The intrinsically unfolded conformation exhibited under physiological condition can 
be altered both in vitro and in vivo, giving rise to a pre-molten globule state when aSyn 
is exposed to condition such as low pH, high temperature, low concentrations of 
organic solvent or the presence of various salt and polications, as well as heparin and 
other glycosaminoglycans46.  
A general preference for secondary structure in the form of α-helices was found in the 
first 100 residues at the N-terminal - that show to have decreased mobility based on 
15N relaxation rates measurement47 – leading to the formation of an extended, 
amphipathic α-helix when aSyn binds to the membrane surface38.  
Upon addition of small unilamellar vesicles (SUVs), it was reported a break in the 
helical pattern of the protein, between the residues 43 and 44, showing an interruption 
of the predicted structure26 and reporting  the formation of two separated alpha-helices 
(corresponding to Val 3–Val 37 and to Lys 45–Thr 92) connected by an extended, 
ordered linker37,48. In both conformations, the acidic C-terminal region (from Asp 98 
to Ala 140) behave as a disordered, flexible tail and remain unstructured even in the 
presence of membranes46,48.  
As will be described in the next sections, aSyn is also able to form morphologically 
distinct oligomers and aggregates, containing both α-helical and β-sheet secondary 
structures. The prolonged in vitro incubation of this protein at high temperatures, as 
Introduction 
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well as with organic solvents over a long time results in a progressive aggregation 
through the formation of dimers and higher-order oligomers species containing 
possibly a rigid tertiary structure46.  
The findings summarized above clearly show that aSyn belongs to the family of the 
IDPs, and more specifically, to the most disordered subfamily members, known as 
natively unfolded proteins: these are characterized by a unique combination of low 
hydrophobicity, low sequence complexity and high net charge38,43.  
 
 
 
 
 
 
 
 
  
Figure 3. Schematic representation of the domains and structure of aSyn.             
(A) Structure of aSyn bound to lipid vesicles. The structure of the protein (human, full length) 
was determined by NMR (PDB ID: 1XQ8). (B) Schematic illustration of the three structural 
domain of aSyn, the seven imperfect repeats (second lane) and the predicted alpha helices (third 
lane). Adapted from Reference 38. 
A 
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1.2 ASYN: PHYSIOLOGICAL FUNCTION AND   
     PATHOLOGICAL BEHAVIOUR 
 
 
1.2.1 ASYN FUNCTION   
 
Although aSyn has been estimated to account for about 1% of the total cytosolic 
protein in the brain49, the exact function of this protein remains elusive. 
For a long time it has been theorized that the predominant physiological state of aSyn 
was monomeric, and that the protein could be found either in a cytosolic, free state, 
either bound to plasma membrane and vesicles, where it acquire a more structured, α-
helical enriched conformation. Recently, multimeric forms of aSyn, mainly tetramers, 
have been isolated from human brains, neuronal and non-neuronal cultured cell lines50–
53, opening a debate about its natural state. Given the recent findings, one of the 
suggested model proposes that the tetrameric form of aSyn could actually be the 
functional form of the protein, and that this would exists in a regulated equilibrium 
with the monomers50–53.  
The close association with membranes and vesicular structures encouraged several 
theories about the putative functions of aSyn, including transport of lipid, packing and 
stabilization of membranes, as well as regulation of phospholipids via the inhibition of 
phospholipase D250,54.  
On the other side its localization at the presynaptic terminals49,55, its association with 
the pool of synaptic vesicles56,57 and the deficits in synaptic transmission observed after 
genetic manipulation of the SNCA gene, suggest that aSyn could be involved in 
synaptic plasticity, through the regulation of synaptic release and trafficking58. SNCA-
knockout mice show a reduced synaptic response in the hippocampus upon intense 
stimulation, as well as a decreased availability of synaptic vesicles, especially of the 
distal pool59.  
In opposition, the overexpression of human aSyn in transgenic mice - as well as in 
cultured neurons - induce a decrease in ready-to-release vesicles and affects the 
recycling of those after endocytosis60. Excess of aSyn reduce the dopamine reuptake in 
nerve terminals and cause impairment in neurotransmitter release too61,62.  
Overwhelming evidence suggest that aSyn may acts as a chaperone for the SNARE 
complex, regulating the degradation and affecting distribution, preservation and 
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assembly of the proteins involved, which are directly implicated in docking and fusion, 
exocytosis of synaptic vesicles and neurotransmitters release63.  
There are still some controversy about the interaction of aSyn with SNARE complex: 
a major study showed an increase in the assembly of SNARE complex in presence of 
aSyn63, while others demonstrated that  aSyn inhibits vesicle fusion to membrane in a 
concentration-dependent manner, claiming for a negative regulatory role of aSyn64–66.  
A direct interaction of oligomeric aSyn with VAMP2 was reported, as a crucial step 
for the inhibition of the vesicle fusion process66, whereas other findings claim that a 
direct binding of aSyn to the complex is unnecessary and that the inhibition is merely 
due to the ability of aSyn to integrate into the lipid surface67,68.  
Together these data draw a still imperfect picture of aSyn function in SNARE complex 
formation, but all of them also highlight a mechanism that relies on preservation of 
membrane curvature, stabilizing lipid packaging defects and preventing – seems likely 
– premature fusion of vesicles64,69. 
The possible role of aSyn in regulating synaptic homeostasis, synaptic plasticity and 
trafficking is not exclusively related to its direct interaction with vesicles and with the 
proteins of the  SNARE complex; aSyn has been show to interact with at least 30 
different proteins and other ligands, as well as with several polyvalent elements 
including Fe2+, Zn2+, Cu2+ and Ca2+.33,70,71 (Figure 4). 
aSyn also binds to calmodulin, a protein that regulates secretory processes at the 
synapses by interacting with the calcium-CaM dependent kinase II and other protein 
targets72–75. The interaction with calmoduline contribute to the release of membrane-
bound aSyn, suggesting that dissociation of aSyn from the membrane surface74 occurs 
through a depolarization-dependent process72.  
In addition to these various, supposed functions, aSyn might also be involved in 
dopamine synthesis. It has been widely reported that aSyn binds to and inhibits 
tyrosine hydroxylase, an enzyme necessary for the biosynthesis of dopamine, as well 
as to hDAT, (human dopamine transporter) and that it prevent the re-uptake of 
dopamine from synapsis72,76.   
Key interactions have been localized to particular fragments of aSyn, showing that the 
majority of them are contained within the C-terminal region. All these mapped 
interactions could possibly be affected by familial mutations in the protein and by post-
translational modifications (PTMs), and they may be involved in the diverse function 
and dysfunction of the protein, contributing or maybe even causing its pathological 
behaviour. 
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1.2.2 FAMILIAL MUTATIONS  
 
aSyn started to attract significant interest in 1997, after a single point mutation in the 
SNCA gene was found to be associated with familial cases of early-onset PD14,38. The 
same year, Spillantini and colleagues identified a strongly immunoreactivity for aSyn 
in LB inclusions present in cases of sporadic PD20.  
Since then, several observations have confirmed and established the involvement of 
aSyn and its aggregated, misfolded forms in the pathogenesis of PD and other 
synucleinopathies. Few mutations in the SNCA gene have been identified (A53T14, 
A30P77, E46K78  and most recently H50Q79, G51D80 and A53E81) and overexpression 
of wild-type aSyn (aSyn WT) due to duplication82 and triplication83 of the SNCA gene 
similarly led to autosomal dominant PD. Therefore, the behaviour and properties of 
these mutants have been studied in details in the attempt to find a recurring motif and 
to shed new light on the mechanisms of aSyn pathogenesis72.  
aSyn contribution to neurodegenerative disorders could be caused either from a toxic 
gain of function (as result of overexpression and disruption of the functional 
pathways), or from the perturbation of its natural, physiological role (as consequence 
of familial mutations and PTMs, or from sequestration into misfolded, aggregated 
forms )72. 
To note, the effects of the familial mutations on the aggregation properties vary 
considerably. E46K, H50Q and A53T accelerate the kinetics of the secondary structure 
changes responsible for  oligomerization  and fibril formation84,85; A30P oligomerize 
rapidly but delays the formation of mature fibrils85–87 while G51D retards aggregation84, 
suggesting that the process that bring toxicity involved are different72.  
Different mutants have also dissimilar effects on membrane binding affinity72: 
compared to aSyn WT, A30P is clearly less effective on bind to the membrane, A53T 
has no effect, and E46K shows enhanced binding88–91,92. Nevertheless, a common 
characteristic in the membrane binding behaviour of these mutants is showed through 
their ability to adopt a partly folded, α-helical enriched structure, where the first 25 aa 
at the N-terminal are bound and the rest of the protein remains mostly free72. The 
H50Q and G51D mutations have been discovered in recent times and there are not 
extensive studies yet. However, G51D reduces the affinity for membranes, while H50Q 
does not show altered membrane binding properties72,84,93. 
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1.2.3 POST-TRANSLATIONAL MODIFICATIONS  
 
Multiple PTMs of aSyn have been reported, including serine/threonine (Ser/Thr) and 
Tyr phosphorylation94, ubiquitination95, sumoylation96, glycation97, acetylation98and  
methionine oxidation99,100.  
The most common, disease-related PTMs of aSyn is the Ser phosphorylation of the 
residue 129, identified as a major, highly conserved phosphorylation site, followed by 
a second one located at Ser 87. It has been estimated that a significantly elevated 
fraction (>90%) of aSyn deposits in LBs is phosphorylated at Ser 129, and that this 
modification promotes the formation of aggregates101–103.  
LBs analysed from PD and DLB patients and cytoplasmic inclusions in MSA are 
abundantly loaded with ubiquitinated aSyn as well. Since ubiquitination is not 
required for the degradation of monomeric aSyn, it appears that this PTMs occurs after 
its aggregation, and although aSyn contains 15 lysine (Lys) residues, only Lys 6, 10 
and 12 were shown to be ubiquitinated in vivo95,104.  
It was recently reported that aSyn is N-terminally acetylated, most likely by the N-
terminal  acetyltransferase B complex (NatB)105, and that such a modification slightly 
increases the helical propensity of the first 10 residues in the N-terminal region72,106,107,  
although additional studies are required to better clarify the exact role of this 
modification. Further studies demonstrated that aSyn is acetylated on Lys 6 and 10 
and that these residues are deacetylated by Sirtuin2, proposing aSyn acetylation as an 
important regulatory mechanism for aSyn aggregation and toxicity98.  
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Figure 4. Schematic representation of aSyn familial mutation, PTMs and map of the 
interactor protein binding site. (A) Representation of aSyn structure with the three 
characteristic structural domain (B) Sites of PTM (methionine: yellow ovals; Tyosine: 
blue squares; phosphorylation: red rings; sumoylation: purple squares;  ubiquitination: 
green boxes;) and PD-related familial mutations (orange arrowheads).  (C) 
Representation of the interaction domains responsible of the protein-protein and 
protein-small molecules interaction of aSyn. Modified from Reference 38. 
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1.2.4 THE PUTATIVE PATHOGENIC ROLE OF ASYN 
 
Due to the clear, widespread accumulation of β-sheet enriched amyloid fibrils in the 
brains of patients with synucleinopathies, intense effort had focused on the study of the 
molecular mechanisms underlying aSyn misfolding and aggregation, as well as on the 
structural and morphological characterization of these fibrils.  
As for many other proteins, the levels of aSyn in the central nervous system (CNS) 
depend on the delicate equilibrium between aSyn synthesis, aggregation and clearance: 
an imbalance between these mechanisms can result in abnormal levels of aSyn and 
therefore in the formation and/or accumulation of oligomers and fibrils.  
It seems also reasonable to suggest that due to the structural polymorphism and the 
numerous interaction and function ascribed, aSyn is a protein potentially prone to 
misfold per se. We could look at the misfolding and aggregation of aSyn as a low rate, 
stochastic event that occurs throughout life. Under some stress conditions (i.e. toxic 
insults, inflammation, cellular stress) this process is promoted. Normally, neurons are 
able to clean up accumulated, dysfunctional proteins, but it is also possible that in some 
occasions the cellular clearance mechanisms fail, letting the pathogenic process start.  
Fibril formation is a multistep process, and several studies tried to better understand 
the specific pathways involved in aSyn aggregation, as well as the toxic contribution 
of any and all the species originated along such pathways, from monomeric aSyn, to 
oligomers, prefibrillar aggregates, and mature amyloid fibrils (Figure 5).  
Early stages of this process involve the partial folding of aSyn into a pre-molten 
globule-like conformation. High protein concentration, point mutations, oxidative 
damages and many other environmental factor may shift the equilibrium in favour of 
this partially folded conformation108 . In the process of oligomerization, dimers are 
formed first109, followed by a series of morphologically different - spherical, chain-like 
and annual - soluble oligomers. 
In vitro, under appropriate conditions, spherical oligomers convert into ring-like 
structures110 and protofibrillar species, that have been reported to permeabilize 
membranes through the formation of pores or channels72,111,112. This could clearly alter 
membrane potential and ion distribution, actively contributing to cellular toxicity72.  
Finally, the protofibrillar species can assemble into large, insoluble aggregates by 
adopting two different morphologies: amorphous aggregates and amyloid-like fibrils.  
The formation of aSyn fibrils occurs in a nucleation- dependent manner, where the 
limiting step is the growth of transient, oligomeric intermediate, also called fibril 
nuclei38,113. Once fibril nuclei have formed, fibrils grow from these seeds by a “dock 
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and lock” mechanism, in which monomers, initially bind to – or “dock onto” – an 
already formed fibril in a reversible manner38. This step is therefore followed by an , 
structural reorganization of the polypeptide, in order to generate an optimal area for 
further fibril growth38.  
An important question regarding the pathobiology of aSyn in neurodegenerative 
disorders is which one, among the one involved in the fibrillization of aSyn, are the 
toxic species. 
Giving the fact that aggregation of aSyn and accumulation of this into insoluble 
deposits occur after cell death in vitro114 and that toxicity is usually documented without 
the presence of heavily aggregated aSyn115, it seems reasonable to suggests that the  
soluble, oligomeric intermediates – rather than mature fibrils - might be the key 
contributors to cellular dysfunction and death. 
The mechanisms proposed to describe the neurotoxic events in synucleinopathies can 
be divided into three major groups: physical disruption of cellular processes or cellular 
compartments, toxic gain of function and loss of physiological function38.  Those 
factors are not necessarily mutually exclusive: they could be, instead, synergistic38.  
One of the most commonly accepted mechanisms of disruption of cellular processes is 
the permeation of cellular membranes. As mentioned before, in vitro studies were able 
to demonstrate that annular protofibrils are capable of modulating membrane 
permeability, enhancing the influx of calcium from the extracellular to intracellular 
space and resulting eventually in cell death116.  
aSyn oligomers might also cause toxicity by damaging mitochondria117, causing 
lysosomal leakage118 or disrupting microtubules119 (Figure 6).  
In light of the potential interaction of aSyn with the SNARE complex and RAB 
proteins, it is not surprising that overexpression and oligomerization of aSyn could 
affect the transport machinery, resulting in endoplasmic reticulum (ER) stress and 
cytotoxicity and blocking ER to Golgi trafficking120. aSyn oligomers impair as well the 
axonal transport of synaptic proteins, resulting in dysfunctional synapses and 
neurodegeneration58. 
Impairment of aSyn degradation via proteasome inhibition and generation of reactive 
species of oxygen (ROS) have been proposed as another possible, neurotoxic 
mechanism.  
However, the previous proposed mechanisms do not excludes the other possibilities: 
on one side, the oligomerization process may perturb the distribution of physiological, 
functional species of aSyn, by trapping monomers into non-functional oligomers and 
therefore leading to a partial loss of function of the protein121.  
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On the other side, intrinsically existing, misfolded forms of monomeric aSyn can play 
a role in the pathogenesis of synucleinopathies through some sort of aggregation-
independent mechanism, possibly triggered by aberrant interactions with proteins, 
membranes and small molecules, or by misplacement of aSyn species in incorrect 
physiological compartments and by disruption of cellular processes, resulting in a gain 
of toxic function121.  
It is worth to mention that unlike stable oligomeric forms of aSyn, which can be easily 
analysed and characterized, the existing experimental tools do not allow a detailed, 
structural characterization of different monomeric forms of aSyn. This strongly limits 
the study of the role of aSyn monomers in health and disease121. 
 
 
 
  
Figure 5. Mechanisms of aSyn aggregation.                                              
In the cytosol, aSyn unfolded monomers start to interact and to create dimers that slowly aggregate 
to generate oligomers with different morphologies. aSyn oligomers eventually convert to fibrils via an 
irreversible, nucleation-dependent mechanism. The accumulation of these amyloidogenic fibrils bring 
to the formation of Lewy bodies. The ring-like oligomers may associate with membranes, creating 
trans-membrane pores. Both aSyn oligomers and fibrils can be transferred from one cell to another 
and induce the spreading of the pathology to other brain regions. Modified from Reference 121. 
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Physiological function 
Pathological behaviour 
Figure 6. aSyn physiological function and pathological behaviour.            
Pathways, membranes and targets potentially involved in the normal, physiological function of aSyn 
(top figure) and in aSyn dysfunction and its role in synucleinopathies (bottom figure).      
Adapted from Reference 72. 
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1.2.5 ASYN: A PRION-LIKE PROTEIN? 
 
Recently, the possibility that the progression of aSyn pathology in synucleinopathies 
would be mediated through cell-to-cell spreading of oligomers or aggregates has 
become an attractive model to explain how aSyn related toxicity and 
neurodegeneration might propagate throughout neuroanatomically connected regions 
of the diseased brain.   
Braak and colleagues hypothesized about the progressive, stereotypic spread of Lewy 
pathology by histopathological studies of PD post-mortem brains11. In the early stage 
of the disease, aSyn positive LB and LNs accumulate mainly in the olfactory bulb and 
in the dorsal motor nucleus of the vagus and then they spread in anatomically 
connected regions with the progression of the disease50,122 (Figure 7).  
Six neuropathological stages of PD were described, with increasing number of regions 
that successively exhibit aSyn pathology, proposing a model where a “spreading 
agent” (e.g. a neurotrophic virus) might propagate through a defined neuronal 
pathway, in a prion-like manner123.  
A supportive observation to this theory resulted from an experimental treatment in 
which embryonic dopaminergic neurons were transplanted into the putamen of human 
PD patients124,125. The finding of LB-like inclusions in these exogenously grafted 
neuronal population significantly influenced the field, leading to the formulation of the 
prion-like hypothesis of aSyn, which postulated that misfolded aSyn is transferred 
between connected cells, acting as a template to initiate aggregation of endogenous 
protein in recipient and otherwise healthy neurons50,126,127.  
 
  
 
 
  
Figure 7. Braak´s staging hypothesis for the progression of PD pathology.                                  
Variable red shading reflects the ascending, rostro-caudal progression of the disease and increasing 
severity of aSyn pathology. From Doty RL, Olfactory dysfunction in Parkinson disease, Nat Rev 
Neurol. 2012; 8(6):329-39. 
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A key premise for the prion-like hypothesis is that aSyn assemblies can be taken up by 
neurons, transported along the axons and finally transferred to neighbouring cells 
through different ways, (i.e. being released into the extracellular space)128.   
So far, numerous in vitro and in vivo studies have addressed different aspects of this 
complex series of events80,128–136. 
First, it has been widely demonstrated that exogenously added aSyn oligomers and 
aggregates can bind to the surface of cultured cells, both in their free state or associated 
in extracellular vesicles, due to the interaction with membranous proteins137,138, or with 
lipid components of the membranes139 (i.e., proteoglycans).  
Several mechanisms for the internalization of aSyn have been proposed, some of them 
appearing to be assembly-state specific. Monomeric aSyn seems to be able to penetrate 
cell membranes and passively diffuse into cells129, while larger assemblies utilize 
specific pathways, including receptor-mediated endocytosis139.  
It has been shown that exogenous aSyn further induced neuronal cell death through 
Rab 5A-dependent endocytosis140, while another study reported that heparan-sulphate 
proteoglycans mediate macropinocytosis of aSyn and other aggregation prone 
proteins139.   
Several findings showed that aSyn oligomers and fibrillary species can enter cells via 
dynamin-dependent endocytosis, and that absorptive endocytosis (an intermediate 
process between fluid-phase endocytosis  and receptor-mediated endocytosis) 
promoted the uptake of both tau and aSyn fibrils50,134,141. However, due to the size of 
fibrillar aggregates, seems unlikely to consider receptor-mediated endocytosis - which 
requires the interaction between ligands and cell-surface receptors -  as a major mode 
of fibril internalization142. 
Based on the above-mentioned mechanisms, it looks like a direct cell contact is not 
necessarily required for the propagation of aSyn aggregates. Nonetheless, recent 
evidence suggests that tunnelling nanotubes could also be involved in the spreading of 
aSyn143. These structures would provide a useful channel for the migration from one 
cell to another, obviating the need for those misfolded proteins, otherwise enclosed 
within an endosome, to cross plasma membrane and to gain access to the cytosolic 
compartment (Figure 8).  
Once inside the naïve cells, exogenous, misfolded aSyn assemblies can amplify by 
recruiting and triggering the aggregation of endogenous, cytosolic aSyn128. Many 
efforts in the last decade were aimed at shedding light into the process responsible of 
the structural conversion of aSyn, suggesting that endogenous aSyn aggregates 
through a seeding process where the imported aSyn act as a template. The intrinsic 
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structure of the seed is preserved by structurally well-defined longitudinal and lateral 
molecular interaction between newly recruited aSyn monomers and the terminal, 
exposed part of the seed, through the use of a “lock and dock” mechanism, as 
described above.  
Part of the aSyn assemblies can also be degraded by lysosomes129, which is particularly 
interesting considering that dysfunction and impairment of the autophagy-lysosomal 
pathway (ALP) are strictly linked to PD pathogenesis.  
Transmission of aSyn fibrils from neuron to neuron can undergo anterograde and 
retrograde transport, and some of the monitored movement of aSyn assemblies occurs 
at a velocity consistent with fast axonal transportation135.  
 
Figure 8. Potential proposed mechanisms mediating cell-to-cell transmission of aSyn.      
Misfolded protein seeds in the form of oligomers or protofibrils are initially formed in the cytoplasm of 
the donor neuron, where soluble monomers are recruited into larger aggregates. A large number of 
propagating seeds can be generated through fragmentation of the existing fibrillary species, or through 
secondary nucleation. Protein aggregates can be released in the extracellular space in a “naked” form (a) 
or via exosomes (b). aSyn can passively diffuse trough the plasma membrane or (1) enter the recipient cell 
by fluid-phase endocytosis (2) or receptor-mediated endocytosis, (3) as well as through the fusion of 
exosomal vesicles with the recipient cell. (4) The transfer of protein could also happen via nanotubes, 
structures that connect directly the cytoplasm of two cells (5). Internalized, misfolded protein then recruit 
native monomers in the recipient neuron, repeating the nucleation process and allowing the spreading of 
pathology. Adapted from Reference 142. 
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Regarding the release of aSyn, intracellular aSyn aggregates can be secreted into the 
extracellular space and therefore uptaken by neighbouring neurons, microglia or 
astrocytes133,135,136.  
The first report highlighting the detection of aSyn in the extracellular space even 
preceded the prion-like propagation hypothesis, and was based on the observation of 
aSyn molecules in biological fluids - including cerebrospinal fluid (CSF) and blood 
plasma - of both healthy and PD subjects144. These results imply that aSyn is typically 
available in the extracellular space in the CNS, regardless of a pathological state.  
Further results obtained from cultured cells confirmed that aSyn can be secreted in an 
active way and that the secretion can be constitutive or regulated50. Furthermore, 
higher cytoplasmic level of the protein - as well as inhibition of the proteasomal and 
lysosomal system128 - lead to an increased release of aSyn, probably due to some 
compensative mechanism necessary to keep balanced the cytosolic level of the protein.  
Pathways leading to the release of toxic aSyn oligomers include exocytosis in clear 
vesicles129, exosomal release145,146 and penetration from the donor cell membrane121. 
Another way through which aSyn can reach the extracellular moiety is throughout 
necrotic cell death, although there are still very little evidences suggesting that the 
amount of aSyn released from these cells and its contribution to the extracellular, 
pathological pool would be determinant for the propagation of the disease50. 
Overall, cellular stress, proteasomal and mitochondrial dysfunction131 as well as 
overexpression and cytosolic accumulation seems to drive aSyn secretion from neural 
cells, supporting the general idea that aSyn exocytosis may increase in the affected 
brains, bringing a fundamental contribution to the disease progression.   
Another essential process for the prion-like hypothesis is the propagation of misfolded 
aSyn and the spreading of the related neuropathology in different, distant brain region.   
This was shown in multiple experiments in rodent and nonhuman primate, using 
intracerebral injection of brain homogenates from PD and DLB patients, brain tissues 
from transgenic animal with aSyn pathology, and preparation of pre-formed fibrils 
(PFFs) generated from recombinant aSyn141,147–149.  
Injection of aSyn PFFs into the striatum not only lead to aggregation of endogenous 
aSyn, but it also had drastic consequences on the viability of dopaminergic neurons, 
leading to a widespread synaptic dysfunction134. Of note, few months after the 
injection aSyn aggregates had spread throughout the brain, while mice injected with 
vehicle remained healthy and free of pathology, indicating that the presence of 
misfolded, exogenously added aSyn is sufficient to trigger and spread aSyn 
pathology150.  
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One of the advantages of using recombinant protein is that the seeding process can be 
controlled carefully in the test tube before the intracellular injection is made, which 
does not apply to a crude mix such a brain homogenate.  
Indeed, one of the latest debate in the field is related to the existence of different 
“strains” of aSyn aggregates and whether their presence could explain the different 
morphological conformation - as well as the cellular and anatomical predilection - of 
aSyn inclusions in different synucleinopathies151. 
Intracerebral or systemic injections of fractionated brain homogenates from PD or 
MSA patients in animal models induce distinct neuropathology with “strain-specific” 
features and characteristic that resemble the pathology of origin, adding further 
support to the idea that different types of aSyn fibrillary assemblies exhibit different 
toxicity and give rise to different type of neuropathology.  
 
  
  Introduction 
 
23 
1.3 ASYN, MEMBRANES AND CELLULAR 
TRAFFICKING  
 
 
1.3.1 ASYN AND MEMBRANES  
 
In presynaptic termini, monomeric aSyn exist in a tightly regulated equilibrium 
between soluble and membrane/vesicle bound states, with approximately 15% of the 
protein associated to the membrane. 
Upon binding to phospholipidic bilayers, aSyn shows a dramatic increase in α-helix 
content, promoting the interaction of the protein with a wide variety of different lipid 
assemblies. This membrane-induced disorder-to-order transition is driven by a specific 
amino acidic pattern in the N-terminal region of the protein and it has been widely 
characterized 72. 
Many distinct helical conformation have been detected, spanning from amphipathic 
helices that lie down along the phospholipidic surface, with their apolar surfaces deeply 
inserted into the membrane and some of the lysine residues “snorkelling” from the 
inner side of the membrane in order to interact with the lipid headgroups72.  
A switching between an extended and a broken helical structure can be initiated by 
changes in the ratio of lipid binding partners or by modifying the curvature of the 
binding surface displayed by micelles, lipid vesicles or SDS-flat bilayers152 (Figure 9).  
 
  
Figure 9. Proposed model for aSyn folding and conformational switching induced by binding to 
small-molecules ligand and stabilizing membrane mimic surfaces. Adapted from Reference 152 
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In the extended helical conformation, aSyn binds to the membranes with the first 100 
residues at the N-terminal, with an unusual 11/3 periodicity27,152,153, while in the broken 
helix conformation two distinct, antiparallel curved α-helices are separated by a non-
helical linker region spanning from residues 39-4526,27,48. Additional binding modes 
observed in the context of phospholipid vesicles include shorter helices involving the 
first 25 residues at the N-terminus, while the remainder of the domain stay unbound. 
Finally, a recent NMR-based study154 revealed the exact amino acid residues involved 
in the membrane binding process (Figure 10). The findings show that the binding of 
aSyn to the membranes generate three dynamically different structures in distinct 
regions of the protein. The first 25 residues at the N-terminal are categorised as the 
membrane “anchor” domain, binding tightly to the membrane and enhancing 
cooperatively the binding of the central region as well. The central portion (from 
residues 26 to 98) includes also the NAC fragment; this bind less tightly and it play a 
key role in the modulation of the affinity of aSyn for cellular membranes. To finish, 
the C-terminal region remains mostly unstructured and uncoupled with membranes.   
Distinct conformational states are certainly contributing to the putative functions of 
aSyn, although a detailed, mechanistic understanding of its behaviour at the membrane 
surface is still an open path of research.  
The interaction with membranes may interfere with the pathogenic behaviour of aSyn 
too, either through the effect of aggregated, misfolded protein on the integrity and 
structure of membranes itself, either through a more direct effect on aSyn aggregation: 
depending on the protein: lipid ratios, membrane binding features could either have a 
protective role against further aggregation  by sequestering aSyn monomers, either 
favour aSyn oligomerization and aggregation by increasing the effective cytosolic 
concentration of this protein on a bidimensional surface72.   
As a consequence of its metamorphic character, aSyn is also able to sense membrane 
curvature and defects, showing an enhanced binding in relation to an increased 
curvature155,156. This may be related to the abundance of packing defects in highly 
curved membranes72. This so called packing defects are portions of the membranes 
where the acyl amphipathic chains of the phospholipids are momentarily exposed, 
resulting in effective protein binding sites68,155–157. Furthermore, current structure-
function relationship suggests that not only aSyn is attracted to highly curved 
membranes, but that can generate and stabilize membrane curvature itself, as part of 
its physiological function.  
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To this end, the presynaptic terminal can be considered as a hot spot for membrane 
remodelling, as synaptic vesicles continuously reach the active zone to release their 
neurotransmitter content. On their side, synaptic vesicles are considered the most 
important membrane-binding target of aSyn in the cell, and are markedly enriched in 
small packaging defects: the membrane curvature stabilizing function of aSyn could 
therefore have an effect on vesicles trafficking and release. In addition to this, aSyn 
could promote these processes via its double-anchor mechanism: by binding to lipid 
membranes with the N-terminal region (aa 1-25) and additionally with the central 
region (aa 65-97), aSyn would be able either to fuse two vesicles to one another, or 
vesicles to the plasma membranes, facilitating the processes for exo and endocytosis.  
 
 
1.3.2 ASYN AND THE RAB GTPASES FAMILY PROTEINS 
 
Presynaptic neurotransmitter release is a process that requires the biogenesis, fusion 
and turnover of vesicles and involves remodelling and movement of membranes and 
other molecules. In this context, small GTPases from the Rab family proteins (RABs) 
play a crucial role as key mediators in several steps and processes related to the 
membrane trafficking pathways, by interacting with and regulating different 
macromolecular complexes in each different stage of the cycle158.  
Notably, mutations affecting RABs and their effectors and regulators have been 
associated to several neurodevelopmental and neurological diseases.  A series of recent 
studies revealed that certain RABs are involved in the modulation of aSyn and that the 
impairment of these proteins could be one of the rare causes for inherited early onset 
Figure 10. Schematic illustration 
of the different regions of aSyn 
based on their interaction with 
lipid bilayers.            The N-terminal 
region (blue) is tightly bound and 
has the function to anchor aSyn  to 
the membrane. The central region 
(grey) feel and modulate the affinity 
of the protein for membranes. The 
C-terminal region (green) maintains 
its unstructured nature and does not 
interact with the membrane surface.  
Adapted from Reference 154. 
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PD159–161. At the same time, it has also been demonstrated that the pathological 
accumulation of aSyn perturbs the homeostasis of RABs as well. 
Whether there is a direct interaction between RABs and aSyn or a general 
compensatory mechanism linked to the vesicle transportation deficits is something that 
need still to be clarified, and the present work will bring some additional information 
about the role of RABs and the related pathways involved in the internalization and in 
the metabolism of aSyn.  
RABs constitute the largest family of small Ras-like GTPases, serving as molecular 
“switches” that alternate between two conformational states: the GTP-bound ‘on’ form 
and the GDP-bound ‘off ’ form162.  They are evolutionarily conserved across eukaryotic 
cells, with more than 60 members in humans, classified in several phylogenetic and 
functional groups163,164  (Table A).  
As all the other members of the Ras superfamily, RABs exhibit a GTPase structure, 
with six-stranded β-sheet and five α-helices; the carboxi-terminal of the GTPase fold is 
the hypervariable region of RABs and it is followed by CAAX boxes containing two 
cysteine (Cys) residues that facilitate the reversible association of RABs to the 
membranes after prenylation158, 161,162,165.  
Nucleotide cycling of RABs is tightly coupled to their membrane association/ 
dissociation cycle. Once transported to the membrane, RABs are activated by the 
exchange of GDP for GTP, a process catalysed by a guanine nucleotide exchange 
factors (GEFs)166,167. The GTP-bound active conformation can therefore interact with 
multiple effector proteins, and is converted back to the GDP-bound inactive form by 
GTPase-activating proteins (GAPs), which accelerate RAB-GTP hydrolysis. RAB-
GDP dissociation inhibitor (RAB GDI) recognize the GDP-bound RAB and 
sequesters it in the cytosol until it is recruited to a membrane again, a process that 
requires the interaction of a GDI displacement factor (GDF)158,162.  
The conversion of the GDP “off” form into the GTP “on” form involves remarkable 
conformational changes  in two regions named switch I and switch II: those are located 
in the surface of the RABs, and bind to the interactor proteins 168. Despite the structural 
similarity, the switch regions possess a degree of variety that confers unique specificity 
to each individual RABs in order to interact with their corresponding effectors and 
pathways, therefore creating an great variety in RABs function and localization158 
(Table A). Indeed, RABs are essential for the definition of the identity of subcellular 
membranes, and trafficking organelles possess their own peculiar set of RABs 
controlling their formation, maturation, and transition as well as their interaction with 
other compartments158 (Figure 11).  
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A large number of studies have tried to clarify the interactions between RABs and 
aSyn, and this can be addressed from two different perspectives.  
On one side, several RABs (Rab 3A, Rab 5, Rab 8, Rab 7 and Rab 11A) were shown 
to have the ability to interact with aSyn and to protect cells from the toxicity and the 
gain of pathological function induced by its overexpression or by mutated forms. This 
was demonstrated throughout co-immunoprecipitation and immunofluorescence 
studies in different cellular and animal models169,170. 
In control brains, Rab 3A appears to be associated only weakly with soluble, 
monomeric aSyn, while in DLB brains aggregates of aSyn sequester Rab 3A and 
prevent its interaction with rabphilin171.  
An NMR spectroscopy study revealed that the C-terminal region of aSyn binds to the 
switch region of Rab 8A, that play a role in the Golgi and in the Trans-Golgi Network 
Figure 11. Localization and function of RABs                                                                                        
An epithelial cell with its vesicle transport pathways and the localizations of selected Rab GTPases. From 
Reference 162.   
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(TGN) trafficking. In line with a direct Rab 8A/aSyn interaction, Rab 8A enhanced 
aSyn aggregation and reduced aSyn-induced cellular toxicity172.  
Finally, a shRNA-based screening additionally confirmed that Rab 8, Rab 11A, and 
Rab 13 act as modulator of aSyn oligomerization and reduce the toxicity induced by 
misfolded aSyn trough the enhancement of secretion in cultured cells173. 
On the other side, RABs were shown to regulate the distribution and recycling of aSyn, 
as well as in other vesicular trafficking pathways connected to the lysosomal 
degradation and the release of this protein.   
As a regulator of synaptic vesicles, it was reported that Rab 3A have a close association 
with aSyn, and that its activity may play a role in the re-distribution of aSyn and the 
modulation of its presynaptic activity174.  
Using a drosophila model of aSyn toxicity, it was reported that overexpression of Rab11 
could significantly reverse the neuromuscular synaptic potentiation by modulating 
synaptic vesicle size. Furthermore, Rab 11 decreases aSyn aggregation and enhances 
several aSyn-dependent phenotypes in both larvae and adult flies, including muscular 
activity and neurodegeneration175. Rab 11 also contribute to maintain the proteostasis 
of aSyn and its level: in addition to the degradation that occurs through lysosomes, 
once internalized aSyn might be secreted or released in the extracellular space via 
exocytosis, a process facilitated by the overexpression of this Rab-GTPases family 
member 169. 
Additional evidences for aSyn/RABs interaction came from extended genetic analyses 
in the yeast S. cerevisiae176. Although yeast does not have an aSyn orthologue, it has 
been used widely for elucidating the mechanism of aSyn toxicity in a general, cellular 
contest and to test potential therapeutic targets177,178.  
It has been demonstrated that one of the processes affected in the very first step, as a 
result of the overexpression of aSyn in yeast is related to the ER-to-Golgi transport. 
aSyn accumulation was indeed responsible for the failure of the processes of tethering 
and fusion to Golgi membranes, leading to the accumulation of morphologically 
undocked vesicles near the plasma membrane and eventually in intracellular vesicle 
clusters, in a both dose and time dependent manner176,179. In this context, YPT1, the 
yeast orthologue of mammalian Rab 1 was shown to associate with aSyn aggregates 
and to rescue trafficking defects and aSyn-related toxicity176. Furthermore, transgenic 
overexpression of Rab 1 protected against the dopaminergic neuron loss induced – or 
related - to aSyn in three different models - drosophila, C. elegans and cultured rat 
midbrain neurons178,179.  
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Further studies have also shown that aSyn aggregation affects the retrograde transport, 
by perturbing the endosome to Golgi trafficking machinery pathway as well180. 
Recently, Rab 35 was identified as a potential biomarker for the diagnosis of PD and 
functional studies also suggested that overexpression of Rab 35 promote the 
aggregation and release of aberrant aSyn161,181.  
In addition, genetic analyses recently identified that defect in Rab 39B lead to 
pathologically defined PD, reporting that altered Rab 39B was quickly degraded by the 
proteasome system, causing mislocalization of aSyn160. According to the latest 
findings, Rab 39B might be involved in the autophagy regulation161,182. 
Taken together, these findings suggest that the aSyn spreading and pathology may be 
attributed, at least in part, to the deregulation of a subset of RABs. 
aSyn overexpression could induce extensive defects in vesicular trafficking, and in 
particular in the neurons and in the synaptic buttons, where the downstream events - 
such as docking and fusion - are affected more extensively178.  This could be explained 
perhaps through the ability of aSyn oligomers or aggregates to interact in a deregulate 
way with RABs, causing dysfunction in the related pathways due to the inability of the 
GTPases to effectively engaging with their effectors178. This inhibition may provoke 
the pathological accumulation of unpacked, dysfunctional vesicles and the 
consequential impairment of the synaptic activity178.  
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Table A. The RABs family: intracellular location, known pathways, effectors and related diseases.      
ER, endoplasmic reticulum; CCVs, clathrin-coated vesicles; TGN, trans-Golgi network; PM, plasma 
membrane; RE, recycling endosome. Adapted from Reference 165.  
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1.3.3 UPTAKE, PROCESSING AND CLEARANCE OF ASYN  
 
While it is still unknown why aSyn misfolds and aggregates, several studies performed 
to address how cells handle aberrant aSyn assemblies.  
As already pointed out in the previous sections, aSyn might have a function in synaptic 
vesicles endocytosis, and the pathological, fibrillary species may use several, different 
endocytic mechanisms to spread from one cell to another.  
There are at least three major endocytic processes to differentiate in synaptic terminals: 
clathrin-mediated endocytosis183 (CME), which occurs in a 10-20 sec range; kiss and 
run of synaptic vesicles184, estimated to occur in less than 1 sec and bulk endocytosis64 
(Figure 12).  
Mechanisms of CME are well established and many contributing elements are known 
nowadays. CME is mediated by the production of small vesicles with a 
morphologically characteristic coat composed by the protein clathrin. Clathrin-coated 
vesicles (CCVs) are found in all the type of cells and can concentrate large extracellular 
molecules in their domains, playing a role in the endocytosis of several ligands as 
well185.  
On the other side, mechanisms responsible of the kiss-and-run endocytosis are still 
under debate, and is still missing a molecular characterization of the key player 
involved in the process. However, according to the latest hypothesis, secretory vesicles 
approaching the plasma membrane do not fully collapse upon membrane fusion: on 
the contrary, they retain their curvature and release chemical substances through a 
restricted fusion pore, thus allowing vesicles to preserve their identity during 
endocytosis186,187. 
Bulk endocytosis is an endocytic process where a larger area of presynaptic membrane 
- if compared with the one related to CME - is internalised as cisternae or endosomes: 
from this newly formed compartment, numerous synaptic vesicles can sprout off. The 
molecular mechanisms of this endocytic process is still partly unclear. Nevertheless, 
few important signalling events have been described. Bulk endocytosis can be 
specifically activated after intense stimulation - as the one obtained with a trains of 
high-frequency action potentials - or as response to membrane depolarization188.  
In hippocampal neurons CME appears to be the main mechanism183, although kiss-
and-run endocytosis has been clearly shown in dopaminergic neurons as well187.   
Regarding aSyn function in endocytosis, some data are pointing out that aSyn could 
be associated with CME, as triple aSyn knockout mice show changes in CME-related 
protein expression and an increase in CCVs after synaptic stimulation189.  
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A study conducted in lamprey displays alterations of CME and an increase in bulk 
endocytosis, suggesting that when aSyn related fast endocytosis mechanisms are 
impaired, a compensatory upregulation of CME can be observed189.  
On the other hand, a role for aSyn in kiss and run endocytosis can also be possible, 
considering the ability of this protein on modelling the curvature of small vesicles. 
Furthermore, the proposed double-anchored mechanisms could influence the tethering 
of  vesicles to the plasma membrane, regulating and preventing the full collapse of 
synaptic vesicles, as it is required for the above mentioned mechanism64,154. 
On the same way, every and each of these mechanisms can contribute to the 
internalization of pathological aSyn from the extracellular space, together with 
macropinocytosis, passive diffusion throughout the plasma membrane and tunnelling 
nanotubes.  
Due to the use of different pathological assemblies, as well as of different cells and 
animal models, a unifying theory about the role of aSyn in endocytosis and about the 
election method for the propagation and spreading of the pathology has not been 
recognised yet.  
 
 
Once the pathological aggregates of aSyn enter the cells, a processing mechanism in 
order to remove those aberrant accumulation starts. Two separate but complementary 
systems – the Autophagy/Lysosomal pathway (ALP) and the Ubiquitin Proteasome 
System (UPS), generally handle the clearance of proteins50.  
Figure 12. Mechanisms of endocytosis.                  
Adapted from Http://images.slideplayer.com/17/5285873/slides/slide_24.jpg 
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Monomeric, physiological aSyn can be degraded by both system while higher 
molecular weight species, such as oligomers and fibrils are generally directed to the 
lysosome for degradation50. 
Under the name of autophagy are grouped several, different cellular process such as 
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) 
(Figure 13).  
CMA is a very complex and specific process based on the recognition of a specific 
aminoacidic motif (KFERQ) by the cytosolic Hsc70-containing complex50. Once 
formed, the complex interacts with and bind to the lysosome associated membrane 
protein type 2A (LAMP2A) on the lysosomal membrane, allowing the substrate 
protein to translocate across the membrane and to enter the lysosomal lumen. Here the 
protein will be assisted by lysosomal Hsc70 chaperone protein for degradation190,191. 
CMA significantly differs from other types of autophagy because of its selective, one-
by-one translocation mechanism of material into the lysosome. While the chaperone 
mediated is an active process, macroautophagy is a non-selective, constitutively 
working mechanisms used mainly to eradicate damaged organelles or unused proteins 
that has undergone through the endosomal pathway50.  
During macroautophagy, a phagophore engulfs the material that needs to be degraded, 
trapping this into a double membrane compartment known as an autophagosome192,193. 
The newly formed autophagosome moves through the cytoplasm and eventually fuse 
together with a lysosome, where its contents is degraded from the acidic lysosomal 
hydrolases192. 
On the other hand, the microautophagy process consist of a direct transmigration of 
cytoplasmic material into the lysosome. This can occurs either through an invagination 
mechanism or via cellular protrusion194.  
So far, degradation of aSyn has only been shown to occur through CMA and 
macroautophagy195. Notably, a KFERQ recognition motif was found in the aSyn 
sequence, suggesting that it can be processed via CMA194. Numerous independent 
studies revealed that macroautophagy is involved in the degradation of this protein as 
well, and that aSyn can perturb actively this pathway, as familial mutations, protein 
overexpression and pathological aggregation have an inhibitory effect on 
macroautophagy related mechanisms196–198. 
Besides its involvement in the degradation of misfolded or harmful intracellular 
components, autophagy play also a major role in the homeostasis of cellular molecules 
by removing redundant proteins and organelles and by keeping optimal the steady-
state level of proteins within the cell. Therefore, it is clear that any failure in this 
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quality-control mechanism can affect irreversibly several biological pathways, leading 
to the accumulation of damaged or abnormally modified proteins and eventually to 
cell death.  
Autophagy is the leading mechanism for aSyn clearance. Under pathological 
conditions, the cells resort to additional or substitutive mechanisms, such as the release 
of these pathological assemblies into the extracellular space, thus helping - in an 
attempt to delay neuronal dysfunction and death - aSyn propagation.  
In fact, inhibition of lysosomal function in SH-SY5Y cells that overexpress aSyn led to 
increased exosome-mediated release of aSyn199, and other studies connected 
autophagic dysfunction, exocytosis and higher uptake by neighbouring cells via cell-
to-cell transfer200.  
In summary, the perturbation of the autophagic process might initiate a cascade of 
events culminating in apoptotic, dying cells jam-packed with misfolded, aberrant aSyn 
proteins that will be eventually released in the extracellular space. These aggregates 
might be internalized by neighbouring cells, acting as seeds for further aggregation and 
promoting the prion-like spreading of aSyn pathology throughout the brain.  
 
 
  
Figure 13. Main type of autophagy in mammalian cells.            
In the figure are represented the three main type of autophagy in mammalian cells: macroautophagy, 
microautophagy, chaperone-mediated autophagy (CMA).               
Modified from http://www.antibodycenter.co.kr/bbs/board.php?bo_table=goods&wr_id=259 
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1.4 CELLULAR MODELS FOR THE STUDY OF 
ASYN PATHOLOGY  
 
Developing new therapeutic strategies for treating PD and, more generally, 
synucleinopathies, requires the use of models.  
The use of PD patients is limited by heterogeneity of disease, by the slow evolution of 
it, by technical difficulties and - last but not least - ethical considerations201.  
Among the methods and the models available, cultured cells offer numerous 
advantages for the study of aSyn-related pathology if compared to animal models or 
directly to humans (patients). Nevertheless, the choice of a specific cell line can 
reproduce only partially the disease, focusing on one aspect of the pathology while 
ignoring others. One of the major pro related to the use of cellular models is that these 
ones - unlike a living organism - develop pathology quickly and reliably, so that 
researchers can be able to test several methodologies in parallel201.  
Currently, this “minimalistic” approach allow us to analyse in deep the contribution 
of specific cellular processes and pathways toward diseases, and in particular, to dissect 
the mechanisms behind the two most relevant hallmark of PD and other related 
synucleinopathies : the degeneration of dopaminergic neurons and the formation of 
aberrant assemblies of aSyn201.  
Given the relevance of aSyn aggregation in the propagation and the spreading of PD 
and synucleinopathies, understanding the driving forces and the mechanisms involved 
in this process is crucial, and several efforts have been made to address this question202. 
However, unlike other amyloidogenic, aggregation-prone proteins, aSyn does not 
easily form intracellular inclusions when overexpressed in cultured cells, as the ability 
of the protein to dimerize and to trigger the formation of high molecular weight species 
appears to be a rate-limiting step in the aggregates formation process202–204. For cell 
cultures-related work, this constitutes an obstacle, as the experiments need to be 
completed in a relatively short time, ideally before the dividing cells will overgrow (2–
4 days) or, for neuronal cultures, according to the survival times of primary cultured 
neurons (1–2 weeks) and it is therefore essential to build up a model that mimic the 
initial steps of aSyn aggregation201. 
A powerful tool to study aSyn dimerization and oligomerization is the Bimolecular 
Fluorescence Complementation assay (BiFC)205,206. This method relies on the 
discoveries that two non-fluorescent fragments of a fluorescent protein can associate 
to form a fluorescent complex, and that the association of the fragments can be 
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facilitated by fusing them to two proteins that interact with each other205. In this specific 
case, the two non-fluorescent fragment are fused to the N-terminal or the C-terminal 
of aSyn, permitting the visualization of aSyn dimers and oligomers in living cells 
through the re-constitution of the functioning fluorophore upon aSyn aggregation207.  
On the other side, manipulations of the C-terminal region of aSyn have proven very 
effective to investigate the formation of mature aggregates and the development of LB-
like inclusions.  
Using a series of aSyn enhanced green fluorescent protein (EGFP)-fusion proteins as 
a tool for studying aSyn aggregation, it was found that, when transfected in cultured 
cells, the 49 kDa aSyn-EGFP fusion protein is partially truncated to a 27 kDa form, 
and that this non-fluorescent carboxy-terminally modified protein, named SynT, 
spontaneously forms inclusions in the neuronal cytoplasm208 (Figure 14).  Aggregation 
of SynT was further enhanced by co-transfection of Synphilin-1, an interactor partner 
of aSyn present in LBs and LNs. Given the presynaptic location and its affinity for 
membranes and lipids209, Synphilin-1 also seems to be required for inclusion 
formation210 and might act as an adaptor protein, supporting the interaction of aSyn 
with other molecules211. Co-transfection  of SynT with Synphilin-1 further increase the 
propensity for aggregation of aSyn, by rising the frequency and the size of inclusions 
and leading to the formation of large, ring-shaped aggregates that mimic the halo 
structure of LB212 and that show Thioflavine S (ThioS) immunoreactivity213,214.  
While powerful and versatile, these models rely on the addition of extraneous amino 
acid sequences to aSyn, which alter its biochemical and biophysical properties.  
 
Introduction 
38 
 
 
 
 
 
 
 
 
 
 
Figure 14. Schematic representation of SynT .           
The overexpression of SynT in cultured cells allow us to investigate the processes related to the formation of 
insoluble aggregates. SynT is a protein of ca 27 kDa resulting from the fusion of aSyn WT with a truncated, 
not-fluorescent fragment of EGFP.   
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2. AIMS OF THE STUDY  
 
 
The first aim of the study was to analyse the mechanisms of interaction of aSyn with 
membranes and trafficking machinery pathways.  
Our goals were to: 
 
 Determine whether different species of aSyn (monomers and fibrils) can enter 
cultured cells and form inclusions. 
 
 Investigate how different species of aSyn can interact with cellular membranes 
and with the trafficking machinery pathways involved in the internalization 
and clearance of aSyn through the use of mutated recombinant proteins (aSyn 
WT, aSyn A30P and aSyn A11P/V70P) and the screening of RAB-GTPases 
family proteins. 
 
The second aim of the project was to characterize the biophysical, structural properties 
of an aggregation-prone variant of aSyn, SynT, able to mimic the pathological 
behaviour of the protein. In this context, we analysed the structural effects of tagging 
aSyn at the C-terminus (SynT), its aggregation propensity and its conformational 
properties by using an in vitro, NMR-based approach. 
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3.1  PURIFICATION AND CHARACTERIZATION 
OF RECOMBINANT PROTEINS  
 
 
3.1.1 PROTEIN PURIFICATION 
 
aSyn WT, aSyn A30P and aSyn A11P/V70P were obtained by transforming E.coli 
BL21-DE3 ultracompetent cells with plasmids encoding corresponding cDNA 
sequences (pET21-aSyn, pET21-A30P, pET21-A11P/V70P).  
 15N isotopically enriched and N-terminally acetylated aSyn and SynT were obtained 
by transforming E.coli BL21 ultracompetent cells with a plasmid carrying the aSyn WT 
gene or the SynT gene together with a second plasmid encoding the components of 
yeast NatB acetylase complex215. Plasmids carried different antibiotic resistance, in this 
case for ampicillin and chloramphenicol, to select E. coli colonies transformed with 
both the plasmids. 
Purification was performed as previously reported36 with some minor modifications.  
Briefly, BL21-DE3 competent cells were grown in LB medium (or in M9 medium 
enriched with NH4Cl when necessary) in the presence of ampicillin (100 μg/ml) or in 
the presence of ampicillin (100 μg/ml) and chloramphenicol (1 mg/ml).  
Protein expression was induced with 1 mM of isopropyl-1-thio-β-D-galactopyranoside 
(IPTG) for 4 h at 37 °C. The cultures were then centrifuged (30 min at 4.500 to 6.000xg) 
and the cell pellet was resuspended in Lysis Buffer (50 mM Tris HCL, 150 mM NaCl, 
1 mM EDTA and Inhibitor Protease cocktail α-complete (La Roche, Basel, 
Switzerland)) at pH 8.0.  
 Cells were recovered, sonicated on ice, boiled for 20 min at 95°C, and cell debris were 
discarded by centrifugation. Subsequent precipitation first with streptomycin sulphate 
(10 mg/ml) and later with ammonium sulphate (361 mg/ml) was performed in order 
to obtain a precipitate enriched with aSyn.  
Anion exchange high-performance liquid-chromatography (AEC) was carried out on 
an Äkta-HPLC Purifier (GE Healthcare). 
The pellet was resuspended then in 25 mM Tris-HCl (pH 7.7), and loaded onto a Mono 
Q column on an Applied Biosystems BIOCAD (Applied Biosystems, Foster City, CA) 
or bounded to an Hi-Trap column (GE Healthcare).  
The monomeric proteins were eluted at ∼300 mM NaCl with a linear gradient of 
elution buffer from 0 mM to 1 M NaCl. The pure proteins (judged by PAGE) were 
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dialyzed overnight against the appropriate buffer and further size exclusion 
chromatography (SEC) purification step using a Superdex 75 column was performed.  
Protein concentration was estimated from the absorbance at 274 nm using an 
extinction coefficient of 5600 M−1 cm−1 for aSyn WT, aSyn A30P, aSyn A11P/V70P 
and of 16055 M-1 cm-1 for SynT.  
Protein samples were dissolved in buffer A (25 mM Tris, pH 7.7) or buffer B (20 mM 
MES, NaCl 100 mM, pH 6.5). The protein stocks were filtered through 0.22 μm filter 
unit and then frozen in aliquots at -80°C. 
 
 
3.1.2 FIBRIL FORMATION  
 
The integrity and stability of aSyn monomers, besides the lack of soluble oligomers at 
the first steps of the reaction was controlled through a gel filtration chromatography 
using a Superdex 75 10/300 column (GE Healthcare Life Sciences). Aliquots of aSyn 
WT were prepared from the protein stocks in triplicates of 0.3 mL each.  The samples 
were then diluted or in phosphate saline buffer (PBS), or in Buffer B for a concentration 
of 60 μM. To the resulting samples it was then added sodium azide at a final 
concentration of 0.02%, followed by incubation at 37°C, 600 rpm in a mixer with 
temperature control (Eppendorf Thermomixer Comfort, Eppendorf, USA). 
The formation of aSyn aggregates was monitored by measuring light scattering with a 
spectrofluorometer (Jasco Inc, MD, USA) with parameters of excitation/emission 
adjusted for 330/320-340 nm. For fluorometric measurements, all samples were 
diluted in native buffer for a concentration of 10 μM. As a negative control solutions 
without protein were used.  
 
 
3.1.3 THIOFLAVINE T ASSAYS 
 
 In vitro aggregation kinetics was obtained using a PolarStar OMEGA microplate 
reader. The plate was shaken at 300 rpm/37ºC and fibril formation was monitored by 
measuring Thioflavine T (Thio-T) fluorescence every 5 min. The excitation 
wavelength was set to 440 nm and the Thio-T emission was measured at 480 nm. Each 
well contained 150 µL of 25 µM aSyn or 25 µM SynT (Buffer A), 1 µM Thio-T, and a 
2 mm glass bead to accelerate fibrillation. In all cases, the reported values correspond 
to the average of five independent aggregation measurements. 
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3.1.4 TRASMISSION ELECTRON MICROSCOPY  
 
To test the effective presence of fibrillar aggregates, samples of aSyn or SynT were 
plated onto carbon-coated grids, treated and stained with 2% (w/v) uranyl acetate. 
After the end of the treatment, samples were analysed and representative fields were 
imaged in a Hitachi H-7000 Transmission Electron Microscopy (TEM) operating with 
a 75kV voltage. 
 
 
 
3.2 CELL CULTURE AND MOLECULAR BIOLOGY 
TECHNIQUES  
 
 
3.2.1 HUMAN CELL CULTURE  
 
Human neuroglioma H4 cells were maintained at 37°C and 5% CO2 environment, in 
Opti-Mem medium (PAN, Germany) supplemented with 10% foetal bovine serum 
(FBS) (ThermoFisher) and 1% penicillin-streptomycin (ThermoFisher). For the in vitro 
experiments related to the internalization of aSyn monomers and fibrils, cells were 
routinely seeded 24 h prior to use in different well-plate formats, at a density of 8.5 to 
10*104 cells/ml. Cell count was determined using a Neubauer counting chamber. The 
day after, cells were treated with different concentrations of aSyn monomers or aSyn 
fibrils for 24h. After the end of the treatment, cells were extensively washed with PBS 
(3 times, 5 min), therefore briefly treated with trypsin in order to remove the residual 
proteins still attached to the dish (for a maximum time of 30 seconds), incubated again 
with medium (in order to stop the trypsinization related reactions) and then washed 
one last time with PBS.  
At this point, it was possible to proceed with the fixation with paraformaldehyde (PFA) 
for the Immunocytochemistry (ICC) or with the cell lysis and protein extraction for the 
immunoblotting analysis.   
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3.2.2 TRANSIENT TRANSFECTION OF CULTURED CELLS  
 
For the Rab-GTPase family screening experiments, as well as for the SynT-Synphilin1 
aggregation model, cells were seeded in different well-plate formats, one day before the 
transfection, and treated during 48 h after transfection.  
Transfections were performed with calcium phosphate method (CaPho method) 
(www.flemingtonlab.com). Shortly, 3h before the transfection it was added to the 
cultured cell fresh medium. DNA was diluted in 1x HBS buffer with 25 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, 140 mM NaCl, 5 mM KCl, 0.75 mM 
Na2HPO4 ·2H2O, 6 mM Dextrose, pH 7.1. Later on, 2.5 M CaCl2 was added dropwise 
and mixed immediately. After 20 min of incubation, the mixture obtained was added 
to the cells. The next morning cells were fed again with fresh medium, and then 
incubated with aSyn monomers or fibrils as described previously.  
 
 
3.2.3 SOLUBILISATION OF PROTEINS AND PROTEIN   
QUANTIFICATION 
 
Cells were solubilized 48 h after transfection step (unless indicated otherwise) using 
radioimmuniprecipitation assay (RIPA) buffer (50 mM Tris pH 8.0, 150 mM NaCl, 
0.1% Sodium-Dodecyl-Sulphate (SDS), 1% Nonidet P40, 0.5% Sodium-
Deoxycholate, α-complete (La Roche, Basel, Switzerland). The resulting cell lysates 
were then centrifuged for 15 min at maximum speed (Sigma 1-15 K, Sigma Aldrich 
Co. LLC, St. Louis, MO, USA). Following centrifugation, the supernatant was then 
transferred into a new microtube. Protein concentration was determined through 
Bradford's assay. Briefly, 1 μl of  the cell lysate was diluted with 49 μl of sterile water 
and 150 μl of Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). Absorbance (595 nm/450 nm) was measured using the 
Infinite M200 PRO (Tecan Ltd., Maennedorf, Switzerland) plate reader. For all the 
experiments performed, samples were measured in triplicate. 
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3.2.4 WESTERN BLOT ANALYSES 
 
Detection of proteins was performed with immunoblot analysis to detect aSyn, V5, β-
actin, tubulin, transferrin receptor and Rab GTPases fused to GFP. 
Cell lysates were separated by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) using reducing conditions, such as 12% separating gels 
and 7% stacking gels (Acrylamide 37.5 (Carl Roth GmbH, Karlsruhe, Germany), 0.01 
% SDS in ddH2O, 0.1 % tetramethylethylenediamine (TEMED), and 1 % ammonium 
persulfate (APS).  
A total amount of 40 μg of sample for each of the lysates was loaded with 5x Laemmli 
buffer (250 mM Tris pH 6.8, 10% SDS, 1.25% Bromophenol Blue, 5% β-
Mercaptoethanol, 50% Glycerol) and boiled for 5 min at 95°C.  
the addition of 5 μl PageRuler Plus Protein Ladder (Perbio Science Deutschland, 
Bonn, Germany), samples were loaded and run in the gel. 
Electrophoresis experiment was performed with the use of SDS-Running Buffer (125 
mM Tris, 960 mM Glycine) for 90 min at 100V in Bio-Rad Mini-Protean 3 Mini 
Vertical Electrophoresis System (Bio-Rad Laboratories, Inc., Hercules, CA, USA).  
Following electrophoresis step, proteins were transferred in a 0.45 µm nitrocellulose 
membranes using a semi-dry transfer chamber Trans-Blot® Turbo™ Transfer Solution 
from Bio-Rad (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Samples run for 30 
min in the chamber with a constant current adjusted for 25 mA.   
In other to block free sites, membranes were incubated with 10 % (w/v) skim milk 
dissolved in TRIS buffered saline supplemented with Tween-20 (TBS-T) (50 mM Tris 
(hydroxymethyl)-aminomethane (TRIS) supplemented with 0.05 % (v/v) Tween-20) 
for 1 h at Room Temperature (RT). For detection of the specific proteins, the primary 
antibodies were dissolved in TBS and incubated on a shaker overnight at 4°C. 
Afterwards, membranes were washed three times (for 10 minutes each) with TBS-T 
and then incubated with secondary antibodies HRP-conjugated (diluted 1:10000 in 
TBS-T) for 2 h at RT. Membranes were visualized using Fusion Fx (Vilber Lourmat, 
Marne-la-Vallée, France) with Immobilon Western Chemiluminescent HRP Substrate 
(Merck Millipore, Billerica, MA, USA). 
 
3.2.5 DOT BLOT ANALYSES  
 
All HPLC samples were incubated for 10 min at 95°C, pulled down at 10,000xg and 
4°C, and then loaded in a 96 well homemade Dot Blot machine.  
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Before loading them, the samples were filtered through a 0.2 μm pore size Protean 
nitrocellulose membrane (Schleicher & Schuell Bioscience GmbH, Dassel, Germany) 
with the use of a vacuum pump. The membrane was then incubated along 1 h with 
blocking buffer containing 5% skim milk in TBS to avoid unspecific staining. Later, 
membranes were exposed to primary antibody diluted in 1% skim milk in TBS or 5% 
bovine serum albumin (BSA) in TBS (aSyn BD transduction, 1:2000) overnight at 4°C. 
After being washed three times with TBS-T for 10 min each, membranes were 
incubated with HRP-conjugated secondary antibody diluted 1:10,000 in TBS. Lastly, 
protein bands were detected using a chemiluminescent substrate (Merck Millipore, 
Billerica, MA, USA), and membranes were imaged in a Fusion Fx photo 
documentation system  (Vilber Lourmat, Marne-la-Vallée, France). 
 
 
3.2.6 TRITON X-100 FRACTIONATION ASSAY 
 
H4 cells were plated and treated (with monomers or fibrils of recombinant aSyn) as 
described above. At the end of the treatment, cells were lysed in Lysis Buffer I (25 mM 
Tris pH 7.5, 150 mM NaCl, 1 mM EDTA  and  cocktail  of  protease  inhibitors)  and 
centrifuged at 100.000 g for 30 minutes at 4C. Supernatants were collected (soluble 
fraction) and the pellets (insoluble fraction) were washed with cold PBS and transferred 
to new tubes.  
Samples were centrifuged once again 14.000 rpm for 10 minutes at 4ºC and the 
resulting pellet, corresponding to the insoluble fraction, was subsequently resuspended 
in Lysis Buffer II (75 mM Tris, pH 6.8, 3% SDS, 15% Glycerin, 3.75 mM EDTA pH 
7.4 and a cocktail of protease inhibitors).  
Finally, samples were sonicated (10 pulse/second) and immunoblotting analysis were 
performed as described above.  
 
 
3.2.7 BIOTINYLATION ASSAY  
 
The day before the experiment, cells were plated in 100 mm Petri Dishes at a density 
of 4*106 cells, and grown until 60-70% confluence. Thereafter, cells were treated with 
1µM of aSyn recombinant monomers or fibrils of different aSyn variants (WT, aSyn 
A30P or aSyn A11P/V70P) for 24 h.  
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At the end of the treatment, cells were rinsed 3 times in ice-cold PBS and further 
incubated in PBS containing 1.5 mg/ml of EZ-Link Sulfo-NHS-SS-Biotin 
(ThermoFisher) with gentle rocking, for 30 min, at 4°C. The non-bound biotin was 
removed by incubating cells with 100 mM solution of Glycine for 15 min at 4°C.  
In order to remove the excess of Glycine, cells were briefly washed with PBS and 
thereafter cell lysate was prepared in PBS containing Protease Inhibitor α-complete 
(La Roche, Basel, Switzerland), 0.1% SDS and 1% Triton X-100. The lysates were 
sonicated for 30 sec and centrifuged for 5 min at 17000 x g.  
The supernatant was further incubated with 100 µL of NeutrAvidin Agarose Resin 
(ThermoFisher) for 2 h, in a rotatory shaker with gentle agitation, at 4°C. 
After the incubation with the resin, the supernatant (corresponding to the Cytoplasmic 
cell lysate fraction) was collected, and a Bradford assay was performed to evaluate the 
amount of total protein concentration in each of the samples.  
Biotinylated proteins were then washed 3 times with PBS and then eluted with 2x 
Sample Loading Bugger (Laemmli Buffer) by boiling the samples at 95°C for 5 min.  
Samples were then processed by western blotting. Transferrin receptor was used as a 
positive control of the biotinylated fraction, whereas tubulin was used as a positive 
control for the cytoplasmic cell lysate fraction.  
This protocol and the many used of biotinylation products were extensively described 
previously216,217. A schematic of the process is shown in Figure 15.  
 
 
 
  
Figure 15. Schematic of the biotinylation assay.                      
Cell surface proteins are covalently modified with sulfo-NHS-SS-biotin, a biotin derivative carrying a cleavable 
linker and reactive toward primary amino  groups. After cell lysis in the presence of detergents, biotin-labeled 
proteins are purified on SA-coated resin. Following their elution, isolated proteins are separated and analyzed 
via immunoblot analysis.  Modified from Reference 217. 
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3.3 IMMUNOFLUORESCENCE, MICROSCOPY 
AND IMAGING 
 
 
3.3.1 IMMUNOCYTOCHEMISTRY   
 
For ICC analysis, cells were plated in multi-well plates with different formats, 
previously coated with coverslips.  
For the in vitro experiments related to the internalization of aSyn monomers and fibrils, 
for the RABs screening experiments and for the SynT-Synphilin-1 aggregation model 
cells were routinely seeded 24 h prior to use in different well-plate formats, at a density 
of 8.5*104 cells/ml. Cell count was determined using a Neubauer counting chamber. 
The day after, cells were transfected when necessary and then treated with different 
concentrations of aSyn monomers or aSyn fibrils for 24h 
24 or 48 h after transfection, H4 cells were washed with PBS and fixed with 4% PFA 
supplemented with 0.4% Sucrose for 10 minutes at RT. A permeabilisation step with 
0.5% Triton X-100 (Sigma Aldrich, St. Louis, MO, USA) for 10 minutes at RT was 
then followed by the blocking process, performed with 10% normal goat serum (PAA, 
Cölbe, Germany)/DPBS for 1 h.  
After the blocking step, cells were incubated with primary antibodies overnight.   
After washing 3 times for 10 min with PBS to remove the unbound primary antibody, 
samples were incubated with secondary antibodies for 2 h at RT.  
In some of the experiments cells were incubated with Phalloidin (Phalloidin 488 or 
Phalloidin 594), in order to stain acting filaments.  Phalloidin (1:50 in PBS) was added 
to the samples after the secondary antibody, for 1-2 hours at RT.  
Finally, cells were washed again 3 times for 10 minutes with PBS and therefore stained 
with Hoechst 33258 (Life Technologies- Invitrogen, Carlsbad, CA,USA) (1:5000 in 
DPBS) for 5 minutes, washed again with PBS and then fixed with Mowiol for 
epifluorescence microscopy. 
All the primary and secondary Antibodies used are reported in Table B.  
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3.3.2 MICROSCOPY AND IMAGING 
 
Images in Figure 16 and in Figure 30 were acquired using a Leica Inverted Microscope 
DMI 6000 B (Leica, Wetzlar, Germany), using a 40x objective (HCX Pl Fluotar) or a 
63x objective (HCX Pl Fluotar).  
For the screening of RAB proteins, images were taken using an Olympus IX81-ZDC 
microscope system, with a 40× objective (FN 26,5). 64 images were randomly taken 
using the Olympus Scan^R Image Analysis Software out of three independent 
experiments. All the other images were acquired using a Confocal Zeiss LSM800 with 
40x or 63x oil immersion objectives.  
For the colocalization analysis in Figure 20, the Pearson´s R value was calculated via 
the use of Coloc2 plugin from ImageJ.  
For the mean fluorescence intensity values in Figures 26, 27, 28 and 29 was used Fiji 
(ImageJ) Software and GraphPad Prism for the statistical analyses and graph 
generation.   
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Table B. List of primary and secondary Antibodies used.  
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3.4 STRUCTURAL BIOLOGY  
 
 
3.4.1 CIRCULAR DICHROISM ANALYSIS  
 
Circular Dichroism (CD) spectra were recorded at 25oC on a JASCO J-1500 
spectropolarimeter. aSyn and SynT samples were diluted in Buffer A at a concentration 
of 20 µM and loaded into 1 mm path-length cuvettes. We averaged 8 scans for each 
sample to increase signal-to-noise ratios.  
 
 
3.4.2 SUVs PREPARATION  
 
SUVs were prepared from a molar ratio of 1:1 of Coagulation Reagent I containing 
DOPE:DOPS:DOPC (5:3:2 w/w) and DOPC (both Avanti Polar Lipids Inc., USA) 
dissolved in chloroform yielding a final molar ratio of DOPE:DOPS:DOPC (5:3:12 
w/w).  The lipid solution formed a thin film under evaporation of the solvent with 
nitrogen gas and was further dried by lyophilisation under vacuum. The dried 
phospholipids were dissolved in MES buffer (20 mM MES, 100 mM NaCl, pH 6.5) 
and underwent several cycles of freeze-thawing and water bath sonication until the 
solution became clear. The size distribution was also checked by DLS. For the NMR 
experiments a SUV stock solution of 85 mM (6.6 % w/v) in respect to the monomers 
was used. 
 
 
3.4.3 NUCLEAR MAGNETIC RESONANCE  
  
All NMR spectra were recorded on a Bruker 600 MHz Advance III spectrometer, 
equipped with a cryogenically cooled triple resonance 1H(13C/15N) TCI probe. 1H-15N 
SOFAST-HMQC218, 1H-15N HSQC, 15N R1 and 15N R2 relaxation rates, 1H-15N het-
NOE and J-coupling HNHA experiments were all recorded at 15oC using protein 
samples dissolved in Buffer B supplemented with 10% D2O. NMR parameters used in 
each experiment are described next.  
1H-15N SOFAST-HMQC and 1H-15N HSQC: we used 16 scans, 1024 complex points 
(sweep-width of 16 ppm in the 1H dimension) and 256 complex points (sweep-width 
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of 26 ppm in the 15N dimension). Sequence-specific assignments for the backbone of 
aSyn and SynT were transferred from previously published work219,106. Only 
unambiguously assigned, well resolved peaks were included in the analysis. The I/I0 
ratios obtained for aSyn and SynT, in the absence or in the presence of PcTS or SUVs 
were plotted as a function of the protein sequence to obtain the intensity perturbation 
profiles220. Mean weighted chemical shifts displacements (MWΔCS) for 1H-15N were 
calculated as [(Δδ1H)2 + (Δδ15N/10)2]1/2. 
15N R1 and R2 relaxation rates, and 1H-15N NOE data were acquired at 600 MHz 
external field using previously described pulse sequences221. Experiments were 
recorded with 1024 complex points and a sweep width of 16 ppm for the 1H dimension, 
and 256 complex points in the 15N dimension with a sweep width of 26 ppm. R1 and 
R2 relaxation rates were obtained by recording the experiments with different T1 and 
T2 relaxation delays. Resonance heights in the spectra at each delay were fit to a two 
parameter exponential decay function to obtain the rates. Steady-state 1H-15N NOE 
(hetNOEs) values were obtained from the ratio of peak heights in spectra collected 
with and without an initial 4 sec period of proton saturation during the recycling delay.  
HNHA experiments were recorded with the following set up: number of points, 1024 
(1H), 80 (15N), 144 (1H); spectral width (ppm), 16 (1H), 26 (15N), 10 (1H); number of 
scans, 16. Three-bound HN-Hα coupling constants (3J HN-Hα) were obtained from 
the ratio between the intensities of the diagonal peaks and cross-peaks in the HN-HA 
correlation region219,222. The aforementioned coupling constants are sensitive to the 
torsion angle  populated by each amide group in the protein backbone, and are 
reflecting on the secondary structure content of the protein analysed219. This coupling 
falls in the range 3.0–6.0 Hz for α-helix and 8.0–11.0 Hz for a β-sheet structures. For a 
random-coil, the weighted average of the values observed ranges typically  between 6.0 
and 8.0 Hz for most residues223.  
Acquisition and processing of NMR spectra were performed using TOPSPIN 3.2 
(Bruker Biospin). 2D spectra analyses were performed with CCPN. For the 3J HN-H 
couplings calculation, the software CARA was used. R1 and R2 relaxation data fitting 
was performed using CCPN routines. 
  
  Materials and Methods 
 
57 
3.5 SOFTWARE AND STATISTCS  
 
Statistical analysis was performed using Microsoft Excel (Microsoft Corporation) and 
GraphPad PRISM 5 (GraphPad Software, San Diego, CA, USA). Images were 
processed with ImageJ V1.41, NIH, USA and/or CorelDRAW X8 (Corel 
Corporation, Ottawa, Canada).  
Figures were composed with CorelDRAW X8 (Corel Corporation, Ottawa, Canada) 
or with Microsoft Power Point (Microsoft Corporation).  
Colocalization in ICC samples was measured by using ImageJ software and Pierson´s 
Coefficient was calculated and detailed colocalization analysis were performed with 
the use of Coloc2 Plugin from Fiji (ImageJ software).  
Statistical tests performed were students-two-tailed t-test, one-way-Analysis of 
Variance (ANOVA) and repeated-measures ANOVA for grouped analysis, followed 
by Dunnet´s or Tukey´s post-hoc tests for multiple comparison.  
Data were expressed as mean ± SEM and a 0.5 % general significance level was 
defined, with significance levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. 
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4.1 UPTAKE OF RECOMBINANT ASYN SPECIES IN 
CULTURED CELLS   
 
4.1.1 ASYN ENTERS H4 CELLS AND FORMS INTRACELLULAR 
INCLUSIONS 
 
Several independent studies demonstrated that aSyn oligomers and pre-formed fibrils 
(PFFs) enter cultured cells and accumulate in the cytoplasm of cells132,134. These 
findings have provided evidence on the spreading capacity of aSyn assemblies. 
However, it is still unclear where aSyn aggregation starts, how it proceeds in these 
models, and how relevant is the interaction of aSyn with membranes in the aggregation 
process.   
In order to investigate the initial steps of the internalization process and aggregation of 
aSyn, we added monomers or fibrillar aggregates (fibrils) of aSyn to the cultured media 
of H4 human neuroglioma cells (Figure 16A).  
First, we produced recombinant aSyn in bacteria and then generated monomeric or 
fibrillar species according to the methods described above. The species were 
characterized by TEM224 and by SDS-Page (Figure 16B). The preparation of aSyn 
monomers showed also the presence of a smaller amount of dimers, as illustrated by 
the band at ~35 kDa. Due to contrasting studies reporting the ability of monomeric 
aSyn to passively enter cultured cells, we tested different concentration (1µM and 5µM) 
of these, while for aSyn fibrils we used the working concentration of 1µM (calculated 
based on the initial concentration of monomeric aSyn).  
Then, recombinant proteins were added to the medium of H4 cells and the 
internalization of the exogenous aSyn into the cells was analysed by immunoblotting 
and by ICC after 24h incubation.  
Immunoblot analysis revealed that exogenous aSyn fibrils can be taken up by cultured 
cells. Surprisingly, the immunoblot clearly showed that monomeric aSyn is uptaken 
by H4 cells as well and that the internalization is dose-dependent (Figure 16C and 
16D). Furthermore, ICC analysis demonstrated that, in cells exposed to monomeric 
aSyn, the protein accumulated in distinct perinuclear puncta, whereas in cells exposed 
to fibrils aSyn accumulated in larger cytosolic inclusions (Figure 16E). 
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Figure 16. Recombinant aSyn monomers and fibrils are internalized by H4 cells. 
(A) Recombinant aSyn monomers (aSyn Mono) or fibrils (aSyn Fibrils) were added to the cell culture medium 
and incubated for 24h. (B) SDS-PAGE and immunoblot analysis of the recombinant monomeric or fibrillar 
species of aSyn used in the experiments. The monomers show also the presence of a small fraction of dimers, 
as displayed by the faint band at 35kDa. In the fibril preparation, one can observe the presence of higher 
molecular weight (aSyn HMW) species that are stable even on an SDS-PAGE. (C) WB of H4 cells after 
treatment with aSyn, confirming the internalization of aSyn monomers or fibrils as seen by the increase in the 
levels of aSyn in cells that were treated with monomers or fibrils. (D) Quantification of the immunoblot. 
Statistical test was performed using one-way ANOVA followed by Tukey´s post-hoc tests.  (E) ICC of cells 
treated using the conditions described. Scale bar: 30µm.    
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4.1.2  ASYN INTERACTS WITH PLASMA MEMBRANE AND FORMS 
HIGH MOLECULAR WEIGHT SPECIES  
 
Whether aggregation of aSyn initiates from its lipid-bound α-helical form or from its 
unstructured state remains controversial. In addition, the relationship between 
membrane binding and aSyn neurotoxicity is still unclear.  
In order to understand whether the uptake of aSyn requires an interaction with the 
plasma membrane, we performed a cell surface biotinylation assay (Figure 17A and 
17B). The biotinylation assay exploits the incubation of living cultured cells with non-
permeable biotin moieties to tag protein domains at the extracellular level or at the 
trans-membrane level. After extensive washing to eliminate the excess unbound biotin 
and cellular solubilisation in dedicated lysis buffer, biotinylated proteins were 
immobilized on a streptavidin-agarose resin and separated from the remaining, 
cytosolic proteins. After cellular lysis, resin capture and elution, two biochemical 
fractions were collected and analysed via WB:  a biotinylated fraction, (containing 
membrane surface proteins and proteins interacting with plasma membrane) and a 
cytosolic fraction. Transferrin receptor and tubulin were used as positive controls for 
the biotinylated and the cytosolic fractions, respectively.  
aSyn was found in the biotinylated fraction of H4 cells treated with monomers or 
fibrils, indicating that the interaction with plasma membrane is required for the uptake 
of exogenously added species in the form of both monomeric and fibrillar aSyn (Figure 
17A and 17B).  
Once internalized in cultured cells, aSyn recombinant proteins are processed through 
some still indeterminate pathway that bring them to cluster in cytoplasmic located, 
punctuated structures, as displayed previously in Figure 16E.  
To further investigate the nature of these inclusions, a dot blot analysis was performed. 
In this case, cell lysates of different conditions (H4 cells untreated (H4 cells NT) as a 
negative control, H4 cells incubated with aSyn monomers (H4 cells Mono) and H4 
cells incubated with aSyn fibrils (H4 cells Fibrils)) were fractionated with the use of 
size-exclusion chromatography (SEC) technique. The collected fractions were then 
transferred in a nitrocellulose membrane and incubated with aSyn Ab. 
Recombinant aSyn monomers were assessed by SEC in parallel, in order to establish 
the elution profile of this form of aSyn (Figure 18A and 18B).  
As expected, the dot blot of H4 cells untreated did not show any positivity to aSyn Ab 
(Figure 18C), whereas H4 cells treated with aSyn monomers show the presence of 
monomeric aSyn - fraction from C1 to C4, black box, Figure 18C - as reported in the 
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chromatogram (Figure 18B).  Interestingly, we could also detect aSyn in the latest 
fractions of the B lane - fractions from B6 to B15, red box, Figure 18C - indicating the 
presence of high molecular weight aSyn species as well.  
Such species were also found in H4 cells treated with aSyn fibrils - fractions from B5 
to B11, red box – while we could not detect any presence of monomeric species in this 
last one. (Figure 18C).  
To further confirm the biochemical difference observed, we performed differential 
fractionation of the cell lysates using Triton X-100. Immunoblot analysis showed 
higher levels of Triton X-100-soluble aSyn in cells treated with monomers, and higher 
levels of Triton X-100-insoluble aSyn in cells treated with fibrils, consistent with the 
results of the SEC analysis (Figure 18D, left side). We also detected the formation of 
insoluble, high molecular weight aSyn species in cells treated with monomeric aSyn, 
suggesting that, upon internalization, aSyn monomers start to  aggregated , to create 
high molecular species and to get insoluble (Figure 18D, right side). The presence of a 
smear on the sample treated with aSyn fibrils confirm the previous observation and 
reflect the insoluble character of the fibrils (Figure 18D).  
Taken together, these results suggest that both monomeric and fibrillar aSyn can enter 
H4 cells and form high molecular weight species.  
  
Figure 17. aSyn associates with membranes during the internalization process in H4 cells.  
(A) Immunoblot of the biotinylation assay of H4 cells treated with aSyn monomers or fibrils. (B) Quantification 
of the levels of aSyn present in the biotinylated fraction (membrane-associated aSyn). Statistical test was 
performed using one-way ANOVA followed by Tukey´s post-hoc test. 
  Results 
 
65 
 
Figure 18. aSyn forms high molecular weight species in H4 cells.  
(A) Protein separation scheme on Superose 6 10/300 column (B) Chromatogram of recombinant aSyn 
monomeric protein by using a Superose 6 10/300 column 
(C) Dot blot of the cell lysate of H4 cells untreated as a control, H4 cells treated with 1µM aSyn monomers and 
H4 cells treated with 1µM aSyn fibrils. The black rectangle highlights the presence of monomeric aSyn, located 
in the corresponding fraction after SEC, while the red boxes highlight the presence of high molecular weight 
species of aSyn. (D) Triton X-fractionation, with the soluble fraction (left panel) and the insoluble fraction (right 
panel) of H4 cells treated as described. 
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4.2 RAB-GTPASE PROTEINS MODULATE ASYN 
INTERNALIZATION AND AGGREGATION   
 
 
After confirming that exogenously added recombinant aSyn can be uptaken by H4 cells 
and interact with the plasma membrane, we investigated membrane trafficking 
machinery pathways that could potentially be involved in the process of 
internalization. 
We then performed a screen of mammalian RAB-GTPase family proteins (RABs) to 
evaluate their effects on aSyn aggregation. The analysis was performed by 
overexpressing each one of the different RABs fused to GFP (Rab-GFP) (Table 2) in 
cultured cells. The day after transfection, H4 cells were treated with aSyn monomers 
or fibrils and, 24h later, were processed for ICC. 
From the initial analysis, a set of RABs that showed changes either in their subcellular 
localization or in the cellular interaction with aSyn recombinant protein was selected 
and further analysed (Table C).  
As previously explained, the activity of RABs is regulated by guanine nucleotide 
exchange factors (GEFs), which catalyse the substitution of GDP for GTP and mediate 
their activation, and GTPase activating proteins (GAPs), which stimulate the intrinsic 
RABs activity, leading to their inactivation. Inactive, prenylated RABs bind to 
Guanine nucleotide dissociation inhibitors (GDIs) which keep them in a soluble state, 
in the cytosol, whereas the GDI displacement factors (GDFs) protein catalyse their 
dissociation from GDIs and their subsequent delivery to specific subcellular 
membranes225. Therefore, increase in the activity of RABs correspond to an increase in 
the membrane-bound, active state of the proteins, whereas an increased cytosolic, 
diffused localization pattern will reflect the inactive state of the protein.  
After a screening performed on the mammalian RABs, we displayed how the presence 
of aSyn monomers or fibrils can influence the distribution of selected RABs (Table C).    
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TABLE C. Selected RABs from the screen.          
RAB-GTPase family members selected in a screen where we assessed alterations in the subcellular distribution 
of the RAB protein or the colocalization with aSyn in cells treated with aSyn monomers or fibrils. In the column 
“morphology”, an “11% more RAB-vesicles” statement means that in the 11% of the cells analysed, the 
localization of RABs is more vesicular (suggesting an increase of 11% in the active, GTP-bound RAB protein) 
compared to the localization pattern shown in naïve cells. In contrast, the statement “15% more cytosolic RAB” 
indicates that, in this case, 15% of the cells analysed showed an increase in the cytosolic, diffuse localization of 
RAB protein when compared to the naive cells (suggesting an increase of 15% in the inactive, GDP-bound 
RAB protein). 
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4.2.1 ASYN  PARTIALLY COLOCALIZES WITH RAB 5A AND RAB 7  
 
The data from our screen revealed that, among the selected RABs, the ones that 
show the strongest colocalization with aSyn or changes in the morphology are Rab 
4A, Rab 5A and Rab 7, especially if we consider their interaction with monomeric 
aSyn more than with the fibrillar species (Table C).  
This findings match very well with the hypothesis that aSyn is internalized via an 
active process and that get processed inside the cells in vesicular compartments 
such as endosomes and lysosomes, especially if we consider the localization and 
function of the above-mentioned RABs members162 (Table A) .    
Rab 4A and Rab 5A are localized in the early endosome, contributing to the 
protein recycling/transport to the plasma membrane and early endosome fusion, 
respectively, while Rab 7 is localized in the late endosome, lysosome and 
phagosome, contributing to the late endosome to lysosome fusion process. 
We then analysed the results obtained from the first screening in greater detail.  
First, we assessed the degree of colocalization of aSyn and Rab5A-GFP or Rab7-
GFP in cells treated with aSyn monomers or fibrils (Figure 19A). The 
colocalization was quantified using the Coloc2 plugin of ImageJ Software (Figure 
19B).  
We observed a strong colocalization between the aSyn-positive inclusions formed 
after the treatment with aSyn monomers (in red) and Rab 5A-GFP vesicles (in 
green) (Figure 19A, left column, central panel), as well as a partial – although 
weaker - colocalization of the aSyn newly formed aSyn inclusions with Rab 7-GFP 
(Figure 19A, right column, central panel ). On the other side, the colocalization 
was not observed when cells were treated with aSyn fibrils. This supports the idea 
that the internalization and sorting of aSyn monomers and fibrils is different, as 
one might expect given their distinct biochemical properties.  
The Pearson´s coefficients obtained from the analysis of several samples show that 
aSyn monomers, but not aSyn fibrils, once internalized, give rise to inclusions that  
partially colocalize with Rab 5A-GFP and with Rab 7-GFP, indicating that the 
endocytic pathways, as well as the lysosomal one are involved in the 
internalization of aSyn monomers (Figure 19B).  
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Figure 19. aSyn partially colocalizes with Rab 5A-GFP and Rab 7-GFP in H4 cells .  
(A) ICC on H4 cells transfected with Rab 5A-GFP (right side of the panel) or with Rab 7-GFP and treated with 
1µM aSyn monomers or 1µM aSyn fibrils. (B) Pearson correlation coefficient confirming colocalization of aSyn 
with Rab 5A or Rab 7 in cells treated with aSyn monomers, but not with fibrils. Scale bar: 30µm 
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4.2.2 ASYN FORMS INCLUSIONS SURROUNDED BY RAB 4A 
POSITIVE VESICLES 
 
Next, we examined more in details the colocalization and the morphological 
changes of Rab 4A-GFP in the presence of aSyn recombinant proteins.  
On the early endosomal membrane Rab 4 and Rab 5 occupy distinct domains, 
where Rab 5 marks the cisternal domain and Rab 4 concentrates in patches that 
undergo fission from the cisternae, called tubular domains. These tubular 
subdomains are highly dynamics, giving rise to multiple classes of carrier vesicles 
that are targeted to different destinations226.  
Based on the ICC results obtained, when H4 cells are transfected with Rab 4A-
GFP and treated with aSyn fibrils, no effects on the morphology of the small 
GTPase protein, neither colocalization with aSyn can be appreciated (Figure 20). 
On the other side, when H4 cells are transfected with Rab 4A-GFP and treated 
with aSyn monomers, it is possible to observe a dramatic increase in the endosome 
size, as well as a massive internalization of aSyn monomers, that accumulate in 
inclusions surrounded by those big, abnormal Rab 4A positive vesicles (Figure 20, 
central panel on the top and lower panels).  
We found that the internalization of aSyn monomers is increased by the 
overexpression of Rab 4A, and that when aSyn monomers are added to cells, aSyn 
forms inclusions surrounded by Rab 4A. We also observed a drastic change in the 
morphology of Rab 4A positive vesicles, and therefore of the early endosome size, 
suggesting that the exposure to aSyn monomers altered the normal biology of 
Rab4A and, therefore, the early endocytosis- related process and vesicle formation.  
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4.3 ASYN MEMBRANE BINDING PROPERTIES  
 
Considering the results obtained, we decided to focus on treatments with aSyn 
monomers in order to further study the interaction with membrane at a molecular and 
structural level.  
 
4.3.1  MEMBRANE BINDING PROPERTIES ARE ESSENTIAL FOR THE  
INTERNALIZATION AND THE INCLUSIONS FORMATION OF 
ASYN IN H4 CELLS  
 
Recent findings support the hypothesis that aSyn multimerizes on lipid membranes53, 
and this raised the question whether such α-helical assemblies directly convert into β-
strand containing neurotoxic properties or whether it is the unstructured, soluble aSyn 
monomeric species that actively trigger the formation to aggregates inside cells, during 
the processing and the compartmentalization in different organelles and the interaction 
with effector proteins.  
Figure 20. aSyn forms inclusions surrounded by Rab 4A positive vesicles in H4 cells  
ICC on cells transfected with Rab 4A-GFP and treated with 1µM of aSyn monomers or fibrils. Inset: zoom and 
separated channels of Rab 4A-GFP aSyn. Arrows point to the large inclusions aSyn (in red, panel on the right) 
matching with the GFP-positive Rab 4A vesicles (in green, panel on the left). Scale bar: 30µm 
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Our findings support the second hypothesis, suggesting that monomeric aSyn, once 
internalized, start to accumulate in endosomal compartments and to form high 
molecular weight species.  
In order to address this central question, we analyzed the rate of internalization of 
different aSyn mutants that have altered membrane binding properties. In particular, 
we used the aSyn A30P familial mutant, known to display weaker binding to 
membranes, and an artificial mutant (A11P/V70P) designed to severely impair 
membrane binding227,228.  
To assess the ability of the different aSyn variants to bind to the plasma membrane, we 
performed a biotinylation assay (Figure 21A and 21B). We detected a clear trend in 
the amount of protein present in the biotinylated fractions that reflected the different 
membrane binding properties of the aSyn mutants (aSyn A30P and aSyn A11P/V70P). 
We also detected a consistent trend in the levels of aSyn dimeric species in the 
biotinylated fraction, suggesting that membrane binding is also important for 
dimerization and aggregation of aSyn.   
Next, we tested the ability of the three different mutants to enter cells and to form 
inclusions, via ICC (Figure 21C) and immunoblotting analysis (Figure 21D and 21E).  
The ICC revealed a significant reduction in the accumulation of aSyn in inclusions in 
cells treated with A30P or A11P/V70P aSyn mutants when compared with cells 
treated with WT (Figure 21C), consistent with a difference in the internalization of the 
mutants.  
The immunoblot analysis allowed us to further quantify the internalization of this 
different monomeric aSyn species, showing that despite they preserve the ability to 
partially dimerize when purified in vitro, , their ability to get uptaken in cultured cells 
is drastically reduced (Figure 21D, low panel).  
Taken together, these results suggest that membrane binding properties are essential 
for the internalization, and therefore, for the formation of intracellular aSyn inclusions 
in cultured cells.  
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Figure 21. Membrane binding is essential for the internalization and inclusion formation of aSyn in H4 
cells.                      
(A and B) Immunoblot and quantification of the comparison of WT aSyn and two mutants (A30P and 
A11P/V70P) with different membrane-binding properties using a biotinylation assay. Dotted bars refer to the 
band corresponding to aSyn dimers (aSyn**), and clear bars refer to aSyn monomers (aSyn*). (C) ICC and (D) 
immunoblotting of non-treated (NT) cells, or cells treated with WT, A30P, or A11P/V70P aSyn for 24h. Scale 
bar: 30µm. (E) Quantification of the immunoblot in panel D. Dotted bars refer to the band corresponding to 
aSyn dimers (aSyn**), and clear bars refer to aSyn monomers (aSyn*). Statistical tests were performed using 
one-way ANOVA with repeated-measures for grouped analysis, followed by Tukey´s post-hoc tests. Data were 
expressed as mean ± SEM and a 0.5 % general significance level was defined, with significance levels as follows: 
*: p < 0.05; **: p < 0.01; ***: p < 0.001. Statistical significance is indicated with the symbol “#” for the 
monomers, “+” for the dimers, and “*” for the summa between monomers and dimers.  
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4.3.2  ASYN A11P/V70P IS UNABLE TO BIND MEMBRANES  
 
Since the discovery of the A30P familial mutation, various groups have extensively 
studied the effect of the mutation on the biochemical and biophysical properties of the 
protein.  
The A11P/V70P artificial mutant was designed as a lipid-binding deficient mutant, 
but has only been studied in vitro, not in cell models.  
First, we confirmed the previous findings and performed an in vitro membrane binding 
assay using small unilamellar vesicles (SUVs), and then we tested the ability of the 
mutant to get internalized and form inclusion by adding different amounts of 
A11P/V70P to H4 cells (Figure 22).  
We generated SUVs from a 5:3:12 mixture of DOPE:DOPS:DOPC.  
NMR spectroscopy revealed that aSyn interacted with DOPE:DOPS:DOPC 
liposomes as previously described229,230 (Figure 22A, panel on the left).  In contrast to 
aSyn WT, the aSyn A11P/V70P mutant induced a drastic reduction (more than 80%) 
of the signal broadening starting from the residue 11 (where the first Pro mutation is 
located) until residue 140 (Figure 22A, panel on the right), confirming the impairment 
in membrane binding. 
Next, we tested the effect of aSyn A11P/ V70P in our cellular model. To do this, we 
tested different concentration of aSyn A11P/V70P (1µM and 5µM) and we compared 
this with aSyn WT (1µM and 5µM). We also used H4 cells transfected with Rab 4A-
GFP, as we observed an increased internalization of aSyn in these cells.  
As it is clearly shown from the immunoblot analysis (Figure 22B and 22C), as well as 
from the ICC (Figure 22D), we observed that the internalization of aSyn WT and the 
formation of inclusions are dose-dependent, and that these are further increased upon 
overexpression of Rab 4A.  
On the other side, the internalization of aSyn A11P/V70P was negligible when 
compared to aSyn WT, and did not increase with higher concentrations nor with the 
overexpression of Rab 4A-GFP.  
The results obtained confirm that aSyn A11P/V70P is a valid model to test the effect 
of membrane binding on the internalization and inclusion formation of aSyn proteins 
in cultured cells.  
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Figure 22. Characterization of aSyn A11P/V70P mutant.                          
(A) Membrane binding properties of WT (left) and of A11P/V70P aSyn (right) in the presence of artificial small 
unilamellar vesicles membranes (SUVs) [1:100 protein:SUVs ratio]. (B) Immunoblotting of Rab 4A-GFP-
expressing cells treated with 1µM or 5µM of WT or A11P/V70P aSyn. (C) Quantification of the immunoblots. 
Dotted bars refer to the band corresponding to aSyn dimers (aSyn**), and clear bars refer to aSyn monomers 
(aSyn*). Statistical tests were performed using one-way-analysis of variance (ANOVA) with repeated-measures 
for grouped analysis, followed by Tukey´s post-hoc tests. Data were expressed as mean ± SEM and a 0.5 % 
general significance level was defined, with significance levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 
0.001. The significance is showed with the symbol “#” for the monomers, with the symbol “+” for the dimers 
and with the symbol “*” for the summa between monomers and dimers. (D) ICC of H4 cells transfected with 
Rab 4A-GFP and treated with 1µM or 5µM of aSyn WTand aSyn A11P/V70P.  Scale bar: 30µm. 
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4.3.3    ASYN A30P AND ASYN A11P/V70P ARE LESS 
INTERNALIZED IN  RAB 4A AND RAB 5A TRANSFECTED 
CELLS  
 
In order to further investigate whether the membrane binding properties of aSyn could 
affect not only in the internalization but also the processing and metabolism of the 
protein via the endocytic pathway, we tested the ability of the three different mutants 
to get internalized in cells overexpressing either Rab 4A-GFP or Rab 5A-GFP.  We 
also tested our aSyn recombinant monomers in H4 cells transfected with a 
constitutively active (CA) form of Rab 5A-GFP (Rab 5ACA-GFP) so to explore 
whether a further deregulation of the endocytic pathway could somehow help or 
overcome the lack of binding properties of these aSyn mutant forms (Figure 23).  
The ICC of H4 cells transfected with Rab 4A-GFP  show a massive internalization of 
aSyn WT, giving rise to these characteristic big inclusions surrounded by Rab 4A 
positive vesicles as already described, and a significant, progressive decrease of the rate 
of internalization of aSyn A30P and aSyn A11P/V70P (Figure 23A and 23B). 
Curiously, the amount of monomeric forms versus dimeric forms internalized in this 
case is higher than the one showed from the not-transfected H4 cells (Figure 21D and 
21E) as well as from the one showed by H4 cells transfected with Rab 5A-GFP, to 
possibly indicate the effect that the overstimulation of the tubular subdomain can have 
in the vesicle formation and in the protein internalization at plasma membrane level.  
The same trend, although with less significance, is observed in the ICC of H4 cells 
transfected with Rab 5A-GFP indicating, once again, that the overexpression of Rab 
5A (as well as of Rab 4A) and the consequential overstimulation of the early steps of 
the endosome formation can surely improve the amount of aSyn internalized, but only 
if the membrane binding properties of the protein are preserved (Figure 23C and 23D). 
In cells overexpressing Rab 5A, we observed an increase in the levels of aSyn dimeric 
species, to indicate the possible role played by endosomes in the dimerization process 
and aSyn aggregation formation.  
Finally, we analysed the rate of internalization of aSyn mutants in H4 cells transfected 
with Rab 5ACA-GFP (Figure 23E and 23F). As in this case the GTPase protein Rab 
5A is deregulated, resulting in a permanent activation, the amount of aSyn internalized 
results to be higher compared to the one observed in H4 cells transfected with Rab 5A, 
further confirming the role of the endocytic pathway in the internalization and 
processing of aSyn. 
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Figure 23. aSyn A30P and A11P/V70P are less internalized in Rab 4A-GFP, Rab 5A-GFP  and Rab 5ACA-
GFP  transfected cells compared to aSyn WT.               
(A) ICC and (B) Immunoblotting of cells transfected with Rab 4A–GFP and treated as in Figure 5. (C and D) 
ICC and Immunoblotting of cells transfected with Rab 5A-GFP and treated as above. (E and F) ICC and 
Immunoblotting of cells transfected with Rab 5ACA-GFP (constitutively active) and treated as above. (B, D 
and F, lower panels) Quantifications of the immunoblots. Dotted bars refer to the band corresponding to aSyn 
dimers (aSyn**), and clear bars refer to aSyn monomers (aSyn*). Statistical tests were performed using one-way 
ANOVA with repeated-measures for grouped analysis, followed by Tukey´s post-hoc tests. Data were expressed 
as mean ± SEM and a 0.5 % general significance level was defined, with significance levels as follows: *: p < 
0.05; **: p < 0.01; ***: p < 0.001. Statistical significance is indicated with the symbol “#” for the monomers, 
“+” for the dimers, and “*” for the summa between monomers and dimers. Scale bar: 30µm 
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4.3.4   OVEREXPRESSION OF RAB 7 REDUCES THE FORMATION OF 
DIMERS IN CELLS TREATED WITH ASYN WT 
 
Next, we investigated the fate of aSyn along the endocytic pathway by using Rab 7 as 
a marker.   
H4 cells were then transiently transfected with Rab 7-GFP or with a dominant negative 
(DN) form of Rab 7 (Rab 7DN-GFP), treated with aSyn WT, aSyn A30P or aSyn 
A11P/V70P, and analysed by ICC and immunoblotting. 
The overexpression of Rab 7 notably decrease the amount of internalized aSyn 
monomeric proteins, as well as the formation of dimers in H4 cells treated with aSyn 
WT, bringing the level of internalized aSyn WT close of the ones showed by H4 cells 
treated with aSyn A30P and with aSyn A11P/V70P (Figure 24A and 24B).  
A possible explanation is that, by overexpressing Rab 7 and, therefore, the lysosomal-
related activity, the exogenously added and internalized aSyn got degraded faster and 
more efficiently, levelling out the differences previously reported and related to a more 
effective internalization of the wild-type form of the protein compared to the mutants, 
so to show finally a base level of internalization similar in all the three different 
conditions.  
The use of the mutated, dominant negative form of Rab 7 further support this 
hypothesis, showing that when transfected with a Rab 7DN-GFP, the levels of 
internalization, the dimerization and the consequential inclusion formation abilities 
are rescued in H4 cells treated with aSyn WT, and that the overexpression of Rab 7DN 
does not affect the degradation of internalized aSyn monomeric proteins (Figure 24C 
and 24D). 
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Figure 24. Rab 7 decreases the formation of dimers in H4 cells treated with aSyn WT monomers.       
(A) ICC and (B) Immunoblotting of H4 cells transfected with Rab 7-GFP and treated as described above. (C 
and D) The overexpression of the Rab 7 dominant negative (DN) does not affect the degradation of the 
internalized aSyn. (B and D, lower panel) Quantifications of the immunoblots. Dotted bars refer to the band 
corresponding to aSyn dimers (aSyn**), and clear bars refer to aSyn monomers (aSyn*). Statistical tests were 
performed using one-way ANOVA with repeated-measures for grouped analysis, followed by Tukey´s post-hoc 
tests. Data were expressed as mean ± SEM and a 0.5 % general significance level was defined, with significance 
levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. The significance is showed with the symbol “#” for 
the monomers, with the symbol “+” for the dimers and with the symbol “*” for the summa between monomers 
and dimers. Scale bar: 30µm 
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4.4 THE ENDOCYTIC PATHWAY AND THE ALP 
ARE INVOLVED IN THE PROCESSING OF ASYN 
 
 
4.4.1 THE INTERNALIZATION OF ASYN IS MEDIATED BY DYNAMIN  
 
We then investigated the endocytic mechanism involved in the internalization of aSyn 
by using two different blockers of endocytosis: PitStop2 (PitStop) and Dyngo 4A 
(Dyngo).  
Pitstop is a novel, selective inhibitor of clathrin terminal domains that interferes with 
receptor-mediated endocytosis and impedes clathrin-mediated endocytosis (CME) by 
blocking the clathrin-coated pit dynamics at several different steps of the process231,232. 
Dyngo is a structural analogue of Dynasore with improved efficiency, and is an 
optimal candidate for the cure of various diseases (i.e., botulism) related to dynamin-
dependent mechanism. Dyngo inhibits CME as well, but it was also reported that 
prevents SNAP25 cleavage, reduces synaptic vesicle endocytosis and activity-
dependent bulk endocytosis in cultured neurons and synaptosomes233.  
For each chemical, we tested two different concentrations, based on what is reported 
in literature. For Pitstop, we used 30µM and 60µM, and for Dyngo, 10µM and 50µM. 
H4 cells, or H4 cells overexpressing Rab 4A-GFP were treated with the selected 
concentrations of the chemicals for 30 min before the treatment with aSyn monomers, 
then incubated for 24h at 37ºC, following the same procedure and the same timing of 
the previous experiments. At the end of the treatment, WB and ICC analysis were 
performed in order to detect possible changes in the internalization rate.  
In cells overexpressing Rab 4A, Dyngo effectively prevented the internalization and 
accumulation of aSyn in Rab 4A-surrounded vesicles. In contrast, PitStop failed to 
produce a significant effect (Figure 25A and 25B). Curiously, in H4 cells that do not 
overexpress Rab 4A, we confirmed the efficacy of Dyngo on blocking the 
internalization of aSyn. Instead, we observed the opposite effect using PitStop: from 
the quantification of the mean fluorescence intensity of the ICC (Figure 26B) and from 
the immunoblotting analysis (Figure 26C and 26D), we found that not only PitStop 
did not block the internalization of aSyn but it even stimulated it, increasing the 
accumulation of intracellular aSyn.  
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This could be related to a possible compensatory mechanisms: when clathrin-mediated 
process are blocked (PitStop- related effect), the clathrin-independent processes (such 
as synaptic vesicle endocytosis and activity-dependent bulk endocytosis) are 
exacerbated, and therefore, more aSyn is internalized. We can speculate that such a 
mechanism was mitigated by the overexpression of Rab 4A-GFP in the previous 
experiment, and therefore, was not possible to observe it so clearly.  
Figure 25. Dyngo effectively prevents the internalization of aSyn in H4 cells overexpressing Rab 4A, 
whereas PitStop does not have a significant effect.  
(A) ICC on H4 Rab 4A-GFP cells, treated with 1uM aSyn monomers and with PitStop 30µM or with Dyngo 
50µM. Both of them are inhibitors of the endocytic processes. (B) Quantification of the aSyn mean fluorescence 
intensity in the three condition reported above. Scale bar: 30µm 
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Figure 26. Dyngo effectively prevents the internalization of aSyn in H4 cells, whereas PitStop has the 
opposite effect.  
(A) ICC of H4 cells treated with 1µM aSyn monomers and with vehicle, PitStop 30µM or with Dyngo 50µM. 
Both PitStop and Dyngo are inhibitors of the endocytic processes. (B) Quantification of the aSyn mean 
fluorescence intensity in the three conditions. (C) Immunoblotting of H4 cells treated with different 
concentrations of PitStop and Dyngo. (D) Quantification of the immunoblot. Dotted bars refer to the band 
corresponding to aSyn dimers (aSyn**), and clear bars refer to aSyn monomers (aSyn*). Statistical tests were 
performed using one-way-analysis of variance (ANOVA), with repeated-measures for grouped analysis, 
followed by Tukey´s post-hoc tests. Data were expressed as mean ± SEM and a 0.5 % general significance level 
was defined, with significance levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. The significance is 
showed with the symbol “#” for the monomers, with the symbol “+” for the dimers and with the symbol “*” 
for the summa between monomers and dimers. Scale bar: 30µm 
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4.4.2  IMPAIRMENT OF AUTOPHAGY INHIBITS THE DEGRADATION 
OF ASYN 
 
Next, we tested whether an impairment of the ALP could have effect on the 
degradation of aSyn, to further explore the results obtained from the overexpression of 
Rab 7-GFP and Rab 7DN-GFP and their interaction with the internalized aSyn. For 
this, we used two different inhibitors of the autophagy/lysosome activity: Bafilomycin 
and Chloroquine.  
Bafilomycin is an inhibitor of the late phase of autophagy. It prevents the maturation 
of autophagic vacuoles preventing the fusion between these and the lysosomes, due to 
the impairment of the vacuolar H+ ATPase (V-ATPase). Chloroquine inhibits 
autophagy as well as it raises the lysosomal pH and this leads to inhibition of both 
fusion of autophagosome with lysosome and lysosomal protein degradation. 
Also in this case, two different concentrations were tested for both the chemicals: for 
Bafilomycin 100nM and 200nM, while for Chloroquine 50µM and 100 µM.  
H4 cells, or H4 cells overexpressing Rab 7-GFP were treated with the selected working 
concentrations 30 min before the inoculation with aSyn monomers, then incubated for 
24h as previously described. 
The ICC analysis  and the corresponding quantification of the mean fluorescence 
intensity of aSyn  showed that the impairment of the autophagy processes via both 
Bafilomycin and Chloroquine strongly inhibited the degradation of aSyn monomers in 
H4 cells transfected with Rab 7-GFP (Figure 27). 
The same results are observed in H4 cells that do not overexpress Rab 7-GFP (Figure 
28, A to D).  
It is worth to note that when treated with Chloroquine, the accumulation of aSyn was 
higher than that observed with Bafilomycin.  This can be attribute to the fact that 
Chloroquine not only inhibits the fusion to the autophagosomes with lysosomes in the 
same way that Bafilomycin do, but also impedes the degradation of those proteins that 
are already accumulating within the lysosomes.  
Taken together, these results suggest that aSyn internalized proteins are internalized 
via the endocytic pathway, processed and then degraded via the autophagy-lysosomal 
degradation system.   
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Figure 27. Impairment of autophagy inhibits degradation of aSyn in H4 cells transfected with Rab 7-GFP.  
(A) ICC of Rab 7-GFP-expressing cells treated with 1µM aSyn monomers and with vehicle, Bafilomycin 100nM 
(Baf 100nM), or with Chloroquine 50µM (Chlq 50µM). Both of them are inhibitors of the ALP. (B) 
Quantification of the aSyn mean fluorescence intensity in the three condition reported above. Scale bar: 30µm 
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Figure 28. Impairment of autophagy inhibits the degradation of aSyn in H4 cells.  
(A) ICC of H4 cells treated with 1µM aSyn monomers and with vehicle, Bafilomycin 100nM (Baf 100nM), or 
with Chloroquine 50µM (Chlq 50µM). Bafilomycin and chloroquine are inhibitors of the ALP. (B) 
Quantification of the aSyn mean fluorescence intensity in the three condition. (C) Immunoblotting of H4 cells 
treated with 1µM aSyn WT and incubated with Bafilomycin 100nM or Chloroquine 50µM. (D) quantification 
of the immunoblot in panel C. Dotted bars refer to the band corresponding to aSyn dimers (aSyn**), and clear 
bars refer to aSyn monomers (aSyn*). Statistical tests were performed using one-way-analysis of variance 
(ANOVA), with repeated-measures for grouped analysis, followed by Tukey´s post-hoc tests.Data were 
expressed as mean ± SEM and a 0.5 % general significance level was defined, with significance levels as follows: 
*: p < 0.05; **: p < 0.01; ***: p < 0.001. The significance is showed with the symbol “#” for the monomers, 
with the symbol “+” for the dimers and with the symbol “*” for the summa between monomers and dimers. 
Scale bar: 30µm 
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4.5 BIOPHYSICAL CHARACTERIZATION OF SYNT 
 
 
The mechanisms triggering aSyn aggregation are still not clear, nor the precise 
relationship between aSyn aggregation and neurotoxicity. Moreover, aSyn aggregates 
are polymorphic, ranging from soluble oligomeric forms, to ring- or string-like 
oligomers, spherical-shaped protofibrils, and insoluble fibrils. Currently, oligomeric 
forms of aSyn are hypothesized to be the most cytotoxic forms of the protein, rather 
than mature fibrillar aggregates. In this section of the results we report the results 
obtained from the structural characterization of a C-terminal modified form of aSyn, 
SynT, which renders aSyn more prone to aggregation in cell models.  
 
 
4.5.1 C-TERMINALLY MODIFIED ASYN FORMS INCLUSIONS IN         
H4 CELLS  
 
As previously described, truncations and C-terminal modifications of aSyn alter its 
propensity to aggregate. In particular, expression of SynT in H4 cells resulted in the 
formation of cytosolic inclusions that exhibit LB-like properties (Figure 29A-B)208. 
Inclusion formation is potentiated by the co-expression of SynT together with 
Synphilin-1, an interactor of aSyn also present in LBs and LNs, as extensively 
described by several groups213,214,234. In contrast, co-expression of untagged aSyn with 
Synphilin-1 did not form discrete inclusions (Figure 29B), suggesting that 
modifications in the C-terminal region alters the aggregation properties of aSyn.  
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Figure 29. C-terminal modified aSyn (SynT) forms inclusions in H4 cells.               
(A) Schematic representation of the structure of human aSyn highlighting the N-terminal (N-term), NAC (NAC) 
and C-terminal (C-term) regions of the protein. Amino acid residue numbers are indicated for aSyn and for SynT. 
(B) aSyn distribution in cells transfected with aSyn, SynT and SynT/Synphilin-1. In cells transfected with aSyn, or 
with aSyn and Synphilin-1, aSyn is diffusely distributed throughout the cell. In contrast, in cells transfected with 
SynT, or with SynT and Synphilin-1, aSyn forms inclusions of various sizes and morphologies.  
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4.5.2 THE INTRINSICALLY DISORDERED NATURE OF ASYN IS NOT 
INFLUENCED BY THE C-TERMINAL MODIFICATION IN SYNT  
 
To analyse the impact that the C-terminal modification in SynT might have on the 
structural features of aSyn, we employed NMR spectroscopy to assess structural 
features of recombinant aSyn and SynT proteins. 
To investigate the molecular dynamics of SynT we produced N-terminally acetylated 
forms of recombinant aSyn and SynT, which we used for in vitro studies.  
Prior to NMR measurements, we analysed the recombinant SynT by SDS-PAGE and 
by gel-filtration chromatography (Figure 30A and 30B), confirming that the modified 
protein was efficiently expressed and purified from the soluble fraction. First, a two-
dimensional 1H-15N heteronuclear single quantum coherence (HSQC) spectrum of a 
100 µM sample of uniformly 15N-labeled SynT in buffer B (MES 20 mM, NaCl 100 
mM pH 6.5) was recorded at 15 °C (Figure 31A). The NMR spectrum of SynT retains 
the excellent resolution of the unmodified aSyn native protein. The resonances are 
defined and well resolved, with a limited dispersion of chemical shifts that reflect the 
unfolded, disordered nature of the protein and the mobility´s degree of the backbone. 
The overlaid spectra of SynT and aSyn demonstrate that the SynT protein remains 
intrinsically disordered upon the C-terminal modification with the EGFP fragment 
(Figure 31A). Notably, although backbone chemical shift changes were observed in a 
discrete number of residues located in the vicinity of the EGFP fragment at the C-
terminal region of the protein, small but measurable chemical shift changes became 
also evident in the region of amino acids 1-10, far from the C-terminus (Figure 31B). 
Finally, we observed that only a small number of new resonances appeared in the SynT 
construct compared to aSyn, likely belonging to the first residues of the EGFP 
fragment fused to aSyn. The rest of the signals corresponding to the EGFP fragment 
are likely broadened beyond detection. To gain insight into the secondary structure of 
the EGFP fragment, we registered the far-UV CD spectra of aSyn and SynT (Figure 
31C). While the spectrum of the untagged protein clearly reflected the intrinsically 
disorder nature of the protein, we found that the SynT presented a substantial change 
in the CD spectra. In addition to the deep minimum at ~198 nm, a minimum around 
220 nm appeared, which is characteristic of β–sheet secondary structural elements 
(Figure 31C). In fact, when subtracting the random coil component measured for aSyn 
in the same conditions, we observed a pure β-sheet signature, likely reflecting the 
conformational features of the EGFP truncated tag, which is expected to be rich in β-
barrel elements according to the 3D structure of full-length EGFP235. 
Results 
 
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Biophysical characterization of SynT.        
(A) Comassie staining of purified aSyn and SynT loaded in PAGE-SDS 12%. (B) Size 
Exclusion Chromatography profiles of aSyn (blue) and SynT (red).  
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Figure 31. NMR characterization of SynT.               
(A) Overlaid 2D 1H -15N HSQC NMR spectra of aSyn (100µM) in blue and SynT (100µM) in red. Boxed cross-
peaks indicate additional SynT signals, most likely from the flexible linker region and the first amino acids of 
the tag. (B) Mean weighted 1H-15N chemical shift perturbation plot of SynT versus aSyn. (C) CD spectra of 
aSyn (blue) and SynT (red). Inset shows the SynT-aSyn difference spectra featuring the β-sheet rich spectra for 
the tag. All NMR experiments were recorded at 15oC using aSyn and SynT samples dissolved in buffer B 
supplemented with 10 % D2O. (D) SynT/aSyn NMR signal intensity ratios. Signal attenuation was observed 
at the N-terminus and the C-terminal residues that are proximal to the EGFP fragment 
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4.5.3 TRANSIENT INTERACTIONS BETWEEN THE N- AND THE C-
TERMINAL REGIONS ARE STRENGTHENED IN SYNT 
 
The anchoring of the truncated EGFP segment at the C-terminus of aSyn in SynT 
resulted in chemical shift changes for resonances in the vicinity of the C-terminus 
(Figure 31B). In addition, chemical shift changes were detected for a discrete number 
of residues located at the N-terminus. To obtain further information about a potential 
role of the N-terminus of SynT, we analysed the 1H-15N HSQC intensity profile of SynT 
and compared it to that of aSyn, which is not C-terminally extended by the EGFP 
fragment (Figure 31D). The comparison showed that NMR signal intensities are 
decreased most strongly at the N-terminus of SynT and steadily increase up to and 
through the NAC region until values similar to aSyn are found for residues 80-120. 
The steady increase is interrupted for residues 38-41, next to the aromatic residue 
Tyr39. Beyond residue 120, NMR signal intensities strongly decreased towards the 
attached EGFP fragment, most likely due to an increase in rotational correlation time 
caused by the EGFP fragment.    
These observations led us to evaluate SynT conformation and its dynamic properties. 
First, we measured an almost complete set of 3JHN-H couplings in aSyn and SynT states, 
in order to have quantitative and reliable information of the time-averaged distribution 
of the backbone torsion angles 219,236.  As shown in Figure 32A, the values measured 
for the two forms of the protein are essentially indistinguishable, indicating that the C-
terminal modification with the EGFP fragment in the SynT form did not influence the 
local conformational propensities adopted by untagged aSyn. 
Next, we evaluated the molecular dynamics properties of SynT. To this end, we 
measured 15N R1 and R2 spin relaxation rates and heteronuclear (1H-15N) steady-state 
NOEs (hetNOEs), which are sensitive to protein motions on multiple time scales. This 
set of experiments was first performed on untagged aSyn at a 1H spectrometer 
frequency of 600 MHz. In agreement with previous results237, R1 values ranged between 
1.3 and 1.7 s-1, R2 values between 2.0 and 3.5 s-1, and hetNOEs in the range 0 to -0.3 
(Figure 32B, 32C and 32D), with lower values observed at the termini and in the NAC 
region. The attachment of the EGFP fragment to aSyn resulted in no significant 
changes in the R1 and hetNOEs values, with the exception of the very terminal 
residues. However, pronounced deviations were observed for the R2 relaxation rates 
(Figure 32C). Consistent with the profile of intensity ratios (Figure 31D), R2 rates were 
increased for the N-terminal half of the aSyn sequence, when the EGFP fragment was 
attached at the C-terminus, which also experienced increased transverse relaxation. 
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Whereas increased R2 rates at the C-terminus can be connected to slower rotational 
tumbling of the β-structure containing EGFP fragment (Figure 31D), the faster 
transverse relaxation in the N-terminal half of the aSyn sequence points to an exchange 
process driven by transient interactions between the N-terminal region of aSyn and the 
EGFP fragment. Notably, Tyr39 had higher R2 rates than its surrounding residues, 
suggesting contributions of aromatic interactions in the exchange process. 
 
 
4.5.4 THE N-TERMINAL REGION OF SYNT IS LESS AVAILABLE 
THAN IN ASYN  
 
To further investigate the influence of the EGFP fragment on the N-terminal region of 
aSyn, we compared the availability of this region for binding known small molecules. 
To address this, we used the phthalocyanine tetrasulfonate (PcTS) molecule as a 
structural probe238, since its binding preference for the N-terminal region results from 
a balance between the presence of aromatic side chains in that region and the degree 
of interaction with the negatively charged C-terminal region. Although the binding of 
PcTS at the N-terminus of aSyn was evident already at 0.25 equivalents of the 
compound, no broadening or chemical shift perturbations were observed under similar 
conditions, nor at higher concentrations, such as 0,5 or 1 equivalent, for the amide 
groups of residues located in the N-terminus of SynT (Figure 33A). The absence of 
PcTS interaction with the N-terminus of SynT construct could be caused by an 
increased binding of PcTS to the EGFP fragment compared to the N-terminus of SynT.  
Alternatively, intra- or intermolecular interactions between the EGFP fragment and 
the N-terminus of SynT could interfere with PcTS binding. For example, interaction 
of the EGFP fragment with the N-terminus of SynT would bring the highly negatively 
charged aSyn residues 100-140 in close proximity to the N-terminal region, possibly 
resulting in electrostatic repulsions between the negatively charged C-terminal region 
and peripheral sulfonate groups in the ligand.  
Finally, we tested whether the EGFP fragment in SynT interfered with binding and 
folding of aSyn on the surface of SUVs, a process that is mainly driven by the N-
terminal region. To address this, we generated SUVs from a 5:3:12 mixture of 
DOPE:DOPS:DOPC. NMR spectroscopy revealed that aSyn interacted with 
DOPE:DOPS:DOPC liposomes (Figure 33B) as previously described229,230. In contrast 
to untagged aSyn, the EGFP fragment in SynT influenced the residue-specific SUV-
induced broadening of the NMR signals. Less broadening was induced at the N-
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terminus of SynT, potentially due to its decreased availability, suggested both by 15N 
spin relaxation measurements and PcTS interaction studies (see above). At the same 
time, residues up to 130 of SynT experienced signal attenuation in the presence of 
SUVs, while the C-terminal residues of untagged aSyn only contribute little to the 
interaction with membranes154.   
 
 
4.5.5 SYNT DOES NOT FORM AMYLOID FIBRILS IN VITRO  
 
Next, we investigated whether the EGFP fragment affected the fibrillization of aSyn 
in vitro, since it affects the aggregation of the protein in cultured cells. Recombinant 
aSyn or SynT were incubated at 37°C, under constant agitation, and fibrillization 
kinetics was monitored by Thio-T binding. Surprisingly, SynT did not show any fibril-
specific increase in Thio-T intensity in vitro (Figure 33C).  
Amyloid fibril formation was further assessed by TEM analysis on negatively stained 
samples of aSyn and of SynT, after the aggregation protocol. Consistently with the 
Thio-T assay, we found that aSyn formed well-defined amyloid filaments (Figure 
33D). In contrast, SynT formed non-fibrillar, amorphous aggregates.   
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Figure 32. Backbone dynamics of SynT.               
(A) 3J HN-Hα coupling constants measured for aSyn (blue) and SynT (red). (B,C) 15N relaxation rates of aSyn 
(blue) and SynT (red). Panels (B) and (C) depict R1 and R2 rates, respectively. Panel (D) shows 1H-15N hNOE 
profiles for both proteins. All experiments were recorded at 15oC using aSyn (100µM) and SynT (90µM) 
dissolved in buffer B supplemented with 10% D2O.  
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Figure 33.  Binding and aggregation properties of SynT.               
Interaction profiles of the backbone amide groups of 90μM aSyn, in blue and 90μM SynT proteins, in red, in 
the presence of 0.5 molar equivalent of PcTS (A). Membrane binding properties of aSyn (Blue) and SynT (red) 
in the presence of artificial small unilamellar vesicles membranes (SUVs) [1:100 protein:SUVs ratio] (B). 
Continuous ThioT aggregation assays of a 25 μM solutions of aSyn (blue) and SynT (red). The proteins were 
diluted in Buffer A (25mM Tris, pH 7.7) (C). TEM images of the resulting aggregates stained with uranyl 
acetate (scale bar, 500 nm) (D). 
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5. DISCUSSION  
 
A key premise for the prion-like spreading hypothesis of PD and other 
synucleinopathies is that aSyn assemblies will be taken up by a recipient cell, 
transported and undergo modifications within the cell, further seeds aggregation by 
misfolding the endogenous, otherwise healthy proteins and finally transferred to 
another cells and propagate the pathology. Although there are compelling evidences 
supporting this hypothesis, is still unclear how this process occurs in PD patients and 
where and how aSyn aggregation initiates.  
In this study, we focused on the very first steps of this complex series of events, and we 
tried to understand how important the interactions with plasma membrane and with 
the trafficking machinery pathways are during the internalization and the processing 
of exogenously added aSyn.  
We examined the internalization of different species of aSyn (in the form of monomers 
and fibrils) via ICC and immunoblot analysis, and we found that aSyn monomers enter 
cultured cells and form perinuclear, punctuated inclusions, possibly composed of high 
molecular weight species.  
Afterwards, we studied the interplay of aSyn with several proteins involved in different 
steps of the trafficking machinery pathway, by screening a family of small GTPases 
collectively known as RABs. In order to achieve this, we transiently transfected our 
cultured cells with a library of EGFP-tagged RABs and we treated them with aSyn 
monomers and fibrils. Then we screened these for morphological changes and 
colocalization between RABs and aSyn.  
We found that aSyn inclusions formed upon the internalization of aSyn monomers 
partially colocalize with Rab 5A and Rab 7, suggesting that the endocytic pathway and 
the lysosomal one are involved in the processing of internalized aSyn. We also found 
that the overexpression of Rab 4A alter the size of aSyn inclusions, inducing a 
considerable increase in the rate of internalized protein. To note, the morphology of 
Rab 4A positive vesicles undergoes significant modifications as well, suggesting that 
aSyn internalization disturbs Rab 4A function and that the protein itself may play an 
important role in aSyn uptake.   
In parallel, we analysed more in depth the role of aSyn membrane binding properties 
and its importance in the internalization and in the interaction with the endocytic and 
the lysosomal pathway. To do this, we used three different mutant that progressively 
lose the ability to bind to membranes.  
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Based on the results obtained, we confirmed that both aSyn monomers and fibrils need 
to temporarily interact and bind to the plasma membrane during the internalization 
process, and that even a partial deficiency in the membrane binding capacities it has a 
remarkable effect on the ability of aSyn monomers to get internalized in cultured cells.   
 Finally, by using selective inhibitors of the endocytic and lysosomal pathways, we 
could demonstrate that aSyn is internalized via a dynamin-dependent process, but not 
throughout CME. We also could prove the involvement of the ALP as a selected 
mechanism in the intracellular degradation process of aSyn 
In the second part of the study, we went forward in the analysis of aSyn pathological 
processes and our focus moved on the dissection of the biophysical properties of an 
aggregation-prone form of aSyn, SynT.  
Using NMR we performed a detailed structural characterization of SynT through a 
systematic comparison with the unmodified aSyn. We found that the conformations 
adopted by SynT resemble those described for the unmodified protein and that the 
intrinsically disordered nature of aSyn is not strongly influenced by the C-terminal 
modification in SynT. Nevertheless, a few differences were observed at the N-terminal 
region, and the transient interactions between the N-terminal and the C-terminal 
regions in SynT resulted strengthened if compared to aSyn.  
The use of small molecules as a structural probe (such as PcTS) as well as the 
membrane-binding assay performed helped us to further demonstrate that the N-
terminal region of SynT is less available than in aSyn, suggesting that disturbances in 
the N-terminal region and a consequent decrease of membrane-binding properties 
might contribute to the pathobiology of aSyn. 
 
 
5.1 ASYN MEMBRANE BINDING PROPERTIES ARE 
ESSENTIAL FOR ITS INTERNALIZATION   
 
While the normal function of aSyn and the mechanisms related to its pathological 
behaviour remains uncertain, it is clear that the interaction of aSyn with membranes 
plays a crucial role in both aSyn biology and pathology.  
The conformational changes acquired by the protein  - mainly related to the N-terminal 
lipid binding domain -  during the transition from a free state to a membrane-bound 
one, are considered functionally important and have been described in details72. 
Recently a detailed, structural characterization of the three distinct regions of aSyn - 
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each one possessing different dynamical behaviour and membrane-bound affinities - 
has been provided154. 
During the internalization process, oligomeric or protofibrillar aSyn species have been 
reported to permeabilize membranes by acting as a pore or channel116,239. One or more 
molecules of monomeric aSyn, too, may at times acquire a more structured 
conformation and cluster together to form membrane permeabilizing channels121, 
although contrasting evidences suggest that they could rather passively diffuse 
throughout membranes129,240. 
The present study revealed that both aSyn monomeric and fibrillary species are 
internalized in cultured cells via an active process that requires, in the very first step, a 
transient interaction with the plasma membrane, as clearly shown from the 
biotinylation assay. The data obtained repeatedly confirmed as well that the membrane 
binding properties of aSyn are extremely important, if not essential, for its 
internalization and for the resulting interaction with the endocytic pathway, the 
transition from one cellular compartment to another (from the early endosome to the 
late endosome and therefore, to the lysosome) and finally for its degradation. 
The use of different mutant together with aSyn WT, such as the PD familial mutant 
A30P and the artificial one A11P/V70P, which show a progressive lack of the 
membrane binding abilities, allowed us to characterize more in details the importance 
of these properties in relation to the uptake, the processing and the inclusion formation.  
Based on the trend observed in the experiments performed, we can clearly state that to 
a greater deficiency of the membrane binding properties correspond a greater reduction 
in the rate of internalization.  
This could also be explained in light of the observation of the three different regions in 
aSyn and their diverse membrane-bound behaviour as recently hypothesized154 (Figure 
10). In fact, the A30P mutation affects the so called “intermediate” central region of 
aSyn (residues 25 to 98), which was suggested to play a role in modulating the affinity 
of aSyn for different type of membranes.  
Structurally, the substitution of an alanine with a proline itself play a fundamental role 
in the disruption of the membrane-bound α-helical formation. Thus, an impairment in 
this region would most likely affect the strength by which the protein interact and bind 
to membranes, exerting a bigger or minor effect accordingly to the curvature of the 
membrane or to the lipid composition. That is the reason why we observe a consistent 
decrease in the internalization of aSyn A30P compared to aSyn WT.  
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On the other side, the double point mutations in aSyn A11P/V70P affect both the N-
terminal region (residues 1 to 25), that is rigidly bound and act as a membrane anchor, 
and the central region (residues 25 to 98).  
In this case, the substitution of the alanine in position 11 and the valine in position 70 
with two prolines disrupts completely both the ability of the mutant to anchor, in a first 
place, to the membrane with its N-terminal region, and, in a second moment, to further 
modulate the binding via its central region.  To confirm the previous hypotheses, the 
membrane-binding assay performed show as, starting from the residue 11, the ability 
of the protein aSyn A11P/V70P to bind to the membranes is completely compromised 
(Figure 24A).  
Thus, although we can observe a consistent decrease in the internalization of aSyn 
A30P compared to aSyn WT, the uptake of this mutant is still bigger than the one 
related to aSyn A11P/V70P.  
Taken together, these results highlight the extreme importance of the membrane 
binding properties during the first step of the internalization of aSyn.  
 
 
5.2 THE RABs SCREENING AND RAB 4A: AN IMPORTANT 
PLAYER IN ASYN PATHOLOGY? 
 
The RABs are a family of small GTPases that organize the shapes and the dynamics 
of intracellular membranes in all the eukaryotic cells, by regulating the trafficking 
machinery pathway241. It is therefore not surprising that mutations and dysregulation 
of RABs and their effectors are implicated in several human pathologies, ranging from 
hereditary disorders to cancer and to neurological and neurodevelopmental 
disorders178,241. As mentioned before, several RABs have indeed been directly or 
indirectly linked to PD and synucleinopathies and it is widely recognised that 
membrane trafficking defects play a key role in the development of the pathology.  
In this study, we performed a comprehensive screen of the RABs members and later 
on, we analysed in greater details a pool of selected RABs that were showing changes 
in the morphology or a direct interaction with aSyn.  
Among the > 60 members analysed, we found stronger effects with Rab 4A, Rab 5A 
and Rab 7 (and to a minor extent with Rab 9A).  
Rab 4A and Rab 5A are localized in the early endosome, contributing to the protein 
recycling/transport to the plasma membrane and early endosome fusion, respectively, 
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while Rab 7 is localized in the late endosome, lysosome and phagosome, contributing 
to the late endosome to lysosome fusion process.  
Our data clearly show that aSyn partially colocalize with Rab 5A and Rab 7, suggesting 
that the endocytic pathway first and the ALP later are involved in the internalization, 
processing and degradation of exogenously added aSyn monomers.  
However, the most interesting result came from the analysis of Rab 4A.  
H4 cells overexpressing Rab 4A showed a greater internalization of aSyn monomers, 
which accumulate in bigger inclusion surrounded by Rab 4A positive vesicles. On the 
same time, a dramatic increase in the size of Rab 4A vesicles (and therefore, in the size 
of the early endosome) was observed, suggesting that Rab 4A might have a direct, 
active role in the internalization of aSyn.   
 Recent evidences suggest that even when different RABs localize on the same 
organelle, they occupy distinct membranes microdomains with different functions, 
called RAB domains. In particular, some studies have shown that early and recycling 
endosomes express multiple combinations of Rab 4, Rab 5 and Rab 11 domains that 
are surely dynamics but still do not significantly intermix over time242.  Similarly, late 
endosomes contain distinct membranes domains positive for Rab 7 and Rab 9 
respectively (Figure 34).  
One of the possible explanation for this segregation mechanism is that it could be, at 
least in part, mediated by effectors proteins and their association with additional 
molecules in the organelle membranes242. 
In the endocytic pathway, early 
endosome play a fundamental 
role as a major sorting “hub” 
from which internalized cargo 
can be recycled back to the 
plasma membranes, to the TGN, 
or routed to lysosome for 
degradation226. 
On the early endosomal 
membranes, Rab5 marks the 
cisternal domain and Rab4 
concentrates in patches that 
undergo fission from the 
cisternae, called tubular 
domains.  
Figure 34.  RABs membranes domains.                
RAB microdomains expressed in organelles like recycling 
endosomes, early endosomes and late endosomes. From 
Reference 162. 
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These tubular subdomains are highly dynamics, giving rise to multiple classes of carrier 
vesicles that often separate to the endosome and that are targeted to different 
destinations226.  
On this behalf, a recent study shown that Rab 4A is essential for the recruitment of 
adaptor proteins to the tubular subdomain of the early endosomal membrane, 
orchestrating a signalling cascade that initiate the formation of a sorting platform from 
which multiple classes of vesicular carrier emerge226.  
In particular, Rab 4A is necessary for the recruitment of Arl1, which then promotes 
assembly of the Arf GEF BIG1 and BIG2, Arfs and adaptor proteins AP1 and AP3 
that drive the sorting and packaging of endosomal cargo.  
Based on the data obtained, we could clearly observe a perturbation in the morphology 
of Rab 4A vesicles due to the presence and the interaction with aSyn monomers.  
Thus, we hypothesize that this particular GTPase cascade nucleated by Rab 4A is 
directly and actively involved into the internalization of aSyn monomers, although 
further experiments will be necessary to identify the exact molecular link between Rab 
4A, Arl1, aSyn and other potential effectors.  
 
 
5.3 ASYN IS INTERNALIZED VIA A DYNAMIN-DEPENDENT 
MECHANISM  
 
In the last decade, the concept that aSyn has a function in endocytosis solidified, 
although different views on the exact role played by this protein are emerging.  
Studies on triple synuclein knockout mice and on receptor-mediated endocytosis of 
transferrin suggested a role of aSyn in CME189,243–245, whereas data from other research 
displayed disturbances in CME and increased bulk endocytosis, proposing instead a 
compensatory upregulation of CME when aSyn-related fast endocytosis mechanisms 
are impaired64,246.  
In this study, we tried to better characterize the mechanism responsible of the 
internalization of aSyn by using two inhibitors of different endocytic pathways: 
Dyngo, which is a selective inhibitor of dynamin, and PitStop, which appears to block 
CME.  
The results obtained showed that the inhibition caused by the use of Dyngo has a 
remarkable effect on the rate of internalized aSyn, both in cultured cells overexpressing 
  Discussion 
 
105 
Rab 4A – that show an increased internalization of aSyn – and in cultured cells not 
transfected, suggesting that aSyn is internalized via a dynamin-dependent mechanism.  
On the other side, the effect observed during the treatment with PitStop were quite 
controversial. On H4 cells transfected with Rab 4A, we could observe a small - 
although not significant - decrease in aSyn internalization, while in H4 not transfected 
cells we noticed an opposite effect, resulting in a bigger uptake of aSyn.  
As mentioned before, Dyngo inhibits not only the dynamin-dependent mechanisms, 
but it was also reported to reduce synaptic vesicle endocytosis and activity-dependent 
bulk endocytosis.  
A possible explanation to the behaviour observed when H4 cells are treated with 
PitStop is to be related to a compensatory mechanism: we can hypothesize that when 
clathrin-mediated mechanisms are blocked (PitStop-related effect), the clathrin-
independent processes otherwise suppressed by Dyngo and supposedly, responsible of 
the internalization of aSyn, - such as synaptic vesicle endocytosis and activity-
dependent bulk endocytosis - are exacerbated. In this way, a larger amount of aSyn 
can be internalized. To note, a similar hypothesis was already reported in previous 
studies246.  
We can also estimate that the overexpression of Rab 4A would interfere with this 
equilibrium, and therefore, mitigate the compensatory mechanism aforementioned, so 
that in the experiments reported in Figure 26 was not possible to observe it so clearly.  
To conclude, based on the data obtained, we can confirm that a dynamin-dependent 
mechanism is responsible of the internalization of aSyn monomers, although further 
experiments will be required to determine in greater details the exact nature of the 
endocytic process involved.  
 
 
5.4 EXTRACELLULAR MONOMERIC ASYN MIGHT BE 
SUFFICIENT TO INITIATE THE SPREADING OF ASYN 
PATHOLOGY  
 
During the last decade, several independent studies demonstrated that aSyn oligomers 
and pre-formed fibrils (PFFs) enter cultured cells, accumulate into the cytosol or in 
organelles compartment, and then get released in the extracellular space or transferred 
from cell-to-cell via several different mechanisms 132,134.  
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Of note, the almost totality of studies present in literature rather focus on the use of 
oligomeric or already misfolded and aggregating species (such as the widely used 
PFFs) to study aSyn propagation and its related pathology in vitro and in vivo132,134,141. 
This can be perhaps related to the fact that those same studies report monomeric aSyn 
is not internalized by cultured cells, or is uptaken much less than aggregates or PFFs 
species138, or that does not propagate as much as the pathogenic ones in vivo.  
On the other side, the idea to use and to study the internalization of aSyn monomers 
came to us from the findings that, whether in a regulated or stochastic way, multiple 
molecular species of aSyn (and monomers as well) are present in the CSF, in the 
plasma and in the extracellular space of both healthy and PD individuals144.  
Thus, we wanted to examine the possibility for regularly available, monomeric aSyn 
to be uptaken and internalized and to understand whether this could somehow impair 
the physiological cellular processes.  
Our first results confirmed that monomeric aSyn could be indeed internalized in a 
dose-dependent manner by cultured cells, and that the process occurs via the binding 
to the plasma membrane. Additionally, the exogenously added aSyn is capable to form 
high molecular weight species once inside the cells, as indicated by the Dot Blot 
analysis. The Triton X-100 fractionation confirm and further suggest that those high 
molecular weight species are, at least in part, insoluble, suggesting that monomeric 
aSyn might be sufficiently able per se to start to assembly, to eventually misfold, to 
initiate the process of aggregation and therefore, the spreading of aSyn-related 
pathology.  
Our results do not find, so far, a big correspondence in the literature. Only two studies 
have reported internalization of aSyn monomers and the involvement of the endocytic 
pathway, although the purpose and the readouts use in those studies were 
different140,240. In these and in other cases, the discrepancy encountered could be 
attribute to the different sensitivity of the systems used, to the different models or to 
the different concentration used and – last but not least – to the focus of the study itself.  
Nevertheless in AD, a comparable study reported analogous results suggesting that 
extracellular monomeric tau is sufficient to initiate the spreading of tau pathology247.  
Additionally, we show that aSyn monomers partially colocalize with Rab 4A and Rab 
5A, two small GTPases belonging to the RABs and involved in the endocytic 
trafficking machinery pathway.  
Consistently with the formation of high molecular weight species, it is possible that 
once in endosomes, aSyn monomers are subjected to a number of physico-chemical 
transformation that are likely to exert an influence on promoting aggregation reaction.  
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In endosomes, pH is reported to vary between 5.0 and 6.0, while within the lysosomes 
the variation of pH is from 4.6 to  5.0.248  The low pH in this compartments might then  
trigger aggregation, as well as other factors as for example the molecular crowding or 
the presence of acidic endosomal proteins might contribute to it, suggesting that 
endocytosis may play a crucial role in the misfolding and aggregation of aSyn, 
facilitating the propagation of aSyn pathology. It is also possible that co-aggregation 
occurs in the late endosome-lysosomal compartments, where it appears to end the 
exogenously added, internalized aSyn monomeric species.  
Autophagy function is particularly crucial in the aged brain and in neurodegeneration, 
due to the accumulation of misfolded and aggregated proteins. Several studies 
demonstrated that aSyn can be degraded either by the proteasome or by autophagy.  
In this study, we demonstrate that also high molecular weight species formed via the 
internalization of aSyn monomeric forms can be degraded by the ALP, and that the 
concentration of aSyn  within the cells is increased when lysosomal activity and protein 
degradation are blocked. These results support the hypothesis that autophagy is a 
major route for degradation of aSyn oligomers and fibrillary species when a 
pathological accumulation is registered146.  
Based on the results obtained, we proposed a mechanism for aSyn internalization and 
interaction with the membrane trafficking machinery pathways (Figure 35).  
After binding to the membrane, aSyn monomers are internalized through the 
endocytic pathway, where Rab 4A plays an important role on the protein sorting and 
on the transport from/to the plasma membrane. aSyn proteins are thereafter found in 
the early endosome (in colocalization with Rab 5A). It is possible that during the 
progress from early to late endosome, due to pH acidification, aSyn monomers start to 
oligomerize, and therefore to assembly in amyloidogenic aggregates.  
From here, the early endosome mature in late endosome and the late endosome – 
where aSyn was found in colocalization with Rab 7 - fuse with lysosome, where aSyn 
is degraded.  
The release of aSyn from those organelles to the cytoplasm, with a consequential 
accumulation of potential pathological, unfolded and aggregating species it may be 
possible, facilitating the propagation and the spreading of aSyn pathology.  
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Figure 35. Proposed mechanism for aSyn internalization and interaction with the membrane trafficking 
machinery pathway. After binding to the membrane, aSyn monomers are internalized through the endocytic 
pathway. Rab 4A plays an important role on the protein sorting and on the transport from/to the plasma 
membrane. Monomers are thereafter found in the early endosome. It is possible that during the progress from 
early to late endosome, due to pH acidification, aSyn monomers start to oligomerize, and therefore to aggregate 
in amyloidogenic aggregates. From here, the late endosome fuse with lysosome, where aSyn get degraded. It is 
possible that in any of those steps a release of aSyn from those organelles to the cytoplasm, with a consequential 
accumulation of potential pathological, unfolded or oligomerized species will happen.   
  Discussion 
 
109 
5.5 C-TERMINAL MODIFICATION IN SYNT AND ITS EFFECT 
ON AGGREGATION PROPENSITY 
 
In order to understand the molecular determinants of aSyn aggregation, several in vitro 
and in vivo models have been employed, in an attempt to mimic the behaviour of the 
protein in synucleinopathies. However, while aSyn has been known to readily fibrillize 
in the test tube, it has not been possible to consistently induce aSyn aggregation in 
cultured cells, just based upon expression.  
To promote aSyn aggregation in cells, different strategies have been employed, 
including co-expression with other proteins 249, oxidative stress250, metal ions251,252, or 
the addition of extraneous amino acid sequences208,253. Whether these manipulations 
mimic relevant aspects of aSyn pathobiology, or simply represent artificial phenotypes 
that are not accessible to the constellation of conformations aSyn can adopt remains 
unclear.  
In the second part of this study, we characterized and determined the effect of an 
artificial fragment of EGFP on the C-terminal region of aSyn in terms of its folding 
and conformation. Our study clarifies the aggregation behaviour of SynT in cells and 
provides the basis for additional investigations of aSyn aggregation.   
From a biophysical perspective, the NMR spectra and general dynamics of the protein 
backbone observed for aSyn and SynT demonstrate that the aSyn part of SynT retains 
the intrinsically disordered character of the untagged protein. However, we observed 
subtle changes in the conformational propensities of the protein ensembles.  
As expected, the C-terminal region of aSyn showed changes in the position and 
intensities of the NMR signals, likely due to changes in the chemical environment 
induced by the nearby EGFP fragment and its contribution to the local rotational 
correlation time. On the other hand, we also detected an attenuation of the intensity 
of the signal of the amide signals in the N-terminal region of SynT that correlated well 
with a chemical exchange process detected by 15N spin relaxation measurements. 
Taken together, these results suggest that the EGFP fragment might transiently interact 
with the N-terminus of the protein in an inter- or intra-molecular manner (Figure 36). 
This transient interaction could explain the attenuated ability of the N-terminal 
residues of SynT to interact with the small molecule PcTS and could contribute to the 
altered binding mode of SynT with membranes. We hypothesise that the proximity of 
the tag could create steric disturbances that influence how SynT interacts with 
membranes and folds into α-helical structures on the membrane surface.  
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Considering recent findings that indicate aSyn aggregation is increased when aSyn is 
in its unstructured monomeric form, and is attenuated/blocked when it is in a alpha-
helical multimeric form associated with membranes228, our results suggest that the 
perturbed interaction of SynT with membranes might, at least in part, be responsible 
for its increased aggregation propensity in cells.  
It has also been shown that the acidic C-terminal region of aSyn can play a role and 
affect the aggregation properties of aSyn both in monomeric and aggregated forms36. 
The aggregation kinetics are sensitive to a wide range of ionic conditions, from weak 
C-terminal charge shielding36, to stronger charge modifications caused by the presence 
of polycations254 or metal ions219,252,251,224, PTMs224,255, truncations256,257 or, as in the case 
of our study, the addition of tags208. Thus, it is possible that changes in the electrostatic 
environment of this region of the protein due to the presence of the tag will overall 
affect the aggregation behaviour.  
The present study indicates that the modification of the C-terminus of aSyn in SynT, 
and the subsequent effect on the N-terminal region, potentiates the ability of the protein 
to form intracellular inclusions, which recapitulate important molecular features of 
synucleinopathies.  
Cellular models based on expression of aSyn variants such as SynT are widely used 
tools for the identification of genetic and pharmacological strategies to treat PD and 
other synucleinopathies. Therefore, a detailed understanding of the molecular 
mechanisms underlying aSyn aggregation is important for the development of novel 
therapeutic strategies for these disorders.    
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Figure 36. Proposed model for the structural properties of SynT.           
The EGFP fragment could transiently interact with the N-terminal region of the protein in an inter-molecular 
or in an intra-molecular way. Overall, the general, chemical properties of aSyn are not affected by the tag, nor 
its propensity to maintain an intrinsically disordered structure. Still, some of the physiological-related properties 
of aSyn appear to be affected by the tag (e.g., membrane binding properties and aggregation propensities in vivo 
and in vitro).  
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6. CONCLUSIONS 
 
In this study, we analysed the mechanisms of aSyn interaction with the plasma 
membrane and with cellular trafficking machinery components during the 
internalization of exogenously-added aSyn recombinant proteins in a cell model. We 
also characterized the structural basis behind the aggregation process in a C-terminally 
modified version of aSyn, SynT, which mimic the pathological behaviour of the 
protein.  
First, we demonstrated that different species of exogenously added aSyn, in the form 
of monomers and fibrils, enter cultured cells and form inclusions. 
Once uptaken, aSyn monomers display a distinct, perinuclear and punctuate pattern, 
suggesting that these may localize in vesicular structures.  
Throughout the screening of a family of small GTPases, the RABs, we could 
demonstrate that aSyn partially colocalize with Rab 5A and Rab 7, suggesting the 
involvement of the endocytic pathway first, and of the ALP later during the processing 
of aSyn.  
Internalization of aSyn is remarkably increased by the overexpression of Rab 4A, 
which orchestrates a signalling cascade for the recruitment of adaptor proteins to the 
early endosomes. This let us hypothesize that this particular GTPase cascade nucleated 
by Rab 4A is directly and actively involved into the internalization of aSyn monomers, 
although further experiments will be necessary to identify the exact molecular link 
between Rab 4A, aSyn monomers and other potential effectors.  
Additional investigations with different mutants of aSyn demonstrated that membrane 
binding properties are essential for the internalization, and therefore, for the inclusion 
formation of aSyn in cultured cells.   
By using selective inhibitors of the endocytic and lysosomal pathways, we 
demonstrated that aSyn monomers are internalized via a dynamin-dependent process, 
but not throughout CME. We also could prove the involvement of the ALP as a 
selected mechanism in the intracellular degradation of aSyn.  
Based on the results obtained, we claim that extracellular monomeric aSyn might be 
sufficient to initiate the spreading of aSyn pathology, and we proposed a detailed 
mechanism for aSyn internalization and processing in cultured cells.  
In the second part of the study, we characterize the biophysical properties of an 
aggregation-prone form of aSyn, known as SynT.  
Conclusions 
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We performed a detailed structural characterization of SynT through a systematic 
comparison with the unmodified aSyn and with the use of NMR-based techniques.  
Our data suggests that the intrinsically disordered nature of aSyn is not strongly 
influenced by the C-terminal modification in SynT, and that the conformations 
adopted by SynT are similar to those described for the unmodified protein. 
Nevertheless, a few differences were observed at the N-terminal region, and the 
transient interactions between the N-terminal and the C-terminal regions in SynT 
resulted strengthened if compared to aSyn.  
The use of small molecules as a structural probe (such as PcTS) as well as the 
membrane-binding assay performed helped us to further demonstrate that the N-
terminal region of SynT is less available than in aSyn, suggesting that disturbances in 
the N-terminal region and a consequent decrease of membrane-binding properties 
might contribute to the pathobiology of aSyn.  
Our data provide insight into the effect of the EGFP fragment on the N-terminus of 
the protein, in an inter- or intra-molecular fashion. The mechanism proposed indicates 
how the modification of the C-terminus of aSyn in SynT, and the subsequent effect on 
the N-terminal region potentiates the ability of the protein to form intracellular 
inclusions, which recapitulate important molecular features of synucleinopathies.  
 
 
 
 
  
 
117 
 
 
 
 
 
 
 
  
- VII - 
BIBLIOGRAPHY 
  
 
118 
 
 
 
119 
7. BIBLIOGRAPHY  
 
1. Kontis, V. et al. Future life expectancy in 35 industrialised countries: projections with 
a Bayesian model ensemble. Lancet 389, 1323–1335 (2017). 
2. Vaupel, J. W. Biodemography of human ageing. Nature 464, 536–542 (2010). 
3. Christensen, K., Doblhammer, G., Rau, R. & Vaupel, J. W. Ageing populations: the 
challenges ahead. Lancet 374, 1196–1208 (2009). 
4. Driver, J. A., Djousse, L., Logroscino, G., Gaziano, J. M. & Kurth, T. Incidence of 
cardiovascular disease and cancer in advanced age: prospective cohort study. Bmj 337, 
a2467–a2467 (2008). 
5. Jin, K., Simpkins, J. W., Ji, X., Leis, M. & Stambler, I. The Critical Need to Promote 
Research of Aging and Aging-related Diseases to Improve Health and Longevity of 
the Elderly Population. Aging Dis. 6, 1 (2015). 
6. Lee, A. & Gilbert, R. M. Epidemiology of Parkinson Disease. Neurol. Clin. 34, 955–
965 (2016). 
7. Mhyre, T. R., Nw, R., Boyd, J. T., Hall, G. & Room, C. Parkinson´s Disease. 65, 
(2012). 
8. Gallagher, D. A., Lees, A. J. & Schrag, A. What are the most important nonmotor 
symptoms in patients with Parkinson’s disease and are we missing them? Mov. Disord. 
25, 2493–2500 (2010). 
9. Simuni, T. & Sethi, K. Nonmotor manifestations of Parkinson’s disease. Ann. Neurol. 
64, 65–80 (2008). 
10. Wales, P., Lázaro, D. F., Pinho, R. & Outeiro, T. F. Limelight on alpha-synuclein: 
Pathological and mechanistic implications in neurodegeneration. J. Parkinsons. Dis. 3, 
415–459 (2013). 
11. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. 
Neurobiol. Aging 24, 197–211 (2003). 
12. Del Tredici, K. & Braak, H. Sporadic Parkinson’s disease: Development and 
distribution of α-synuclein pathology. Neuropathol. Appl. Neurobiol. 42, 33–50 (2016). 
13. Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy 
pathology. Nat. Rev. Neurol. 9, 13–24 (2012). 
14. Polymeropoulos, M. H. Mutation in the -Synuclein Gene Identified in Families with 
Parkinson’s Disease. Science (80-. ). 276, 2045–2047 (1997). 
15. Golde, T. E., Borchelt, D. R., Giasson, B. I. & Lewis, J. Thinking laterally about 
neurodegenerative proteinopathies. J. Clin. Invest. 123, 1847–1855 (2013). 
16. Bayer, T. A. Proteinopathies, a core concept for understanding and ultimately treating 
degenerative disorders? Eur. Neuropsychopharmacol. 25, 713–724 (2015). 
17. Goedert, M., Spillantini, M. G. & Davies, S. W. Filamentous nerve cell inclusions in 
  
 
120 
neurodegenerative diseases. Curr. Opin. Neurobiol. 8, 619–632 (1998). 
18. Spillantini, M. G., Goedert, M. & Spillantini, M. G. The α-Synucleinopathies: 
Parkinson’s Disease, Dementia with Lewy Bodies, and Multiple System Atrophy. 
Ann. N. Y. Acad. Sci. 920, 16–27 (2000). 
19. John Q. Trojanowski, V. M.-Y. L. Parkinson’s disease and related alpha-
synucleiopathies are brain amyloidoses. Ann N.Y. Acad. Sci 991, 107–110 (2003). 
20. Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q. & Goedert, M. 
a-Synuclein in Lewy bodies. Nature 839–840 (1997). 
21. Wakabayashi, K., Yoshimoto, M., Tsuji, S. & Takahashi, H. a -Synuclein 
immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. 
Lett. 249, 180–182 (1998). 
22. Trojanowski, J. Q., Goedert, M., Iwatsubo, T. & Lee, V. M. Fatal attractions: 
abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy 
body dementia. Cell Death Differ. 5, 832–837 (1998). 
23. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-
Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and 
dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95, 6469–73 (1998). 
24. Takeda, A. et al. Abnormal accumulation of NACP/α-synuclein in neurodegenerative 
disorders. Am. J. Pathol. 152, 367–372 (1998). 
25. Maroteaux, Luc., J. T. C. and R. H. S. Synuclein : A Neuron-Specific Protein 
Localized to the Nucleus and Presynaptic Nerve Terminal. J. Neurosci. 8, 2804–2815 
(1988). 
26. Chandra, S., Chen, X., Rizo, J., Jahn, R. & Su, T. C. A Broken a-Helix in Folded a-
Synuclein. J. Biol. Chem. 278, 15313–15318 (2003). 
27. Bussell, R. J. & Eliezer, D. A Structural and Functional Role for 11-mer Repeats in a -
Synuclein and Other Exchangeable Lipid Binding Proteins. J. Mol. Biol. 2836, 763–
778 (2003). 
28. Davidson, W. S., Jonas,  a, Clayton, D. F. & George, J. M. Stabilization of alpha-
synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 
273, 9443–9 (1998). 
29. Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q. & Lee, V. M. A Hydrophobic 
Stretch of 12 Amino Acid Residues in the Middle of a-Synuclein Is Essential for 
Filament Assembly. J. Biol. Chem. 276, 2380–2386 (2001). 
30. Du, H. et al. A Peptide Motif Consisting of Glycine , Alanine , and Valine Is Required 
for the fibrillization and Cytotoxicity of Human a-Synuclein. Biochemistry 8870–8878 
(2003). 
31. Ueda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of 
amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. 90, 11282–11286 (1993). 
32. Bayer, T. A. et al. α-Synuclein accumulates in Lewy bodies in Parkinson’s disease and 
dementia with Lewy bodies but not in Alzheimer’s disease β-amyloid plaque cores. 
Neurosci. Lett. 266, 213–216 (1999). 
  
 
121 
33. Souza, M. Y., Giasson, B. I., Lee, V. M. & Y, H. I. Chaperone-like activity of 
synucleins. FEBS Lett. 474, 116–119 (2000). 
34. Kim, T. D., Paik, S. R. & Yang, C.-H. Structural and functional implications of C-
terminal regions of alpha-synuclein. Biochemistry 41, 13782–13790 (2002). 
35. Park, S. M. et al. Distinct Roles of the N-terminal-binding Domain and the C-
terminal-solubilizing Domain of A-Synuclein , a Molecular Chaperone. J. Biol. Chem. 
277, 28512–28520 (2002). 
36. Hoyer, W., Cherny, D., Subramaniam, V. & Jovin, T. M. Impact of the Acidic C-
Terminal Region Comprising Amino Acids 109 - 140 on a-Synuclein Aggregation in 
Vitro. Biochemistry 16233–16242 (2004). 
37. Eliezer, D., Kutluay, E., Bussell, R. & Browne, G. Conformational properties of α-
synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061–1073 (2001). 
38. Breydo, L., Wu, J. W. & Uversky, V. N. α-Synuclein misfolding and Parkinson’s 
disease. Biochim. Biophys. Acta - Mol. Basis Dis. 1822, 261–285 (2012). 
39. Cho, M. K. et al. Amino acid bulkiness defines the local conformations and dynamics 
of natively unfolded α-synuclein and tau. J. Am. Chem. Soc. 129, 3032–3033 (2007). 
40. Allison, J. R., Varnai, P., Dobson, C. M. & Vendruscolo, M. Determination of the 
free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance 
measurements. J. Am. Chem. Soc. 131, 18314–18326 (2009). 
41. Salmon, L. et al. NMR characterization of long-range order in intrinsically disordered 
proteins. J Am Chem Soc 132, 8407–8418 (2010). 
42. Rao, J. N., Jao, C. C., Hegde, B. G., Langen, R. & Ulmer, T. S. A combinatorial 
NMR and EPR approach for evaluating the structural ensemble of partially folded 
proteins. J. Am. Chem. Soc. 132, 8657–8668 (2010). 
43. Lee, J. C., Bert, L. T., Kozak, J. J., Gray, H. B. & Winkler, J. R. a-Synuclein tertiary 
contact dynamics. J phys Chem B 2017–2112 (2007). doi:10.1038/nn.2120.Red-shifted 
44. Dedmon, M. M., Lindorff-Larsen, K., Christodoulou, J., Vendruscolo, M. & Dobson, 
C. M. Mapping long-range interactions in alpha-synuclein using spin-label NMR and 
ensemble molecular dynamics simulations. J. Am. Chem. Soc. 127, 476–477 (2005). 
45. Bertoncini, C. W. et al. From The Cover: Release of long-range tertiary interactions 
potentiates aggregation of natively unstructured -synuclein. Proc. Natl. Acad. Sci. 102, 
1430–1435 (2005). 
46. Uversky, V. N. Neuropathology, biochemistry, and biophysics of a-synuclein 
aggregation. J. Neurochem. 103, 17–37 (2007). 
47. Bussell, R. & Eliezer, D. Residual Structure and Dynamics in Parkinson’s Disease-
associated Mutants of a-Synuclein. J. Biol. Chem. 276, 45996–46003 (2001). 
48. Ulmer, T. S. & Bax, A. Comparison of structure and dynamics of micelle-bound 
human α-synuclein and Parkinson disease variants. J. Biol. Chem. 280, 43179–43187 
(2005). 
49. Iwai, A. et al. The precursor protein of non-AB component of Alzheimer’s disease 
amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467–475 
  
 
122 
(1995). 
50. Tyson, T., Steiner, J. A. & Brundin, P. Sorting out release, uptake and processing of 
alpha-synuclein during prion-like spread of pathology. J. Neurochem. 139, 275–289 
(2016). 
51. Bartels, T., Choi, J. G., Selkoe, D. J. & Hospital, W. That Resists Aggregation. 477, 
107–110 (2012). 
52. Wang, W. et al. A soluble a-synuclein construct forms a dynamic tetramer. Proc. Natl. 
Acad. Sci. 108, 17797–17802 (2011). 
53. Burré, J., Sharma, M. & Südhof, T. C. a-Synuclein assembles into higher-order 
multimers upon membrane binding to promote SNARE complex formation. Proc. 
Natl. Acad. Sci. (2014). doi:10.1073/pnas.1416598111 
54. Payton, J. E., Perrin, R. J., Woods, W. S. & George, J. M. Structural determinants of 
PLD2 inhibition by a-synuclein. J. Mol. Biol. 337, 1001–1009 (2004). 
55. Withers, G. S., George, J. M., Banker, G. A. & Clayton, D. F. Delayed localization 
of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal 
neurons. Dev. Brain Res. 99, 87–94 (1997). 
56. Kahle, P. J. et al. Subcellular localization of wild-type and Parkinson’s disease-
associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 
20, 6365–6373 (2000). 
57. Lee, S.-J., Jeon, H. & Kandror, K. V. Alpha-synuclein is localized in a subpopulation 
of rat brain synaptic vesicles. Acta Neurobiol. Exp. (Wars). 68, 509–15 (2008). 
58. Scott, D. A., Tabarean, I., Tang, Y., Cartier, A. & Masliah, E. a pathologic cascade 
leading to synaptic dysfunction in a-synuclein induced neurodegeneration. J. Neurosci. 
30, 8083–8095 (2010). 
59. Abeliovich, A. et al. Mice Lacking α-Synuclein Display Functional Deficits in the 
Nigrostriatal Dopamine System. Neuron 25, 239–252 (2000). 
60. Nemani, V. M. et al. NIH Public AccessIncreased Expression of Alpha-Synuclein 
Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering After 
Endocytosis. Neuron 65, 66–79 (2011). 
61. Gaugler, M. N. et al. Nigrostriatal overabundance of α-synuclein leads to decreased 
vesicle density and deficits in dopamine release that correlate with reduced motor 
activity. Acta Neuropathol. 123, 653–669 (2012). 
62. Lundblad, M., Decressac, M., Mattsson, B. & Bjorklund, A. Impaired 
neurotransmission caused by overexpression of  -synuclein in nigral dopamine 
neurons. Proc. Natl. Acad. Sci. 109, 3213–3219 (2012). 
63. Burré, J., Sharma, M., Tsetsenis, T., Buchman, V. & Südhof, T. C. α -Synuclein 
Promotes SNARE-Complex Assembly in vivo and in vitro. Science (80-. ). 329, 1663–
1667 (2010). 
64. Lautenschläger, J., Kaminski, C. F. & Kaminski Schierle, G. S. a-Synuclein - 
Regulator of Exocytosis, Endocytosis, or Both? Trends Cell Biol. 27, (2017). 
65. Lai, Y. et al. Nonaggregated α-synuclein influences snare-dependent vesicle docking 
  
 
123 
via membrane binding. Biochemistry 53, 3889–3896 (2014). 
66. Choi, B.-K. et al. Large  -synuclein oligomers inhibit neuronal SNARE-mediated 
vesicle docking. Proc. Natl. Acad. Sci. 110, 4087–4092 (2013). 
67. DeWitt, D. C. & Rhoades, E. a-synuclein can inhibit SNARE-mediated Vesicle 
Fusion through direct interaction with lipid bilayers. Biochemistry 119, 5124–5136 
(2010). 
68. Kamp, F. & Beyer, K. Binding of a-synuclein affects the lipid packing in bilayers of 
small vesicles. J. Biol. Chem. 281, 9251–9259 (2006). 
69. Fusco, G. et al. Structural Ensembles of Membrane-bound α-Synuclein Reveal the 
Molecular Determinants of Synaptic Vesicle Affinity. Sci. Rep. 6, 27125 (2016). 
70. Uversky, V. N., Li, J. & Fink, A. L. Metal-triggered structural transformations, 
aggregation, and fibrillation of human α-synuclein: A possible molecular link between 
parkinson’s disease and heavy metal exposure. J. Biol. Chem. 276, 44284–44296 
(2001). 
71. Binolfi, A. et al. Interaction of a-Synuclein with Divalent Metal Ions Reveals Key 
Differences : A Link between Structure , Binding Specificity and Fibrillation 
Enhancement. J. Am. Chem. Soc. 2045–2047 (2006). 
72. Snead, D. & Eliezer, D. Alpha-Synuclein Function and Dysfunction on Cellular 
Membranes. Exp. Neurobiol. 23, 292 (2014). 
73. Ly, T. & Julian, R. R. Protein-Metal Interactions of Calmodulin and a-Synuclein 
Monitored by Selective Noncovalent Adduct Protein Probing Mass Spectrometry. J. 
Am. Soc. Mass Spectrom. 19, 1663–1672 (2008). 
74. Lee, D., Lee, S. Y., Lee, E. N., Chang, C. S. & Paik, S. R. a-Synuclein Exhibits 
Competitive Interaction Between Calmodulin and Synthetic Membranes. J. 
Neurochem. 82, 1007–1017 (2002). 
75. Martinez, J., Moeller, I., Erdjument-Bromage, H., Tempst, P. & Lauring, B. 
Parkinson’s disease-associated α-synuclein is a calmodulin substrate. J. Biol. Chem. 
278, 17379–17387 (2003). 
76. Wersinger, C. & Sidhu, A. Attenuation of dopamine transporter activity by α-
synuclein. Neurosci. Lett. 340, 189–192 (2003). 
77. Krüger, R. et al. Ala30Pro mutation in the gene encoding a-synuclein in Parkinson´s. 
Nat. Genet. 18, 231–236 (1998). 
78. Zarranz, J. J. et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and 
Lewy body dementia. Ann. Neurol. 55, 164–73 (2004). 
79. Appel-Cresswell, S. et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for 
Parkinson’s disease. Mov. Disord. 28, 811–813 (2013). 
80. Lesage, S. et al. G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal 
syndrome. Ann. Neurol. 73, 459–471 (2013). 
81. Pasanen, P. et al. A novel α-synuclein mutation A53E associated with atypical 
multiple system atrophy and Parkinson’s disease-type pathology. Neurobiol. Aging 35, 
1–5 (2014). 
  
 
124 
82. Chartier-Harlin, M.-C. et al. α-synuclein locus duplication as a cause of familial 
Parkinson’s disease. Lancet 364, 1169–1171 (2004). 
83. Singleton,  a B. et al. a-Synuclein Locus Triplication Causes Parkinson ’ s Disease. 
Science (80-. ). 302, 841 (2003). 
84. Rutherford, N. J., Moore, B. D., Golde, T. E. & Giasson, B. I. Divergent effects of 
the H50Q and G51D SNCA mutations on the aggregation of α-synuclein. J. 
Neurochem. 131, 859–867 (2015). 
85. Ono, K., Ikeda, T., Takasaki, J. ichi & Yamada, M. Familial Parkinson disease 
mutations influence ??-Synuclein assembly. Neurobiol. Dis. 43, 715–724 (2011). 
86. Narhi, L. et al. Both familial Parkinson’s disease mutations accelerate α-synuclein 
aggregation. J. Biol. Chem. 274, 9843–9846 (1999). 
87. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared 
property of both alpha -synuclein mutations linked to early-onset Parkinson’s disease: 
Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. 97, 571–576 (2000). 
88. Bussel, R. & Eliezer, D. Effects of Parkinson ’ s Disease-Linked Mutations on the 
Structure of lipid-associated a-Synuclein. Biochemistry 4810–4818 (2004). 
89. Jo, E., Fuller, N., Rand, R. P., St George-Hyslop, P. & Fraser, P. E. Defective 
membrane interactions of familial Parkinson’s disease mutant A30P α-synuclein 1 
1Edited by I. B. Holland. J. Mol. Biol. 315, 799–807 (2002). 
90. Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, G. & Goedert, M. Binding of alpha-
synuclein to brain vesicles is abolished by familial parkinsons-disease mutation. J. Biol. 
Chem. 273, 26292–26294 (1998). 
91. Bodner, C. R., Maltsev, A. S., Dobson, C. M. & Bax, A. Differential phospholipid 
binding of α-synuclein variants implicated in Parkinson’s disease revealed by solution 
NMR spectroscopy. Biochemistry 49, 862–871 (2010). 
92. Choi, W. et al. Mutation E46K increases phospholipid binding and assembly into 
filaments of human α-synuclein. FEBS Lett. 576, 363–368 (2004). 
93. Khalaf, O. et al. The H50Q mutation enhances αα-synuclein aggregation, secretion, 
and toxicity. J. Biol. Chem. 289, 21856–21876 (2014). 
94. Oueslati, A. Implication of Alpha-Synuclein Phosphorylation at S129 in 
Synucleinopathies: What Have We Learned in the Last Decade? J. Parkinsons. Dis. 6, 
39–51 (2016). 
95. Nonaka, T., Iwatsubo, T. & Hasegawa, M. Ubiquitination of alpha-synuclein. 
Biochemistry 44, 361–368 (2005). 
96. Krumova, P. et al. Sumoylation inhibits α-synuclein aggregation and toxicity. J. Cell 
Biol. 194, 49–60 (2011). 
97. Vicente Miranda, H. et al. Glycation potentiates α-synuclein-associated 
neurodegeneration in synucleinopathies. Brain 140, 1399–1419 (2017). 
98. de Oliveira, R. M. et al. The mechanism of sirtuin 2–mediated exacerbation of alpha-
synuclein toxicity in models of Parkinson disease. PLoS Biol. 15, 1–27 (2017). 
  
 
125 
99. Glaser, C. B., Yamin, G., Uversky, V. N. & Fink, A. L. Methionine oxidation, α-
synuclein and Parkinson’s disease. Biochim. Biophys. Acta - Proteins Proteomics 1703, 
157–169 (2005). 
100. Beyer, K. α-Synuclein structure, posttranslational modification and alternative 
splicing as aggregation enhancers. Acta Neuropathol. 112, 237–251 (2006). 
101. Chen, L. & Feany, M. B. α-Synuclein phosphorylation controls neurotoxicity and 
inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657–
663 (2005). 
102. Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell 
Biol. 4, 160–164 (2002). 
103. Nishie, M. et al. Accumulation of phosphorylated a-synuclein in the brain and 
peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 107, 
292–298 (2004). 
104. da Fonseca, T. L., Villar-Piqué, A. & Outeiro, T. F. The interplay between alpha-
synuclein clearance and spreading. Biomolecules 5, 435–471 (2015). 
105. Fauvet, B. et al. Characterization of Semisynthetic and Naturally N-Acetylated a-
Synuclein in Vitro and in Intact Cells. J. Biol. Chem. 287, 28243–28262 (2012). 
106. Maltsev, A. S., Ying, J. & Bax, A. Impact of N-terminal acetylation of a-synuclein on 
its random coil and lipid binding properties. Biochemistry 51, 5004–5013 (2012). 
107. Kang, L. et al. N-terminal acetylation of a-synuclein induces increased transient 
helical propensity and decreased aggregation rates in the intrinsically disordered 
monomer. Protein Sci. 21, 911–917 (2012). 
108. Uversky, V. N., Li, J. & Fink, A. L. Evidence for a Partially Folded Intermediate 
in ??-Synuclein Fibril Formation. J. Biol. Chem. 276, 10737–10744 (2001). 
109. Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M. Y. & Ischiropoulos, H. Dityrosine 
cross-linking promotes formation of stable α-synuclein polymers: Implication of 
nitrative and oxidative stress in the pathogenesis of neurodegenerative 
synucleinopathies. J. Biol. Chem. 275, 18344–18349 (2000). 
110. Ding, T. T., Lee, S., Rochet, J. & Lansbury, P. T. Annular a-Synuclein Protofibrils 
Are Produced When Spherical Protofibrils Are Incubated in Solution or Bound to 
Brain-Derived Membranes †. Biochemistry 10209–10217 (2002). 
111. Volles, M. J. et al. Vesicle permeabilization by protofibrillar alpha-synuclein: 
implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry 
40, 7812–7819 (2001). 
112. Volles, M. J. & Lansbury, P. T. Vesicle permeabilization by protofibrillar α-synuclein 
is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like 
mechanism. Biochemistry 41, 4595–4602 (2002). 
113. Wood, S. J. et al. a-Synuclein Fibrillogenesis is Nucleation-dependent. Biochemistry 
19509–19512 (1999). doi:10.1074/jbc.274.28.19509 
114. Gosavi, N., Lee, H. J., Lee, J. S., Patel, S. & Lee, S. J. Golgi fragmentation occurs in 
the cells with prefibrillar ??-synuclein aggregates and precedes the formation of fibrillar 
inclusion. J. Biol. Chem. 277, 48984–48992 (2002). 
  
 
126 
115. Xu, J. et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for 
selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600–606 (2002). 
116. Danzer, K. M. et al. Different species of α-synuclein oligomers induce calcium influx 
and seeding. J. Neurosci. 27, 9220–9232 (2007). 
117. Hsu, L. J. et al. Α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress. 
Am. J. Pathol. 157, 401–410 (2000). 
118. Hashimoto, M. et al. The Role of alpha-synuclein assembly and metabolism in the 
pathogenesis of Lewy body disease. J. Mol. Neurosci. 24, 343–52 (2004). 
119. Alim, M. A. et al. Demonstration of a role for a-synuclein as a functional microtubule-
associated protein. J. Alzheimer’s Dis. 6, 435–442 (2004). 
120. Takeda, S. et al. Neuronal uptake and propagation of a rare phosphorylated high-
molecular-weight tau derived from Alzheimer’s disease brain. Nat. Commun. 6, 8490 
(2015). 
121. Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of α-
synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–
48 (2013). 
122. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. & Del Tredici, K. Stages in the 
development of Parkinson’s disease-related pathology. Cell Tissue Res. 318, 121–134 
(2004). 
123. Hawkes, C. H., Del Tredici, K. & Braak, H. Parkinson’s disease: A dual-hit 
hypothesis. Neuropathol. Appl. Neurobiol. 33, 599–614 (2007). 
124. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy 
body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. 
Nat. Med. 14, 504–506 (2008). 
125. Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease 
suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008). 
126. Brundin, P., Li, J., Holton, J. L., Lindvall, O. & Revesz, T. Research in motion: the 
enigma of Parkinson’s disease pathology spread. Nat. Rev. Neurosci. 9, 741–745 (2008). 
127. Brundin, P., Melki, R. & Kopito, R. Prion-like transmission of protein aggregates in 
neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 11, 301–307 (2010). 
128. Brundin, P. & Melki, R. Prying into the Prion Hypothesis for Parkinson’s Disease. J. 
Neurosci. 37, 9808–9818 (2017). 
129. Lee, H. J. et al. Assembly-dependent endocytosis and clearance of extracellular α-
synuclein. Int. J. Biochem. Cell Biol. 40, 1835–1849 (2008). 
130. Danzer, K. M., Krebs, S. K., Wolff, M., Birk, G. & Hengerer, B. Seeding induced by 
a-synuclein oligomers provides evidence for spreading of a-synuclein pathology. J. 
Neurochem. 111, 192–203 (2009). 
131. Desplats, P. et al. Inclusion Formation and Neuronal Cell Death through Neuron-to-
Neuron Transmission of Alpha-Synuclein. J. Neurochem. 110, 137 (2009). 
132. Luk, K. C. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-
  
 
127 
like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 106, 20051–6 
(2009). 
133. Hansen, C. et al. α-Synuclein propagates from mouse brain to grafted dopaminergic 
neurons and seeds aggregation in cultured human cells. 121, 715–725 (2011). 
134. Volpicelli-daley, L. a et al. exogenous aSynuclein fibrils induce Lewy Body Pathology 
leading to Synaptic Dysfunction and Neuron Death. Neuron 72, 57–71 (2011). 
135. Freund, E. C. et al. neuron-to-neuron transmission of aSynuclein fibrils through 
axonal transport. 72, 517–524 (2013). 
136. Reyes, J. F. et al. A cell culture model for monitoring α-synuclein cell-to-cell transfer. 
Neurobiol. Dis. 77, 266–275 (2015). 
137. Shrivastava, A. N. et al. aSynuclein assemblies sequester neuronal a3-Na+/K + -
ATPase and impair Na + gradient. EMBO J. 34, 2408–2423 (2015). 
138. Mao, X. et al. Pathological a-synuclein transmission initiated by binding lymphocyte-
activation gene 3. Science (80-. ). 353, aah3374-aah3374 (2016). 
139. Holmes, B. B. et al. Heparan sulfate proteoglycans mediate internalization and 
propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. 110, E3138–E3147 
(2013). 
140. Sung, J. Y. et al. Induction of Neuronal Cell Death by Rab5A-dependent Endocytosis 
of a-Synuclein. J. Biol. Chem. 276, 27441–27448 (2001). 
141. Luk, K. C. et al. pathological a-synuclein transmission initiates parkinson-like 
Neurodegeneration in non-transgenic mice. Science (80-. ). 338, 949–953 (2013). 
142. Guo, J. L. & Lee, V. M. Y. Cell-to-cell transmission of pathogenic proteins in 
neurodegenerative diseases. Nat. Med. 20, 130–138 (2014). 
143. Abounit, S. et al. Tunneling nanotubes spread fibrillar α‐synuclein by intercellular 
trafficking of lysosomes. EMBO J. 35, 2120–2138 (2016). 
144. El-Agnaf, O. M. A.  -Synuclein implicated in Parkinson’s disease is present in 
extracellular biological fluids, including human plasma. FASEB J. 1945–1947 (2003). 
doi:10.1096/fj.03-0098fje 
145. Emmanouilidou, E. et al. Cell-Produced -Synuclein Is Secreted in a Calcium-
Dependent Manner by Exosomes and Impacts Neuronal Survival. J. Neurosci. 30, 
6838–6851 (2010). 
146. Danzer, K. M. et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. 
Mol. Neurodegener. 7, 42 (2012). 
147. Sacino, A. N. et al. Amyloidogenic a-synuclein seeds do not invariably induce rapid, 
widespread pathology in mice. Acta Neuropathol. 127, 645–665 (2014). 
148. Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger α-
synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 
351–362 (2014). 
149. Peelaerts, W. et al. a-Synuclein strains cause distinct synucleinopathies after local and 
systemic administration. Nature 522, 340–344 (2015). 
  
 
128 
150. Dunning, C. J. R., George, S. & Brundin, P. What’s to like about the prion-like 
hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? Prion 7, 
92–7 (2013). 
151. Melki, R. Role of different alpha-synuclein strains in synucleinopathies, similarities 
with other neurodegenerative diseases. J. Parkinsons. Dis. 5, 217–227 (2015). 
152. Ferreon, A. C. M., Gambin, Y., Lemke, E. A. & Deniz, A. A. Interplay of a-
synuclein binding and conformational switching probed by single-molecule 
fluorescence. Proc. Natl. Acad. Sci. 106, 5645–5650 (2009). 
153. Jao, C. C., Hegde, B. G., Chen, J., Haworth, I. S. & Langen, R. Structure of 
membrane-bound alpha-synuclein from site-directed spin labeling and computational 
refinement. Proc. Natl. Acad. Sci. U. S. A. 105, 19666–19671 (2008). 
154. Fusco, G. et al. Direct Observation of the Three Regions in α -Synuclein that 
Determine its Membrane-Bound Behaviour. Nat Commun 1–17 (2014). 
doi:10.1038/ncomms4827.Direct 
155. Kjaer, L., Giehm, L., Heimburg, T. & Otzen, D. The influence of vesicle size and 
composition on α-synuclein structure and stability. Biophys. J. 96, 2857–2870 (2009). 
156. Middleton, E. R. & Rhoades, E. Effects of curvature and composition on α-synuclein 
binding to lipid vesicles. Biophys. J. 99, 2279–2288 (2010). 
157. Jensen, M. B. et al. Membrane curvature sensing by amphipathic helices: A single 
liposome study using a-synuclein and annexin B12. J. Biol. Chem. 286, 42603–42614 
(2011). 
158. Binotti, B., Jahn, R. & Chua, J. J. E. Functions of rab proteins at presynaptic sites. 
Cells 5, 1–10 (2016). 
159. Lesage, S. et al. Loss-of-function mutations in RAB39B are associated with typical 
early-onset Parkinson disease. Neurol. Genet. 1, e9 (2015). 
160. Wilson, G. R. et al. Mutations in RAB39B cause X-linked intellectual disability and 
early-onset parkinson disease with α-synuclein pathology. Am. J. Hum. Genet. 95, 729–
735 (2014). 
161. Shi, M., Shi, C. & Xu, Y. Rab GTPases: The Key Players in the Molecular Pathway 
of Parkinson’s Disease. Front. Cell. Neurosci. 11, 1–8 (2017). 
162. Stenmark, H. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 
10, 513–525 (2009). 
163. Pereira-Leal, J. B. & Seabra, M. C. The mammalian Rab family of small GTPases: 
definition of family and subfamily sequence motifs suggests a mechanism for 
functional specificity in the Ras superfamily 1 1Edited by M. Yaniv. J. Mol. Biol. 301, 
1077–1087 (2000). 
164. Pereira-Leal, J. B. & Seabra, M. C. Evolution of the rab family of small GTP-binding 
proteins. J. Mol. Biol. 313, 889–901 (2001). 
165. HUTAGALUNG, A. A. & NOVICK, P. J. Role of Rab GTPases in Membrane 
Traffic and Cell Physiology. Physiol Rev 91, 119–149 (2011). 
166. Barr, F. & Lambright, D. G. RAB GEFs and GAPs. Curr. Opin. Cell Biol. 22, 461–470 
  
 
129 
(2011). 
167. Cherfils, J. & Zeghouf, M. Regulation of Small GTPases by GEFs, GAPs, and GDIs. 
Physiol. Rev. 93, 269–309 (2013). 
168. Vetter, I. R. The Guanine Nucleotide-Binding Switch in Three Dimensions. Science 
(80-. ). 294, 1299–1304 (2001). 
169. Chutna, O. et al. The small GTPase Rab11 co-localizes with α-synuclein in 
intracellular inclusions and modulates its aggregation, secretion and toxicity. Hum. 
Mol. Genet. 23, 6732–6745 (2014). 
170. Hasegawa, T. et al. The AAA-ATPase VPS4 regulates extracellular secretion and 
lysosomal targeting of α-synuclein. PLoS One 6, (2011). 
171. Dalfó, E., Barrachina, M., Rosa, J. L., Ambrosio, S. & Ferrer, I. Abnormal α-
synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. 
Neurobiol. Dis. 16, 92–97 (2004). 
172. Yin, G. et al. α-Synuclein interacts with the switch region of Rab8a in a Ser129 
phosphorylation-dependent manner. Neurobiol. Dis. 70, 149–161 (2014). 
173. Gonçalves, S. A. et al. shRNA-Based Screen Identifies Endocytic Recycling Pathway 
Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, 
Secretion and Toxicity. PLoS Genet. 12, 1–26 (2016). 
174. Chen, R. H. C. et al. a-Synuclein membrane association is regulated by the Rab3a 
recycling machinery and presynaptic activity. J. Biol. Chem. 288, 7438–7449 (2013). 
175. Breda, C. et al. Rab11 modulates α-synuclein-mediated defects in synaptic 
transmission and behaviour. Hum. Mol. Genet. 24, 1077–1091 (2015). 
176. Cooper, A. A. et al. a-Synuclein blocks ER-Golgi Traffic and Rab1 Rescues Neuron 
Loss in Parkinson´s Models. Science (80-. ). 313, 324–328 (2007). 
177. Outeiro, T. F. & Lindquist, S. Yeast Cells provide insight into alpha-synuclein biology 
and pathobiology. Science (80-. ). 302, 1772–1775 (2003). 
178. Chua, C. E. L. & Tang, B. L. Rabs, SNAREs and α-synuclein - Membrane trafficking 
defects in synucleinopathies. Brain Res. Rev. 67, 268–281 (2011). 
179. Gitler, A. D. et al. The Parkinson’s disease protein  -synuclein disrupts cellular Rab 
homeostasis. Proc. Natl. Acad. Sci. 105, 145–150 (2008). 
180. Soper, J. H., Kehm, V., Burd, C. G., Bankaitis, V. A. & Lee, V. M. Y. Aggregation of 
α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and 
phospholipid biosynthesis. J. Mol. Neurosci. 43, 391–405 (2011). 
181. Chiu, C.-C. et al. Increased Rab35 expression is a potential biomarker and implicated 
in the pathogenesis of Parkinson&amp;rsquo;s disease. Oncotarget 7, 54215–54227 
(2016). 
182. Sellier, C. et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ 
Ataxin‐2 to induce motor neuron dysfunction and cell death. EMBO J. 35, 1276–1297 
(2016). 
183. Granseth, B., Odermatt, B., Royle, S. J. & Lagnado, L. Clathrin-Mediated 
  
 
130 
Endocytosis Is the Dominant Mechanism of Vesicle Retrieval at Hippocampal 
Synapses. Neuron 51, 773–786 (2006). 
184. Alabi, A. A. & Tsien, R. W. Perspectives on Kiss-and-Run: Role in Exocytosis, 
Endocytosis, and Neurotransmission. Annu. Rev. Physiol. 75, 393–422 (2013). 
185. Doherty, G. & McMahon, H. Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 
857–902 (2009). 
186. Staal, R., Mosharov, E. & Sulzer, D. Dopamine neurons release transmitter via a 
flickering fusion pore. Nat. Neurosci. 341–346 (2004). 
187. Wightman, R. M. & Haynes, C. L. Synaptic vesicles really do kiss and run. Nat. 
Neurosci. 7, 321–322 (2004). 
188. Royle, S. J. & Lagnado, L. Clathrin-Mediated Endocytosis at the Synaptic Terminal: 
Bridging the Gap Between Physiology and Molecules. Traffic 11, 1489–1497 (2010). 
189. Vargas, K. J. et al. Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis. 
J. Neurosci. 34, 9364–9376 (2014). 
190. Cuervo, A. M. & Dice, J. F. A Receptor for the Selective Uptake and Degradation of 
Proteins by Lysosomes. Science (80-. ). 273, 501–503 (1996). 
191. Agarraberes, F. a & Dice, J. F. A molecular chaperone complex at the lysosomal 
membrane is required for protein translocation. J. Cell Sci. 114, 2491–2499 (2001). 
192. Mizushima, N., Ohsumi, Y. & Yoshimori, T. Autophagosome Formation in 
Mammalian Cells. Cell Struct. Funct. 27, 421–429 (2002). 
193. Hafner Česen, M., Pegan, K., Špes, A. & Turk, B. Lysosomal pathways to cell death 
and their therapeutic applications. Exp. Cell Res. 318, 1245–1251 (2012). 
194. Mak, S. K., McCormack, A. L., Manning-Bog, A. B., Cuervo, A. M. & Di Monte, D. 
A. Lysosomal degradation of a-synuclein in vivo. J. Biol. Chem. 285, 13621–13629 
(2010). 
195. Cuervo, A. M., Wong, E. S. P. & Martinez-Vicente, M. Protein degradation, 
aggregation, and misfolding. Mov. Disord. 25, (2010). 
196. Winslow, A. R. et al. α-Synuclein impairs macroautophagy: Implications for 
Parkinson’s disease. J. Cell Biol. 190, 1023–1037 (2010). 
197. Tanik, S. A., Schultheiss, C. E., Volpicelli-Daley, L. A., Brunden, K. R. & Lee, V. M. 
Y. Lewy body-like a-synuclein aggregates resist degradation and impair 
macroautophagy. J. Biol. Chem. 288, 15194–15210 (2013). 
198. Yan, J. Q. et al. Overexpression of Human E46K Mutant α-Synuclein Impairs 
Macroautophagy via Inactivation of JNK1-Bcl-2 Pathway. Mol. Neurobiol. 50, 685–
701 (2014). 
199. Alvarez-Erviti, L. et al. Lysosomal dysfunction increases exosome-mediated alpha-
synuclein release and transmission. Neurobiol. Dis. 42, 360–367 (2011). 
200. Lee, H. J. et al. Autophagic failure promotes the exocytosis and intercellular transfer 
of α-synuclein. Exp. Mol. Med. 45, e22-9 (2013). 
  
 
131 
201. Falkenburger, B. H., Saridaki, T. & Dinter, E. Cellular models for Parkinson’s 
disease. J. Neurochem. 121–130 (2016). doi:10.1111/jnc.13618 
202. Lázaro, D. F., Pavlou, M. A. S. & Outeiro, T. F. Cellular models as tools for the 
study of the role of alpha-synuclein in Parkinson’s disease. Exp. Neurol. 298, 162–171 
(2017). 
203. Roostaee, A., Beaudoin, S., Staskevicius, A. & Roucou, X. Aggregation and 
neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization. Mol. 
Neurodegener. 8, 5 (2013). 
204. Krishnan, S. et al. Oxidative dimer formation is the critical rate-limiting step for 
Parkinson’s disease alpha-synuclein fibrillogenesis. Biochemistry 42, 829–837 (2003). 
205. Kerppola, T. Design and implementation of bimolecular fluorescence 
complementation (BiFC) assays for the visualization of protein interactions in living 
cells. Nat. Protoc. 1, 1278–1286 (2006). 
206. Gonçalves, S. A., Matos, J. E. & Outeiro, T. F. Zooming into protein oligomerization 
in neurodegeneration using BiFC. Trends Biochem. Sci. 35, 643–651 (2010). 
207. Outeiro, T. F. et al. Formation of toxic oligomeric α-synuclein species in living cells. 
PLoS One 3, 1–9 (2008). 
208. McLean, P. J., Kawamata, H. & Hyman, B. T. α-Synuclein-enhanced green 
fluorescent protein fusion proteins form proteasome sensitive inclusions in primary 
neurons. Neuroscience 104, 901–912 (2001). 
209. Swinnen, E. et al. Aggresome formation and segregation of inclusions influence 
toxicity of α-synuclein and synphilin-1 in yeast. Biochem. Soc. Trans. 39, 1476–1481 
(2011). 
210. Büttner, S. et al. Synphilin-1 enhances a-synuclein aggregation in yeast and contributes 
to cellular stress and cell death in a sir2-dependent manner. PLoS One 5, (2010). 
211. Lücking, C. B. & Brice, A. Review Alpha-synuclein and Parkinson’s disease. C. Cell. 
Mol. Life Sci 57, 1894–1908 (2000). 
212. Engelender, S. et al. Synphilin-1 associates with alpha-synuclein and promotes the 
formation of cytosolic inclusions. Nat.Genet. 22, 110–114 (1999). 
213. Klucken, J. et al. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive 
autophagy pathway. Autophagy 8, 754–766 (2012). 
214. Poehler, A. M. et al. Autophagy modulates SNCA/α-synuclein release, thereby 
generating a hostile microenvironment. Autophagy 10, 2171–2192 (2014). 
215. Johnson, M., Geeves, M. A. & Mulvihill, D. P. Production of amino-terminally 
acetylated recombinant proteins in E . coli. Methods Mol Biol 1–7 (2015). 
doi:10.1007/978-1-62703-305-3 
216. Elia, G. Biotinylation reagents for the study of cell surface proteins. Proteomics 8, 
4012–4024 (2008). 
217. Scheurer, S. B. et al. Identification and relative quantification of membrane proteins 
by surface biotinylation and two-dimensional peptide mapping. Proteomics 5, 2718–
2728 (2005). 
  
 
132 
218. Schanda, P., Kupĉe, E. & Brutscher, B. SOFAST-HMQC experiments for recording 
two-dimensional deteronuclear correlation spectra of proteins within a few seconds. J. 
Biomol. NMR 33, 199–211 (2005). 
219. Miotto, M. C. et al. Copper Binding to the N-Terminally Acetylated, Naturally 
Occurring Form of Alpha-Synuclein Induces Local Helical Folding. J. Am. Chem. Soc. 
137, 6444–6447 (2015). 
220. Lamberto, G. R. et al. Structural and mechanistic basis behind the inhibitory 
interaction of PcTS on alpha-synuclein amyloid fibril formation. Proc. Natl. Acad. Sci. 
U. S. A. 106, 21057–21062 (2009). 
221. Farrow, N. A., Zhang, O., Forman-Kay, J. D. & Kay, L. E. Comparison of the 
backbone dynamics of a folded and an unfolded SH3 domain existing in equilibrium 
in aqueous buffer. Biochemistry 34, 868–878 (1995). 
222. Binolfi, A., Fernández, C. O., Sica, M. P., Delfino, J. M. & Santos, J. Recognition 
between a short unstructured peptide and a partially folded fragment leads to the 
thioredoxin fold sharing native-like dynamics. Proteins Struct. Funct. Bioinforma. 80, 
1448–1464 (2012). 
223. Serrano, L. Comparison between the phi distribution of the amino acids in the protein 
database and NMR data indicates that amino acids have various phi propensities in 
the random coil conformation. J. Mol. Biol. 254, 322–333 (1995). 
224. Villar-Piqué, A. et al. Environmental and genetic factors support the dissociation 
between α-synuclein aggregation and toxicity. Proc. Natl. Acad. Sci. 201606791 (2016). 
doi:10.1073/pnas.1606791113 
225. Konstantinopoulos, P. A., Karamouzis, M. V. & Papavassiliou, A. G. Post-
translational modifications and regulation of the RAS superfamily of GTPases as 
anticancer targets. Nat. Rev. Drug Discov. 6, 541–555 (2007). 
226. D’Souza, R. S. et al. Rab4 orchestrates a small GTPase cascade for recruitment of 
adaptor proteins to early endosomes. Curr. Biol. 24, 1187–1198 (2014). 
227. Burré, J., Sharma, M. & Südhof, T. C. Systematic mutagenesis of aSyn reveals 
distinct sequence requirements for physiological and pathological activities. J. 
Neurochem. 15227 15242 (2012). doi:10.1016/j.jacc.2007.01.076.White 
228. Burré, J., Sharma, M. & Südhof, T. C. Definition of a Molecular Pathway Mediating 
a-Synuclein. J. Neurosci. 35, 5221–5232 (2015). 
229. Fonseca-Ornelas, L. et al. Small molecule-mediated stabilization of vesicle-associated 
helical α-synuclein inhibits pathogenic misfolding and aggregation. Nat. Commun. 5, 
5857 (2014). 
230. Lee, J. H., Ying, J. & Bax, A. Nuclear Magnetic Resonance Observation of a-
Synuclein Membrane Interaction by Monitoring the Acetylation Reactivity of Its 
Lysine Side Chains. Biochemistry 55, 4949–4959 (2016). 
231. Smith, C. M., Haucke, V., McCluskey, A., Robinson, P. J. & Chircop, M. Inhibition 
of clathrin by pitstop 2 activates the spindle assembly checkpoint and induces cell 
death in dividing HeLa cancer cells. Mol. Cancer 12, 1–15 (2013). 
232. Soohoo, A. L. & Puthenveedu, M. a. Divergent modes for cargo-mediated control of 
clathrin-coated pit dynamics. Mol. Biol. Cell 24, 1725–34, S1-12 (2013). 
  
 
133 
233. Mccluskey, A. et al. Building a better dynasore: The dyngo compounds potently 
inhibit dynamin and endocytosis. Traffic 14, 1272–1289 (2013). 
234. Lázaro, D. F. et al. Systematic Comparison of the Effects of Alpha-synuclein 
Mutations on Its Oligomerization and Aggregation. PLoS Genet. 10, (2014). 
235. Ormo, M. et al. Crystal Structure of the Aequorea victoria Green Fluorescent Protein. 
Science (80-. ). 273, 1392–1395 (2016). 
236. Minch, M. J. Orientational dependence of vicinal proton‐proton NMR coupling 
constants: The Karplus relationship. Concepts Magn. Reson. 6, 41–56 (1994). 
237. Cho, M. K. et al. Structural characterization of a-synuclein in an aggregation prone 
state. Protein Sci. 18, 1840–1846 (2009). 
238. Valiente-Gabioud, A. A. et al. Phthalocyanines as Molecular Scaffolds to Block 
Disease-Associated Protein Aggregation. Acc. Chem. Res. 49, 801–808 (2016). 
239. Pacheco, C., Aguayo, L. G. & Opazo, C. An extracellular mechanism that can 
explain the neur effects of α-synuclein aggregates in the brain. Front. Physiol. 3 JUL, 
1–10 (2012). 
240. Ahn, K. J., Paik, S. R., Chung, K. C. & Kim, J. Amino acid sequence motifs and 
mechanistic features of the membrane translocation of a-synuclein. J. Neurochem. 97, 
265–279 (2006). 
241. Tang, B. L. Rabs, Membrane Dynamics, and Parkinson’s Disease. J. Cell. Physiol. 232, 
1626–1633 (2017). 
242. Sönnichsen, B., De Renzis, S., Nielsen, E., Rietdorf, J. & Zerial, M. Distinct 
membrane domains on endosomes in the recycling pathway visualized by multicolor 
imaging of Rab4, Rab5, and Rab11. J. Cell Biol. 149, 901–913 (2000). 
243. Kisos, H., Ben-Gedalya, T. & Sharon, R. The clathrin-dependent localization of 
dopamine transporter to surface membranes is affected by α-Synuclein. J. Mol. 
Neurosci. 52, 167–176 (2014). 
244. Cheng, F. et al. α-Synuclein promotes clathrin-mediated NMDA receptor endocytosis 
and attenuates NMDA-induced dopaminergic cell death. J. Neurochem. 119, 815–825 
(2011). 
245. Ben, G. T. et al. Alpha-synuclein and polyunsaturated fatty acids promote clathrin 
mediated endocytosis and synaptic vesicle recycling. Traffic 10, 218–234 (2009). 
246. Busch, D. J. et al. Acute increase of α-synuclein inhibits synaptic vesicle recycling 
evoked during intense stimulation. Mol. Biol. Cell 25, 3926–41 (2014). 
247. Michel, C. H. et al. Extracellular monomeric tau protein is sufficient to initiate the 
spread of tau protein pathology. J. Biol. Chem. 289, 956–967 (2014). 
248. Casey, J. R., Grinstein, S. & Orlowski, J. Sensors and regulators of intracellular pH. 
Nat. Rev. Mol. Cell Biol. 11, 50–61 (2010). 
249. Lindersson, E. et al. p25a Stimulates a-Synuclein Aggregation and Is Co-localized 
with Aggregated a-Synuclein in a-Synucleinopathies *. J. Biol. Chem. 280, 5703–5715 
(2005). 
  
 
134 
250. Dias, V., Junn, E. & Mouradian, M. M. The Role of Oxidative Stress in Parkinson’s 
Disease. J Park. Dis 3, 461–491 (2014). 
251. Valiente-Gabioud, A. A. et al. Structural basis behind the interaction of Zn2+ with the 
protein α-synuclein and the Aβ peptide: A comparative analysis. J. Inorg. Biochem. 
117, 334–341 (2012). 
252. Wolozin, B. & Golts, N. Iron and Parkinson ’ s Disease. Neurosci. 60153, 22–32 
(2002). 
253. Opazo, F., Krenz, A., Heermann, S., Schulz, J. B. & Falkenburger, B. H. 
Accumulation and clearance of α-synuclein aggregates demonstrated by time-lapse 
imaging. J. Neurochem. 106, 529–540 (2008). 
254. Gomes-Trolin, C., Nygren, I., Aquilonius, S.-M. & Askmark, H. Increased Red Blood 
Cell Polyamines in ALS and Parkinson’s Disease. Exp. Neurol. 177, 515–520 (2002). 
255. Lu, Y., Prudent, M., Fauvet, B., Lashuel, H. A. & Girault, H. H. Phosphorylation of 
a-synuclein at Y125 and S129 alters its metal binding properties: Implications for 
understanding the role of a-synuclein in the pathogenesis of Parkinson’s disease and 
related disorders. ACS Chem. Neurosci. 2, 667–675 (2011). 
256. Li, W. et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a 
normal cellular process and is enhanced by the familial Parkinson’s disease-linked 
mutations. Proc. Natl. Acad. Sci. U. S. A. 102, 2162–7 (2005). 
257. Beyer, K. & Ariza, A. Alpha-Synuclein Posttranslational Modification and 
Alternative Splicing as a Trigger for Neurodegeneration. Mol. Neurobiol. 1–16 (2012). 
doi:10.1007/s12035-012-8330-5 
 
  
 
 
 
135 
 
 
  
  
 
136 
 
  
  
 
137 
ACKNOWLEDGEMENTS  
 
 
To begin this journey, and even more, to conclude it, was not easy.  
It was a period full of frustration, full of disappointment, and lately, full of awareness. 
However, people say that the best things come from the uncomfortable, painful 
moments and I am confident none of this happened in vain.  
My first thanks go to Prof. Dr. Tiago Outeiro, for giving me the opportunity to conduct 
my doctoral studies at the Department of Experimental Neurodegeneration in 
Göttingen, providing me with the necessary equipment, time and space to develop my 
research and my ideas.  
On the same way, I need to thank my co-supervisor, Prof. Dr. Claudio Fernández, for 
allowing me to perform part of my experiment in his lab, at the MPLbioR, UNR-
Sociedad Max Planck in Rosario. The period I spent there was one of the happiest 
moment of my PhD, turning in an incredibly amusing experience both from a 
professional and a personal side.  
I also want to thank the member of my thesis committee, Prof. Dr. Markus 
Zweckstetter and Prof. Gerhard Braus, for the cooperation and the helpful suggestions 
received during the meetings. Thanks as well to the further members of my 
Examination Board, Dr. Ira Milosevic, Dr. Mauricio Menacho Marquez and Prof. 
Reinhard Jahn, for taking the time to be present at my PhD Defense. 
 
A huge, grateful thank you goes to my two scientific mentors, one for each hemisphere 
of the Earth: Dr. Andrés Binolfi and Dr. Ira Milosevic. 
I will be eternally grateful to Andrés for showing me the kind of person I want to be: a 
brilliant – extremely brilliant - scientist that look at the world with a critical eye, a 
childlike spirit but yet with extreme humbleness and with the conscious that we – 
everyone - have still, and always, a lot to learn.  
Thank you Andrés, thank you for supervising me so carefully and thank you for 
listening to all my ideas, even the silliest, without ever discouraging or crushing me.  
To Ira goes my deepest gratitude for showing me how beautiful is to preserve and to 
promote such a genuine passion for Science. For showing me that is possible to be a 
woman, to have a family, to manage a lab and to do excellent research, altogether. 
Thank you Ira, for being always so enthusiastic about our collaboration, for believing 
in me since the beginning and for motivating me. Thank you for your time, for all the 
precious advices, for the professional and personal suggestions, for all the help.     
  
 
138 
I should also thank my colleagues and former colleagues: Joana, Francisca, Tomás 
and his brilliant ideas, Isabel, Mariana, the other Mariana, Maria, Vaishali, Omar and 
Dani, my queridisima Anka and Laetitia The Warrior, for all the moment spent 
together, for the help, for the support, for the lunch together and all the talk.  
 To Elly goes a special thank, from the bottom of my heart, for being the strongest, and 
for all the wine and the extremely pleasant dinners together.  
It was wonderful Elly, and I am honoured to be your friend! (Oh my god! I have a 
German Friend! Can you believe it???) 
 
A special mention goes to Shamina.  
Grazie more for saving me from mental illness in lovely, warm and friendly Göttingen. 
Without you, I wouldn´t probably manage it. Ti voglio bene Shamina!  
Thank as well to Frau Karboni, to Chiappetta, to Judith and Moritz, to make some of 
my days – and the Department Party – funnier and lighter.  
 
A huge thank goes to all the people I met in Argentina, where I spent one of the greatest 
year of my life, where I could feel at home, where I was always smiling, where 
everything was easy even if nothing ever – EVER – works, but well, Who cares?  
It is sunny outside, tomate un mate, hacemo un asado, Che! 
Thanks to Mauge, Vero, Pablito, Charliero, Franco, Timo, Flor, Antonio, Gonzalito 
(sos el orgullo del pais Gonzalito, pero vamos en Cambridge, que increible!!!) y 
Marcolino, obviamente! 
Thanks to Tomé, for being the nicest person, the nicest friend, the nicest Apoyo 
Tecnico in the entire world! You deserve the best, Tomé, and I am really lucky to have 
meet you, and extremely grateful to be your friend.  
 
To Ariel, or better, to Dr. Valiente, goes all my sympathy, my affection and my 
admiration, before than all my thanks, for being such a good and funny – incredibly 
funny - friend, such a precise, methodical, impeccable scientist and collaborator, for 
his humour above the lines, for the trips, the time and the philosophy about work and 
politics done together. Muchisimas gracias Ariel, por ser exactamente como eres!  
 
Thanks to my old and less old friends: La Giulia, the crazy part of me, my beautiful, 
wonderful Sofia, the person everyone should know and fall in love with, La Prunety, 
that follow me even in the other side of the Ocean (Non te ne andare Prunetyyyyyyy, 
  
 
139 
non te ne andareeeeeeeeee!), and Sarah, my crucca but not-at-all crucca friend, and of 
course, Shamina again.  
Thanks to all of you, you are literally the best part of every place, every experience, 
and every fundamental step of my life.  
 
Last but not least, Thanks to my Family.  
Young Rita would never though Old Rita would become so sentimental, so attached 
to the family, so worried and concerned and homesick for Mummy and Papino.  
But well, la vecchiaia é una brutta bestia, so…  
A simple “thank you” will never be enough, for all the efforts, the time, the money, 
the concerns and everything else you spent on me. For me.  
What to say? I just hope you could feel proud even 1/10 of how much I feel proud, 
lucky and grateful to have you.  
 
As a special part of my family, thanks to you Mon Amour.  
You are definitely the best thing coming from my PhD, from these last 4 years.  
And – as you know – I couldn´t have asked for more. 
I couldn´t even have imagined more.  
So, thank you for being my special Unicorn.  
Love you chatinho! 
 
 
 
  
 
 
  
  
 
140 
 
 
 
 
 
  
  
 
141 
  
 
CATERINA MASARACCHIA 
 
PERSONAL INFORMATION 
Current address:  Heidelberg, Baden-Württemberg, Germany. 
Date of Birth:   08  April  1987 
Citizenship:   Italian 
Languages:   Italian    (mother tongue) 
English and Spanish (full professional proficiency) 
French   (intermediate proficiency) 
German   (elementary proficiency) 
 
EDUCATION 
International PhD on Biosciences and Molecular Biomedicine         2014- current  
Georg-August Universität, Göttingen  - Germany –  and  
MPLbioR, UNR-Sociedad Max Planck – Rosario, Santa Fe – Argentina  
 
Master Degree in Molecular and Cellular Biology          2010 – 2012  
 
Alma Mater Studiorum. University of Bologna - Bologna, Italy 
 110/110 cum laude (with honors) 
  
Bachelor Degree in Biological Sciences           2006 – 2010 
 
Alma Mater Studiorum. University of Bologna - Bologna, Italy 
 
 
APPOINTMENTS  
 
 CUAA-DAHZ International PhD on Biosciences and Molecular Biomedicine 
 and PhD in Biology - GAUSS Program        2014- current 
Dissertation: “Analysis of the mechanisms of interaction of alpha-synuclein and 
membranes in cellular models of Parkinson´s Disease” 
Georg-August University of Gottingen – Department of Experimental 
Neurodegeneration  - Georg-August Universität – Göttingen, Germany  
Supervisor : Prof. Dr. Tiago Fleming Outeiro 
 
Institute for the Drug discovery of Rosario (IIDEFAR, CONICET-UNR) and 
(MPLbioR, UNR-Sociedad Max Planck) – Rosario, Santa Fe – Argentina  
Supervisors: Prof. Dr. Claudio O. Fernández and Dr. Andrés Binolfi 
  
 
Department of Experimental Neurodegeneration  
DFG Center for Nanoscale Microscopy and Molecular Physiology of the Brain  
UMG – Universität Medizin Göttingen 
Waldweg, 33 – 37073 Göttingen, Niedersachsen -  Germany 
 
Phone:   +49 176 2746 4171 
E-mail:  caterina.masaracchia87@gmail.com 
 
  
 
142 
U4 Graduate School  2014                  September 2014 
“The Ageing Brain” 
U4 Network – Göttingen, Germany  
 
John Van Geest Centre for Brain Repair Spring School 2014          April 2014 
“The Spreading Pathology of Neurodegenerative disorders”  
Department of Clinical Neuroscience, University of Cambridge – Cambridge, UK  
 
  Visiting Researcher        Apr. 2013 – Feb. 2014 
UNI, ULB Neuroscience Institute  
  Laboratory of General Histology, Neuroanathomy and Neuropathology  
  ULB, Univeristè Libre de Bruxelles  - Bruxelles, Belgium  
Supervisor: Prof. Jean-Pierre Brion 
 
Master Degree´s Internship                    Feb. 2012 – Nov. 2012 
 
Molecular Pathology Laboratory,  
Department of Experimental, Diagnostic and  Specialty Medicine – Unity of 
Hematopathology - Bologna University Medical School – Bologna, Italy 
Supervisor: Prof. Dr. Stefano Pileri 
 
Bachelor Degree´s Internship        Nov 2009 – Feb 2010 
 
Department of Pharmacy and Biotechnology,  
Alma Mater Studiorum, University of Bologna – Bologna, Italy 
Supervisor: Prof. Paolo Bernardo Trost 
 
 
PROFESSIONAL SKILLS 
Cellular Biology: cell cultures;  vitality and proliferation essays (CellTiter Glo, Alamar Blue, 
MTT assay); transfections (calcium phosphate, lipofectamine); 
immunocytochemistry, immunoblotting and electrophoresis.  
Imaging and live imaging (Fluorescence, Confocal, Spin Disc Microscopy) 
 
Molecular Biology: plasmid cloning, bacterial transformation, extraction and purification of  
  nucleic acid from FFPE tissues, human blood, cryopreserved samples.  
Extraction and purification of recombinant proteins, High-Pressure Liquid  
  Chromatography (HPLC), aggregation assay.   
 
Structural Biology: Nuclear Magnetic Resonance (NMR) 
 
Computer Skills: Office, ImageJ, Graph Pad , CorelDraw, CCPN, TopSpin. 
 
Teaching: Supervision of Master students during lab rotations (Saskia Kohen, Marilena 
  Hnida); Supervision of visiting researcher in practical work – (Maria Eugenia Chesta 
  and Mauricio Menacho) 
 
 
  
 
143 
PRESENTATIONS AND PANELS 
- Biophisical characterization of an aggregation-prone variant of alpha-synuclein as a 
model of synucleinopathies - AD/PD 2017:13th International Conference on 
Alzheimer´s Disease and Parkinson´s Disease – Vienna, Austria (poster presentation) 
 
- The interaction between α-synuclein, membranes and trafficking machinery: insights 
into the mechanisms of spreading; C2 Retreat, April 2015 – Göttingen, Germany 
(poster presentation) 
 
- Internalization and behavior of monomeric, oligomeric and filamentous aSyn in 
cultured cells – U4 Graduate School 2014 – Göttingen, Germany (poster 
presentation) 
 
 
PUBLICATIONS 
 High-Molecular-Weight Paired Helical Filaments from Alzheimer Brain Induces 
Seeding of Wild-Type Mouse Tau into an Argyrophilic 4R Tau Pathology in Vivo  
 
Audouard E, Houben S, Masaracchia C, Yilmaz Z, Suain V, Authelet M, De Decker R, 
Buée L, Boom A, Leroy K, Ando K, Brion JP. 
Am J Pathol. 2016 Oct;186(10):2709-22. doi: 10.1016/j.ajpath.2016.06.008. - 
PMID: 27497324 
 
 Environmental and genetic factors support the dissociation between α-synuclein 
aggregation and toxicity 
 
Villar-Piqué A, Lopes da Fonseca T, Sant'Anna R, Szegö ÉM, Fonseca-Ornelas L, Pinho 
R, Carija A, Gerhardt E, Masaracchia C, Abad Gonzalez E, Rossetti G, Carloni P, 
Fernández CO, Foguel D, Milosevic I, Zweckstetter M, Ventura S, Outeiro TF. 
       Proc Natl Acad Sci U S A. 2016 Oct 5. pii: 201606791. 
       PMID: 27708160 
 
 Characterization of an aggregation-prone variant of alpha-synuclein as a model 
for synucleinopathies 
 
Masaracchia C, Valiente-Gabioud AA, Peralta P, Favretto F, Strohäker T, Lázaro FD, 
Zweckstetter M, Binolfi A, Fernandez CO, Outeiro TF 
- Submitted to Biochemistry   -  
 
 
 
 
 
 
 
 
 
  
 
144 
 
